# CITATION REPORT List of articles citing

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

DOI: 10.1016/j.jacc.2013.05.019 Journal of the American College of Cardiology, 2013, 62, e147-239.

Source: https://exaly.com/paper-pdf/55880094/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2270	Estrogens, progestins, menopause and neurodegeneration: basic and clinical studies. <b>2005</b> , 62, 271-80		61
2269	Contribution of vascular and neural segments to baroreflex sensitivity in response to postural stress. <b>2009</b> , 46, 469-77		14
2268	What should we tell patients with heart failure about sodium restriction and how should we counsel them?. <b>2013</b> , 10, 219-26		15
2267	Insights into heart failure with preserved ejection fraction among admitted Nigerian patients. <b>2013</b> , 170, e36-7		1
2266	Common threads in atrial fibrillation and heart failure. <b>2013</b> , 9, 373-83, vii		4
2265	Changes in renal function in congestive heart failure. <b>2013</b> , 10, 285-95		8
2264	The emerging epidemic of heart failure with preserved ejection fraction. <b>2013</b> , 10, 401-10		186
2263	Treatment strategies for the prevention of heart failure. <b>2013</b> , 10, 331-40		7
2262	Prognostic factors in patients hospitalized for heart failure. <b>2013</b> , 10, 380-6		6
2261	Update on heart failure with preserved ejection fraction. <b>2013</b> , 7, 495-502		15
2260	Physical Activity and Exercise for Secondary Prevention among Patients with Cardiovascular Disease. <b>2013</b> , 7, 411		21
2259	Dietary sodium: a perspective on recent sodium evidenceits interpretation and controversies. <b>2013</b> , 15, 765-8		11
2258	Cardiac rehabilitation exercise and self-care for chronic heart failure. 2013, 1, 540-7		120
2257	Pro-HEART - a randomized clinical trial to test the effectiveness of a high protein diet targeting obese individuals with heart failure: rationale, design and baseline characteristics. <b>2013</b> , 36, 371-81		15
2256	Role of left ventricular biopsy in the management of heart disease. <b>2013</b> , 128, 1492-4		15
2255	Cardiovascular disease self-care interventions. <b>2013</b> , 2013, 407608		18
2254	Association of age and BP variability with long-term mortality in hemodialysis patients. <b>2013</b> , 38, 172-8	0	7

DBlockers and chronic obstructive pulmonary disease: inappropriate avoidance?. <b>2013</b> , 15, 925-30	10
2252 Health-related quality of life in elderly patients hospitalized with chronic heart failure. <b>2013</b> , 8, 153	<b>39-46</b> 29
Medical management to full recovery in patients with severe ischemic cardiomyopathy. <b>2014</b> , 2,	
2250 Efficiency of individual dosage of digoxin with calculated concentration. <b>2014</b> , 9, 1205-10	3
Determinants of noninvasive ventilation success or failure in morbidly obese patients in acute respiratory failure. <b>2014</b> , 9, e97563	42
Combined effects of admission serum creatinine concentration with age and gender on the prognostic significance of subjects with acute ST-elevation myocardial infarction in China. <b>2014</b> , 9,	e108986 <sup>3</sup>
2247 Inotropes do not increase mortality in advanced heart failure. <b>2014</b> , 7, 237-51	25
The basic social medical insurance is associated with clinical outcomes in the patients with ST-elevation myocardial infarction: a retrospective study from Shanghai, China. <b>2014</b> , 11, 905-17	7
Evolution of biomarker guided therapy for heart failure: current concepts and trial evidence. <b>2015</b> , 11, 80-9	11
2244 Management of heart failure? an update. <b>2014</b> , 43, 36-45	
The life cycle of the heart failure patient. <b>2015</b> , 11, 2-3	3
Elevated soluble ST2 and depression increased the risk of all-cause mortality and hospitalization in patients with heart failure. <b>2014</b> , 55, 445-50	18
2241 Cholinergic activity as a new target in diseases of the heart. <b>2015</b> , 20, 527-37	47
2240 Current treatments for acute heart failure: focus on serelaxin. <b>2014</b> , 169	1
ACE inhibitors: upper respiratory symptoms. <b>2014</b> , 2014,	8
Short-term mechanical circulatory support by veno-arterial extracorporeal membrane oxygenation in the management of cardiogenic shock and end-stage heart failure. <b>2014</b> , 12, 145-53	7
Atrial synchronous left ventricular only pacing with VDD pacemaker system - a cost effective alternative to conventional cardiac resynchronization therapy. <b>2014</b> , 66, 612-6	4
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safet and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. <b>2014</b> , 40, 572-81	y 27

2235 Nuevos agentes para el tratamiento de la hipertensi[h pulmonar. **2014**, 21, 399-408

2234	Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews. <b>2014</b> , CD011273	100
2233	Clinical features, management, and short- and long-term outcomes of patients with acute decompensated heart failure: phase I results of the HEARTS database. <b>2014</b> , 16, 461-9	33
2232	The global relevance of disease management programmes for heart failure. <b>2014</b> , 16, 927-8	2
2231	Natriuretic peptide testing in high-risk pregnancy: a preventive opportunity?. <b>2014</b> , 11, 471-6	5
2230	Left atrial expansion index is an independent predictor of diastolic dysfunction in patients with preserved left ventricular systolic function: a three dimensional echocardiography study. <b>2014</b> , 30, 1315-23	8
2229	Machines versus medication for biventricular heart failure: focus on the total artificial heart. <b>2014</b> , 10, 593-609	8
2228	Effect of fluid and dietary sodium restriction in the management of patients with heart failure and preserved ejection fraction: study protocol for a randomized controlled trial. <b>2014</b> , 15, 347	4
2227	Neprilysin inhibition for heart failure. <b>2014</b> , 371, 2336-7	33
2226	Biomarkers in ACS and heart failure: should men and women be interpreted differently?. <b>2014</b> , 60, 35-43	32
2225	Defining heart failure in adult congenital heart disease. <b>2014</b> , 38, 3-7	5
2224	Novel biomarkers in heart failure: usefulness in clinical practice. <b>2014</b> , 12, 311-21	6
2223	Copeptin as a biomarker in heart failure. <b>2014</b> , 8, 841-54	25
2222	Chapter 5. Treatment with antihypertensive drugs. <b>2014</b> , 37, 291-300	2
2221	Insuficiencia cardlica. <b>2014</b> , 21, 9-36	
2220	Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. <b>2014</b> , 16, 1362-71	22
2219	Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. <b>2014</b> , 7, 123-30	97
2218	Prognostic value of pulmonary vascular resistance estimated by cardiac magnetic resonance in patients with chronic heart failure. <b>2014</b> , 15, 1391-9	11

A meta-analysis of proinflammatory cytokines in chronic heart failure. <b>2014</b> , 6, 130-6	21
2216 Antithrombotics in heart failure. <b>2014</b> , 55, 621-7	1
Heart failure: gaps in knowledge and failures in treatment. <b>2014</b> , 11, e1001702	3
Changes in left ventricular relaxation after azelnidipine treatment in hypertensive patients with diabetes: subanalysis of a prospective single-arm multicentre study. <b>2014</b> , 4, e006136	1
2213 Congestive heart failure adherence redesign trial: a pilot study. <b>2014</b> , 4, e006542	7
2212 Clinician's guide to the updated ABCs of cardiovascular disease prevention. <b>2014</b> , 3, e001098	17
Using telehealth for heart failure: Barriers, pitfalls and nursing service models. <b>2014</b> , 9, 396-406	13
Herzinsuffizienz als Risikofaktor filden akuten ischinischen Schlaganfall Eine Kombination mit vergleichsweise schlechter Prognose. <b>2014</b> , 43, 510-516	
Predictors and outcome of sustained improvement in left ventricular function in dilated cardiomyopathy. <b>2014</b> , 37, 687-92	8
Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. <b>2014</b> , 115, 730-7	48
2207 🛮 blockers, atrial fibrillation, and heart failure. <b>2014</b> , 384, 2181-3	6
History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. <b>2014</b> , 7, 960-6	28
2205 Cardiac regeneration using pluripotent stem cellsprogression to large animal models. <b>2014</b> , 13, 654-65	70
2204 Lessons from the TOPCAT trial. <b>2014</b> , 370, 1453-4	40
Nonsense mutations in BAG3 are associated with early-onset dilated cardiomyopathy in French Canadians. <b>2014</b> , 30, 1655-61	43
2202 A call to arms: new approaches to an old heart failure problem. <b>2014</b> , 20, 878-80	
2201 Provocative issues in heart disease prevention. <b>2014</b> , 30, S401-9	20
2200 Hemoconcentration-guided diuresis in heart failure. <b>2014</b> , 127, 1154-9	32

2199	Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. <b>2014</b> , 16, 1125-32		72
2198	Multidisciplinary rehabilitation program in recently hospitalized patients with heart failure and preserved ejection fraction: rationale and design of a randomized controlled trial. <b>2014</b> , 168, 830-7.e1		10
2197	Indications for revascularization in patients with left ventricular dysfunction: evidence and uncertainties. <b>2014</b> , 148, 2461-5		
2196	Changes of ventricular and peripheral performance in patients with heart failure and normal ejection fraction: insights from ergometry stress echocardiography. <b>2014</b> , 16, 888-97		14
2195	Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2281-93	15.1	313
2194	Sizing up models of heart failure: Proteomics from flies to humans. <b>2014</b> , 8, 653-64		22
2193	C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction. <b>2014</b> , 16, 758-66		40
2192	Engaging heart failure clinicians to increase palliative care referrals: overcoming barriers, improving techniques. <b>2014</b> , 17, 753-60		33
2191	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcomean analysis from RELAX-AHF. <b>2014</b> , 16, 1230-40		95
2190	Fontan-like circulation as a criterion for heart transplantation in arrhythmogenic right ventricular dysplasia. <b>2014</b> , 126, 705-9		2
2189	Intravenous therapies in acute heart failurelack of effect or lack of well powered studies?. <b>2014</b> , 16, 355-7		9
2188	Using ST2 in cardiovascular patients: a review. <b>2014</b> , 10, 525-39		44
2187	Defining "severe" secondary mitral regurgitation: emphasizing an integrated approach. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2792-801	15.1	129
2186	Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2743-9	15.1	65
2185	Left ventricular reverse remodeling, device-related adverse events, and long-term outcome after cardiac resynchronization therapy in the elderly. <b>2014</b> , 7, 437-44		17
2184	Chemotherapy-Induced Cardiomyopathy in the Elderly. <b>2014</b> , 8, 1		
2183	Trial of a family-based education program for heart failure patients in rural Thailand. <b>2014</b> , 14, 173		7
2182	Incorporating patients with chronic heart failure into outpatient cardiac rehabilitation: practical recommendations for exercise and self-care counseling-a clinical review. <b>2014</b> , 34, 223-32		23

2181	A quality improvement plan to reduce 30-day readmissions of heart failure patients. <b>2014</b> , 29, 280-6	13
2180	Pharmacogenomics in heart failure: where are we now and how can we reach clinical application?. <b>2014</b> , 22, 193-8	13
2179	Atrial fibrillation in the elderly: management strategies to achieve performance measures. <b>2014</b> , 25, 205-12	3
2178	Management of perioperative heart failure. <b>2014</b> , 27, 140-5	2
2177	Is there still a role for low-dose dopamine use in acute heart failure?. <b>2014</b> , 20, 467-71	3
2176	Reversed reverse remodeling: can biomonitoring solve the clinical conundrum of the 3Rs?. <b>2014</b> , 7, 388-90	3
2175	Frequent utilization of the emergency department for acute heart failure syndrome: a population-based study. <b>2014</b> , 7, 735-42	24
2174	Effects of glucocorticoids in potentiating diuresis in heart failure patients with diuretic resistance. <b>2014</b> , 20, 625-9	21
2173	Temporary mechanical circulatory support: a review of the options, indications, and outcomes. <b>2014</b> , 8, 75-85	49
2172	The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature. <b>2014</b> , 52, 911-8	10
2171	Multidisciplinary group clinic appointments: the Self-Management and Care of Heart Failure (SMAC-HF) trial. <b>2014</b> , 7, 888-94	35
2170	Association of Psychosocial Factors and Heart Rate Variability in Heart Failure Patients. <b>2014</b> , 36, 769-87	3
2169	Identifying predictors of high sodium excretion in patients with heart failure: a mixed effect analysis of longitudinal data. <b>2014</b> , 13, 549-58	6
2168	Estimation of cardiac output and pulmonary vascular resistance by contrast echocardiography transit time measurement: a prospective pilot study. <b>2014</b> , 12, 44	7
2167	IOM and DHHS meeting on making clinical practice guidelines appropriate for patients with multiple chronic conditions. <b>2014</b> , 12, 256-9	27
2166	Cardiac and renal fibrosis in chronic cardiorenal syndromes. <b>2014</b> , 127, 106-12	27
2165	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. <b>2014</b> , 130, e199-267	1016
2164	A randomized pilot study of aortic waveform guided therapy in chronic heart failure. <b>2014</b> , 3, e000745	32

2163	Serum parathyroid hormone and 25-hydroxyvitamin D concentrations and risk of incident heart failure: the Multi-Ethnic Study of Atherosclerosis. <b>2014</b> , 3, e001278		52
2162	Chemotherapy-induced cardiotoxicity: detection, prevention, and management. <b>2014</b> , 30, 869-78		75
2161	Exploring the role of aldosterone in right ventricular function. <b>2014</b> , 30, 155-8		3
2160	Implications of coronary artery disease in heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2817-27	15.1	161
2159	Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). Journal of the American College of	15.1	125
2158	Cardiology, <b>2014</b> , 63, 2356-62 Single measurement of serum N-terminal pro-brain natriuretic peptide: the best predictor of long-term mortality in patients with chronic systolic heart failure. <b>2014</b> , 25, 458-62		5
2157	ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart		31
2156	HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. <b>2014</b> , 11, 1271-303		14
2155	Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy?. <b>2014</b> , 127, 574-8		2
2154	Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 853-71	15.1	80
2153	Biomarkers in cardiorenal syndromes. <b>2014</b> , 164, 122-34		16
2152	Guidelines in review: 2013 ACCF/AHA Guideline for the Management of Heart Failure. <b>2014</b> , 21, 397-9		14
2151	Angiotensin II, from vasoconstrictor to growth factor: a paradigm shift. <b>2014</b> , 114, 754-7		33
2150	2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, e57-185	15.1	1905
2149	Natriuretic peptide-guided heart failure management. <b>2014</b> , 35, 16-24		134
2148	Triage of patients with moderate to severe heart failure: who should be referred to a heart failure center?. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 661-671	15.1	28
2147	Proposal for a functional classification system of heart failure in patients with end-stage renal disease: proceedings of the acute dialysis quality initiative (ADQI) XI workgroup. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1246-1252	15.1	42
2146	Critical appraisal of the obesity paradox in cardiovascular disease: how to manage patients with overweight in heart failure?. <b>2014</b> , 19, 637-44		14

2145	Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure. <b>2014</b> , 11, 31-9	3
2144	Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. <b>2014</b> , 143, 531-9	40
2143	Determinants of survival following hospitalization for acute heart failure. <b>2014</b> , 11, 201-11	8
2142	Left ventricular mechanical dyssynchrony by phase analysis as a prognostic indicator in heart failure. <b>2014</b> , 21, 67-70	2
2141	Diagnostic approach of myocarditis: strike the golden mean. <b>2014</b> , 22, 80-4	6
2140	Medication adherence and heart failure. <b>2014</b> , 16, 458	17
2139	Cardiac rehabilitation in the United States. <b>2014</b> , 56, 522-9	80
2138	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, e1-76	2768
2137	What can three-dimensional speckle-tracking echocardiography contribute to evaluate global left ventricular systolic performance in patients with heart failure?. <b>2014</b> , 172, 132-7	22
2136	Medical therapy in adults with congenital heart disease. <b>2014</b> , 10, 167-78	14
2135	Decongestion in acute heart failure. <b>2014</b> , 16, 471-82	90
2134	ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart	439
2133	The autonomic nervous system and heart failure. <b>2014</b> , 114, 1815-26	295
2132	Exercise-based rehabilitation for heart failure. <b>2014</b> , CD003331	205
2131	Heart failure with preserved ejection fraction: a clinical dilemma. <b>2014</b> , 35, 1022-32	136
2130	The role of coronary artery disease in heart failure. <b>2014</b> , 10, 353-65	61
2129	Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort. <b>2014</b> , 113, 691-6	39
2128	The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. <b>2014</b> , 167, 193-202.e1	40

2127	Management of ACCF/AHA Stage C heart failure. <b>2014</b> , 32, 73-93, viii	7
2126	The renin-angiotensin-aldosterone system and heart failure. <b>2014</b> , 32, 21-32, vii	98
2125	Serelaxin: a potential new drug for the treatment of acute heart failure. <b>2014</b> , 23, 1017-26	11
2124	Clinical implications of chronic heart failure phenotypes defined by cluster analysis. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1765-74	132
2123	Atrial fibrillation: Challenging the status quo: 🛭 blockers for HF plus AF. <b>2014</b> , 11, 690-2	4
2122	Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). <b>2014</b> , 16, 817-25	119
2121	Sodium Current Disorders. <b>2014</b> , 6, 819-824	1
2120	Association of quality of life with anticoagulant control in patients with heart failure: the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. <b>2014</b> , 177, 715-7	2
2119	Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews. <b>2014</b> , 177, 348-61	73
2118	Targeting Sleep Disordered Breathing to Prevent Heart Failure: What is the Evidence?. <b>2014</b> , 8, 403	1
2117	Current perspectives on systemic hypertension in heart failure with preserved ejection fraction. <b>2014</b> , 16, 545	22
2116	Is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients? Real-world evidence from a retrospective analysis of a large United States hospital database. <b>2014</b> , 20, 853-63	6
2115	Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. <b>2014</b> , 168, 721-30	212
2114	The palliative care in heart failure trial: rationale and design. <b>2014</b> , 168, 645-651.e1	39
2113	Cardiomyopathy associated with cancer therapy. <b>2014</b> , 20, 841-52	14
2112	Characteristics and outcomes of patients with acute decompensated heart failure developing after hospital admission. <b>2014</b> , 114, 1530-6	2
2111	Clinical update on nursing home medicine: 2014. <b>2014</b> , 15, 786-801	7
2110	New-onset atrial fibrillation predicts heart failure progression. <b>2014</b> , 127, 963-71	29

2109	From acute decompensated to chronic heart failure. <b>2014</b> , 114, 1923-9		9
2108	Nonsternotomy Approaches for Left Ventricular Assist Device Placement. <b>2014</b> , 19, 276-291		5
2107	Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. <b>2014</b> , 35, 3434-41		68
2106	Acute heart failure with and without concomitant acute coronary syndromes: patient characteristics, management, and survival. <b>2014</b> , 20, 723-730		23
2105	The case for treating refractory congestive heart failure with ultrafiltration. <b>2014</b> , 37 Suppl 2, 51-60		3
2104	2014 AHA/ACC Guideline for the Management of Patients With NonBT-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2014</b> ,	15.1	132
2103	Are peripherally inserted central catheters associated with increased risk of adverse events in status 1B patients awaiting transplantation on continuous intravenous milrinone?. <b>2014</b> , 20, 630-7		9
2102	Diagnosis of heart failure with preserved ejection fraction. <b>2014</b> , 10, 399-406		18
2101	Current therapeutic approach in heart failure with preserved ejection fraction. <b>2014</b> , 10, 525-38		11
2100	2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: Executive Summary. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2373-2405	15.1	64
2099	Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure. <b>2014</b> , 34, 1121-31		7
2098	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <b>2014</b> , 35, 2797-815		231
2097	Management of oral chronic pharmacotherapy in patients hospitalized for acute decompensated heart failure. <b>2014</b> , 176, 321-6		8
2096	Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 938-45	15.1	385
2095	Left ventricular diastolic function in relation to the urinary proteome: a proof-of-concept study in a general population. <b>2014</b> , 176, 158-65		36
2094	ROSE-AHF and lessons learned. <b>2014</b> , 11, 260-5		8
2093	Acute coronary syndromes: Treatment for low-risk patients with STEMIchallenges remain. <b>2014</b> , 11, 440-2		
2092	Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial. <b>2014</b> , 32, 2496-502		39

2091 Sleep and breathing in congestive heart failure. **2014**, 35, 521-34

10

2090	In search of a solution from the STICH trial. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 562-4.	5.1	
2089	2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American	5.1	497
2088	AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. <i>Journal of the American</i>	5.1	87
2087	Seeing the unseen fibrosis in heart failure with preserved ejection fraction. <b>2014</b> , 7, 998-1000		1
2086	Impact of transpulmonary thermodilution-based cardiac contractility and extravascular lung water measurements on clinical outcome of patients with Takotsubo cardiomyopathy after subarachnoid hemorrhage: a retrospective observational study. <b>2014</b> , 18, 482		31
2085	Polypharmacy in heart failure: drugs to use and avoid. <b>2014</b> , 10, 577-90		8
2084	Management strategies for heart failure with preserved ejection fraction. <b>2014</b> , 10, 591-8		10
2083	Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients. <b>2014</b> , 10, 607-20		6
2082	Lipid-modifying treatments for heart failure: is their use justified?. <b>2014</b> , 10, 621-34		5
2081	Current approaches to antiarrhythmic therapy in heart failure. <b>2014</b> , 10, 635-52		2
2080	The role of heart failure pharmacotherapy after left ventricular assist device support. <b>2014</b> , 10, 653-60		3
2079	Association Task Force on practice guidelines. <i>Journal of the American College of Cardiology</i> , <b>2014</b> ,	5.1	855
2078	64, e77-137 Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review. <b>2014</b> , 19, 541-51		6
2077	National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1407-15	5.1	296
2076	Causes of exercise intolerance in heart failure with preserved ejection fraction: searching for consensus. <b>2014</b> , 20, 762-778		16
2075	Heart failure risk prediction models: what have we learned?. <b>2014</b> , 2, 437-9		18
2074	Impact of general and central adiposity on ventricular-arterial aging in women and men. <b>2014</b> , 2, 489-99		50

2073	Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. <b>2014</b> , 2, 457-65		84
2072	Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. <b>2014</b> , 2, 466-73		66
2071	2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, e139-e228	15.1	1822
2070	A prediction model for 5-year cardiac mortality in patients with chronic heart failure using "—metaiodobenzylguanidine imaging. <b>2014</b> , 41, 1673-82		38
2069	Novel drug mechanisms in development for heart failure. <b>2014</b> , 466, 1219-25		1
2068	MedikamentBe Therapie der akuten Herzinsuffizienz. <b>2014</b> , 17, 293-299		1
2067	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2246-2280	15.1	505
2066	Cardiac biomarkers in heart failure. <b>2014</b> , 47, 327-37		39
2065	Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. <b>2014</b> , 96, 175-81		61
2064	Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. <b>2014</b> , 174, 360-7		47
2063	Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. <b>2014</b> , 115, 79-96		322
2062	Sodium restriction in heart failure: benefit or harm?. <b>2014</b> , 16, 286		13
2061	Preventing Heart Failure in Inflammatory and Immune Disorders. <b>2014</b> , 8, 1		5
2060	ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart		35
2059	Subclinical Myocardial Disease in Heart Failure Detected by CMR. <b>2014</b> , 7, 9269		5
2058	The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1823-32	15.1	67
2057	Transthoracic echocardiography in women with treated severe pre-eclampsia. 2014, 69, 436-44		15
2056	Cardiogenic shock. <b>2014</b> , 30, 391-412		17

2055	Real-time assessment of myocardial viability in the catheterization laboratory using the intracoronary electrograms recorded by the PTCA guidewire in patients with left ventricular dysfunction: comparison with delayed-enhancement magnetic resonance imaging. <b>2014</b> , 7, 988-96	2
2054	Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. <b>2014</b> , 7, 935-44	256
2053	Disparities in heart failure care: now is the time to focus on health care delivery. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 808-10	7
2052	The acute cardiorenal syndrome type I: considerations on physiology, epidemiology, and therapy. <b>2014</b> , 11, 382-92	12
2051	Evaluation and management of patients with heart disease and cancer: cardio-oncology. <b>2014</b> , 89, 1287-306	217
2050	Long-term survival for patients with acute decompensated heart failure according to ejection fraction findings. <b>2014</b> , 114, 862-8	25
2049	Contemporary strategies in the diagnosis and management of heart failure. <b>2014</b> , 89, 662-76	18
2048	Obesity and the obesity paradox in heart failure. <b>2014</b> , 56, 409-14	111
2047	Cardiac biomarkers and risk assessment in patients undergoing major non-cardiac surgery: time to revise the guidelines?. <b>2014</b> , 52, 959-63	9
2046	Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. <b>2014</b> , 114, 151-9	18
2045	Are renin-angiotensin-aldosterone system inhibitors lifesaving in chronic kidney disease?. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 659-660	4
2044	AXL receptor tyrosine kinase is increased in patients with heart failure. <b>2014</b> , 173, 402-9	37
2043	Exercise training for chronic heart failure (ExTraMATCH II): protocol for an individual participant data meta-analysis. <b>2014</b> , 174, 683-7	21
2042	2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <b>2014</b> , 148, e1-e132	728
2041	Comparison of patients with peripartum heart failure and normal (85%) versus low (. <b>2014</b> , 114, 290-3	7
2040	2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force 15.1 on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2438-88	1349
2039	Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). <b>2014</b> , 2, 187-97	24
2038	Utilization pattern of mineralocorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: a single-center experience. <b>2014</b> , 20, 229-35	16

2037	The impact of peripheral arterial disease on patients with congestive heart failure. <b>2014</b> , 10, 327-38		6
2036	Surgery casualties: do not leave hearts behind enemy lines. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 181-3	15.1	2
2035	Mortality outcomes among status Aboriginals and whites with heart failure. <b>2014</b> , 30, 619-26		6
2034	Ischemic and functional mitral regurgitation in heart failure: natural history and treatment. <b>2014</b> , 16, 517		26
2033	Fragmented QRS predicts the arrhythmic events in patients with heart failure undergoing ICD implantation for primary prophylaxis: more fragments more appropriate ICD shocks. <b>2014</b> , 19, 351-7		15
2032	Cardiomyopathy in pregnancy. <b>2014</b> , 38, 309-17		21
2031	Heart failure with preserved ejection fraction. <b>2014</b> , 12, 743-50		6
2030	Phenotypic spectrum of heart failure with preserved ejection fraction. <b>2014</b> , 10, 407-18		86
2029	Charting a roadmap for heart failure biomarker studies. <b>2014</b> , 2, 477-88		54
2028	A novel algorithm to assess risk of heart failure exacerbation using ICD diagnostics: validation from RAFT. <b>2014</b> , 11, 1626-31		19
2027	Modulation of the renin-angiotensin-aldosterone system in heart failure. <b>2014</b> , 16, 403		13
2026	Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. <b>2014</b> , 168, 142-9		25
2025	[The MitraClip procedure]. <b>2014</b> , 43, 803-8		
2024	Echocardiographic differences between preeclampsia and peripartum cardiomyopathy. <b>2014</b> , 23, 260-6		23
2023	Calling for targeted trials in cardiorenal syndromes. <b>2014</b> , 64, 10-2		1
2022	Frequency and predictors of normalization of left ventricular ejection fraction in recent-onset nonischemic cardiomyopathy. <b>2014</b> , 113, 1705-10		15
2021	Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. <b>2014</b> , 160, 661-71		62
2020	Inclusion of older people in interventional clinical trials. <b>2014</b> , 4, 87-99		3

2019 Potential future denervation targets. 2014, 6, 569-579

2018	Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D heart failure in Japan. Report from the CHART-2 study. <b>2014</b> , 78, 428-35	41
2017	Challenges in long-term mechanical circulatory support and biological replacement of the failing heart. <b>2014</b> , 78, 288-99	6
2016	Diabetes-related heart failure. <b>2014</b> , 78, 576-83	46
2015	Novel diuretic strategies for the treatment of heart failure in Japan. <b>2014</b> , 78, 1816-23	26
2014	Health and cost benefits associated with the use of metoprolol in heart attack patients. <b>2014</b> , 7, 687-9	
2013	Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews. <b>2014</b> ,	24
2012	Temporary left ventricular assist device through an axillary access is a promising approach to improve outcomes in refractory cardiogenic shock patients. <b>2015</b> , 61, 253-8	13
2011	Cumulative Cardiovascular Polypharmacy Is Associated With the Risk of Acute Kidney Injury in Elderly Patients. <b>2015</b> , 94, e1251	41
2010	In-hospital journey of patients with heart failure. <b>2015</b> , 1, 31-35	1
2009	Safety and Efficacy of Catheter Ablation for Ventricular Tachycardia in Elderly Patients With Structural Heart Disease. <b>2015</b> , 1, 52-58	8
2008	Current Epidemiology and Outcome of Infective Endocarditis: A Multicenter, Prospective, Cohort Study. <b>2015</b> , 94, e1816	85
2007	Recent advances in dyspnea. <b>2015</b> , 147, 232-241	85
2006	Lipids, blood pressure and kidney update 2015. <b>2015</b> , 14, 167	44
2005	Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice. <b>2015</b> , 65, 628-39	9
2004	Clinical Practice Patterns in Constrictive Pericarditis Patients With Heart Failure: A Retrospective Cohort Study Using a National Inpatient Database in Japan. <b>2015</b> , 38, 740-6	7
2003	Impact of a nurse-led home and clinic-based secondary prevention programme to prevent progressive cardiac dysfunction in high-risk individuals: the Nurse-led Intervention for Less Chronic Heart Failure (NIL-CHF) randomized controlled study. <b>2015</b> , 17, 620-30	19
2002	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <b>2015</b> , 17, 544-58	236

2001	Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. <b>2015</b> , 17, 1057-65	106
<b>2</b> 000	Increasing exercise capacity and quality of life of patients with heart failure through Wii gaming: the rationale, design and methodology of the HF-Wii study; a multicentre randomized controlled trial. <b>2015</b> , 17, 743-8	40
1999	Telecardiology Tools and Devices. <b>2015</b> , 463-488	
1998	Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents. <b>2015</b> , 5, 17213	5
1997	Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. <b>2015</b> , 79, 574-82	40
1996	Plasma renin activity is a strong and independent prognostic indicator in patients with acute decompensated heart failure treated with renin-angiotensin system inhibitors. <b>2015</b> , 79, 1307-14	21
1995	Predicting short-term mortality in advanced decompensated heart failure - role of the updated acute decompensated heart failure/N-terminal pro-B-type natriuretic Peptide risk score. <b>2015</b> , 79, 1076-83	14
1994	Seasonal changes in systemic volume overload are to be considered. <b>2015</b> , 79, 670	
1993	Diastolic dysfunction. 2015, 79, 470-7	80
1992	Decreased Intrathoracic Impedance Associated With OptiVol Alert Can Diagnose Increased B-Type Natriuretic Peptide - MOMOTARO (Monitoring and Management of OptiVol Alert to Reduce Heart Failure Hospitalization) Study <b>2015</b> , 79, 1315-22	7
1991	Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure. <b>2015</b> , 79, 1237-47	16
1990	Novel echocardiographic approach to the accurate measurement of pulmonary vascular resistance based on a theoretical formula in patients with left heart failure pilot study. <b>2015</b> , 79, 2408-13	3
1989	Recent progress and next challenges in the treatment of symptomatic heart failure in Japan. <b>2015</b> , 79, 2322-3	
1988	Acute myocarditis mimicking ST-elevation myocardial infarction: A case report and review of the literature. <b>2015</b> , 10, 459-464	8
1987	Increased B-type-natriuretic peptide promotes myocardial cell apoptosis via the B-type-natriuretic peptide/long non-coding RNA LSINCT5/caspase-1/interleukin 1\(\Pi\)signaling pathway. <b>2015</b> , 12, 6761-7	22
1986	Class effect of beta-blockers in survivors of ST-elevation myocardial infarction: A nationwide cohort study using an insurance claims database. <b>2015</b> , 5, 13692	6
1985	Devices in heart failurethe new revolution. <b>2015</b> , 79, 237-44	5
1984	Common Carotid Artery Stiffness Is Associated with Left Ventricular Structure and Function and Predicts First Hospitalization for Acute Heart Failure. <b>2014</b> , 2, 18-28	6

Acute Kidney Injury and Renal Recovery with the Use of Aminoglycosides: A Large Retrosp Study. <b>2015</b> , 131, 153-60	pective 33
Mapping the Terrain of Competing Risk Following Primary Prevention Defibrillator Implan <b>2015</b> , 8, 847-9	itation.
Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer The <b>2015</b> , 9, 47-51	егару. 8
1980 Frailty in Advanced Heart Failure: A Consequence of Aging or a Separate Entity?. <b>2015</b> , 9, 3	39-46 24
1979 New Perspectives of the Pathophysiology and Management in Heart Failure. <b>2015</b> , 350, 24	49
1978 Update of treatment in chronic heart failure. <b>2015</b> , 145, 545-550	
1977 Update on Immune Monitoring in Heart Transplantation. <b>2015</b> , 2, 329-337	2
1976 Preventing Heart Failure with Exercise Training. <b>2015</b> , 9, 1	4
1975 Cardiac Magnetic Resonance Imaging in Ventricular Remodelling. <b>2015</b> , 8, 1	
Back to the future: the crucial role of clinical registries in the era of randomized controlled identifying the optimal medical therapy of heart failure. <b>2015</b> , 1, 37-8	d trials for
Exploration of Self-Care Following Distribution of Acute Management Tool for Elder Hear Patients in Clinic Setting. <b>2015</b> , 8, 215-221	t Failure
1972 Home-based versus centre-based cardiac rehabilitation. <b>2015</b> , CD007130	65
Impact of age on the prognostic value of left ventricular function in relation to procedura outcomes following percutaneous coronary intervention: insights from the British Cardiov Intervention Society. <b>2015</b> , 85, 944-51	
Dual renin-angiotensin system blockade and outcome benefits in hypertension: a narrative <b>2015</b> , 30, 373-7	e review. 5
1969 Preventing heart failure: the role of physical activity. <b>2015</b> , 30, 543-50	27
What is the evidence status of Appropriate Use Criteria (AUC)? Insight from a matching ex with the guidelines for echocardiography. <b>2015</b> , 45, 864-9	ercise 4
Noninvasive Hemodynamic Monitoring for Heart Failure: A New Era of Heart Failure Mana <b>2015</b> , 1, 57-64	gement.
Determinants of outcome in patients with chronic ischemic left ventricular dysfunction ur percutaneous coronary interventions. <b>2015</b> , 15, 137	ndergone 3

1965	Left ventricular diastolic dysfunction in nonhuman primate model of dysmetabolism and diabetes. <b>2015</b> , 15, 141	11
1964	Effect of Corticosteroid on Renal Water and Sodium Excretion in Symptomatic Heart Failure: Prednisone for Renal Function Improvement Evaluation Study. <b>2015</b> , 66, 316-22	9
1963	Cardiac Resynchronization Therapy in 2015: Lessons Learned. <b>2015</b> , 1, 93-106	
1962	Ivadradine. <b>2015</b> , 50, 806-17	
1961	Efficacy and safety of ultrafiltration in decompensated heart failure patients with renal insufficiency. <b>2015</b> , 56, 319-23	7
1960	Response and tolerance to oral vasodilator up-titration after intravenous vasodilator therapy in advanced decompensated heart failure. <b>2015</b> , 17, 956-63	5
1959	Continuous Flow Left Ventricular Assist Device Therapy: A Focused Review on Optimal Patient Selection and Long-Term Follow-up Using Echocardiography. <b>2015</b> , 1, 107-118	
1958	Wideband arrhythmia-Insensitive-rapid (AIR) pulse sequence for cardiac T1 mapping without image artifacts induced by an implantable-cardioverter-defibrillator. <b>2015</b> , 74, 336-45	16
1957	Angiographic Evaluation of Coronary Microvascular Dysfunction in Patients with Heart Failure and Preserved Ejection Fraction. <b>2015</b> , 22, 528-33	18
1956	Effect of 10-Week Supervised Moderate-Intensity Intermittent vs. Continuous Aerobic Exercise Programs on Vascular Adhesion Molecules in Patients with Heart Failure. <b>2015</b> , 94, 898-911	25
1955	Management of Noncardiac Comorbidities in Chronic Heart Failure. <b>2015</b> , 33, 300-15	22
1954	PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. <b>2015</b> , 33, 2278-85	29
1953	Nurse-Led Multidisciplinary Heart Failure Group Clinic Appointments: Methods, Materials, and Outcomes Used in the Clinical Trial. <b>2015</b> , 30, S25-34	24
1952	A new porcine model of hypertensive cardiomyopathy: a helpful tool to explore the HFpEF mystique. <b>2015</b> , 309, H1390-1	1
1951	Is there a role for albumin and C-reactive protein levels for prognostication in acute heart failure?. <b>2015</b> , 16, 401-3	1
1950	Prognosis of new-onset heart failure outpatients and collagen biomarkers. <b>2015</b> , 45, 842-9	17
1949	Third heart sound in hospitalised patients with acute heart failure: insights from the ATTEND study. <b>2015</b> , 69, 820-8	6
1948	The Interventional Heart Failure Initiative: a mission statement for the next generation of invasive cardiologists. <b>2015</b> , 86, 353-5	6

1947	Biomechanics of Cardiac Function. <b>2015</b> , 5, 1623-44	43
1946	In-hospital worsening heart failure. <b>2015</b> , 17, 1104-13	43
1945	Readmissions After Continuous Flow Left Ventricular Assist Device Implantation: Differences Observed Between Two Contemporary Device Types. <b>2015</b> , 61, 410-6	21
1944	Agents with vasodilator properties in acute heart failure: how to design successful trials. <b>2015</b> , 17, 652-64	24
1943	Can circulating biomarkers identify heart failure patients at low risk?. <b>2015</b> , 17, 1213-5	3
1942	Epidemiological Study of Heart Failure in China. <b>2015</b> , 1, 47-55	3
1941	Relationship between calcium channel blocker class and mortality in dialysis. <b>2015</b> , 24, 1249-58	9
1940	Update on perioperative care of the cardiac patient for noncardiac surgery. <b>2015</b> , 28, 342-8	7
1939	Heart Failure and Perioperative Care. <b>2015</b> , 43, 7-14	
1938	Heart Failure With Preserved Ejection Fraction: What Is in a Name?. <b>2015</b> , 23, 161-7	8
1937	Frequent Premature Ventricular Contractions: An Electrical Link to Cardiomyopathy. <b>2015</b> , 23, 168-72	6
1936	Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital. <b>2015</b> , 65, 438-43	21
1935	Stem cell therapy for chronic heart failure. <b>2015</b> , 30, 301-10	18
1934	Chronic heart failure: what does the horizon look like?. <b>2015</b> , 30, 344-53	4
1933	How to Improve Time to Diagnosis in Acute Heart Failure - Clinical Signs and Chest X-ray. <b>2015</b> , 1, 69-74	7
1932	Biomarkers in Acute Decompensated Heart Failure. <b>2015</b> , 7, CMT.S18476	
1931	Role of Cardiac Troponin Levels in Acute Heart Failure. <b>2015</b> , 1, 102-106	30
1930	Cardiorenal Syndromes: Advances in Determining Diagnosis, Prognosis and Therapy. <b>2015</b> , 03,	3

1929	Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. <b>2015</b> , 7, 808-16	24
1928	Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats. <b>2015</b> , 9, 6043-54	37
1927	Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. <b>2016</b> , 106, 145-52	45
1926	Soluble ST2 has a prognostic role in patients with suspected sepsis. <b>2015</b> , 35, 570-7	19
1925	Stem Cells Transplantation in Myocardial Tissue Induces Pro- Arrhythmic Effects and Promotes 4 Reperfusion. Comparison between Intramyocardial and Intravenous Approach. <b>2015</b> , 06,	
1924	Combination pharmacotherapy in lipid management. <b>2015</b> , 58, 745	
1923	Treating Heart Failure with Preserved Ejection Fraction: A Challenge for Clinicians. 2015, 50, 454-9	6
1922	Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?. <b>2015</b> , 16, 14056-74	19
1921	Use of Inotropic Agents in Treatment of Systolic Heart Failure. <b>2015</b> , 16, 29060-8	65
1920	An integrative literature review on nursing interventions aimed at increasing self-care among heart failure patients. <b>2015</b> , 23, 753-68	17
1919	Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. <b>2015</b> , 11, 283-95	15
1918	Frailty syndrome and self-care ability in elderly patients with heart failure. <b>2015</b> , 10, 871-7	34
1917	Biomarker Guided Therapy in Chronic Heart Failure. <b>2015</b> , 1, 96-101	2
1916	Biomarkers in Acute Heart Failure - Cardiac And Kidney. <b>2015</b> , 1, 107-111	3
1915	A systematic review concerning the relation between the sympathetic nervous system and heart failure with preserved left ventricular ejection fraction. <b>2015</b> , 10, e0117332	33
1914	The emperor's new clothes: PDE5 and the heart. <b>2015</b> , 10, e0118664	26
1913	The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists. <b>2015</b> , 10, e0119160	16
1912	MicroRNA profiling of pericardial fluid samples from patients with heart failure. <b>2015</b> , 10, e0119646	47

1,25-Dihydroxyvitamin D to PTH(1-84) Ratios Strongly Predict Cardiovascular Death in Heart Failure. <b>2015</b> , 10, e0135427	27
1910 Regulation of the renal sympathetic nerves in heart failure. <b>2015</b> , 6, 238	10
Evolution from electrophysiologic to hemodynamic monitoring: the story of left atrial and pulmonary artery pressure monitors. <b>2015</b> , 6, 271	9
1908 Implantable cardioverter defibrillators: state of the art. <b>2015</b> , 29	O
1907 Accuracy in inference of nursing diagnoses in heart failure patients. <b>2015</b> , 68, 603-9, 690-6	11
Correlation between B-Type Natriuretic Peptide and Functional/Cognitive Parameters in Discharged Congestive Heart Failure Patients. <b>2015</b> , 2015, 239136	10
1905 Mechanisms linking red blood cell disorders and cardiovascular diseases. <b>2015</b> , 2015, 682054	4 63
Chinese Herbal Medicine in the Treatment of Chronic Heart Failure: Three-Stage Study Proto a Randomized Controlled Trial. <b>2015</b> , 2015, 927160	ocol for
1903 Rehabilitation for patients with heart failure. <b>2015</b> , 26, 168-171	1
1902 Diuretic Therapy in Heart Failure - Current Approaches. <b>2015</b> , 10, 42-47	31
1901 Diagnosis and management of acute heart failure. <b>2015</b> , 15, 860-89	17
Healing the orphaned heart: heart failure in a patient with glucose-6-phosphate dehydroger deficiency. <b>2015</b> , 2015,	nase 2
1899 Palliative care. <b>2015</b> , 10, 38-44	
1898 Hypertension in minority populations: new guidelines and emerging concepts. <b>2015</b> , 22, 145	:-53 21
Comparing Sodium Intake Strategies in Heart Failure: Rationale and Design of the Prevent A Outcomes in Heart Failure by Limiting Sodium (PROHIBIT) Study. <b>2015</b> , 8, 636-45	dverse 16
Association of peripheral nerve conduction in diabetic neuropathy with subclinical left ventr systolic dysfunction. <b>2015</b> , 14, 47	ricular 21
1895 The Importance of NLRP3 Inflammasome in Heart Failure. <b>2015</b> , 21, 586-93	70
Risk stratification for the development of heart failure after acute coronary syndrome at the of hospital discharge: Predictive ability of GRACE risk score. <b>2015</b> , 66, 224-31	e time

1893	Chagas Heart Disease: An Opdate. <b>2015</b> , 128, 1251.e7-9	21
1892	Future Therapeutic Prospects for Treatment of Cardiorenal Syndromes. <b>2015</b> , 189-195	
1891	The role of echocardiography in heart failure. <b>2015</b> , 56 Suppl 4, 31S-38S	28
1890	Prognostic Significance and Determinants of the 6-Min Walk Test in Patients With Heart Failure and Preserved Ejection Fraction. <b>2015</b> , 3, 459-466	32
1889	Comparison of delayed transvenous reimplantation and immediate surgical epicardial approach in pacing-dependent patients undergoing extraction of infected permanent pacemakers. <b>2015</b> , 12, 1209-15	22
1888	Performance of CMR Methods for Differentiating Acute From Chronic MI. <b>2015</b> , 8, 669-79	16
1887	The changes in cardiac physiology with aging and the implications for the treating oncologist. <b>2015</b> , 6, 178-84	3
1886	Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. <b>2015</b> , 13, 627-36	4
1885	Imaging Techniques in Acute Heart Failure. <b>2015</b> , 68, 612-23	
1884	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).	147
1883	Treatment of Chronic Right Heart Failure. <b>2015</b> , 401-418	
1882	Ventricular assist devices for treatment of acute heart failure and chronic heart failure. <b>2015</b> , 101, 1091-6	16
1881	Clinical features of subclinical left ventricular systolic dysfunction in patients with diabetes mellitus. <b>2015</b> , 14, 37	51
1880	Current indications, strategies, and outcomes with cardiac transplantation for cardiac amyloidosis and sarcoidosis. <b>2015</b> , 20, 584-92	10
1879	The economic impact of patients with heart failure on the Lebanese healthcare system. <b>2015</b> , 2, 178-183	12
1878	The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease. <b>2015</b> , 38, 565-9	54
1877	Shared Decision-Making in Older Persons with Cardiovascular Disease. <b>2015</b> , 9, 1	O
1876	Epidemiology of "Heart Failure with Recovered Ejection Fraction": What do we do After Recovery?. <b>2015</b> , 12, 360-6	3

1875	Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. <b>2015</b> , 101, 1800-6	73
1874	Ventricular conduction and long-term heart failure outcomes and mortality in African Americans: insights from the Jackson Heart Study. <b>2015</b> , 8, 243-51	16
1873	Regenerative Therapy Prevents Heart Failure Progression in Dyssynchronous Nonischemic Narrow QRS Cardiomyopathy. <b>2015</b> , 4,	18
1872	Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. <b>2015</b> , 11, 585-95	16
1871	Diagnostic Accuracy of Cardiac Magnetic Resonance Imaging in the Evaluation of Newly Diagnosed Heart Failure With Reduced Left Ventricular Ejection Fraction. <b>2015</b> , 116, 1082-7	10
1870	Global Longitudinal Strain Is a Superior Predictor of All-Cause Mortality in Heart Failure With Reduced Ejection Fraction. <b>2015</b> , 8, 1351-1359	203
1869	Levosimendan and nesiritide as a combination therapy in patients with acute heart failure. <b>2015</b> , 349, 398-405	6
1868	Estrategia multimarcador para estratificar el pron©stico en insuficiencia cardiaca. Valor de los marcadores neurohumorales: neprilisina frente a NT-proBNP. <b>2015</b> , 68, 1075-1084	22
1867	Clinical evaluation of the Heart Check system, a new quantitative measurement of fresh capillary BNP. <b>2015</b> , 9, 1323-30	6
1866	Heart failure in pregnant women: is it peripartum cardiomyopathy?. <b>2015</b> , 120, 638-643	5
1865	Updates in antiarrhythmic therapy for atrial fibrillation in geriatric patients. <b>2015</b> , 30, 82-91	1
1864	Medication-related cognitive artifacts used by older adults with heart failure. <b>2015</b> , 4, 387-398	32
1863	Magnitude of and Prognostic Factors Associated With 1-Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings. <b>2015</b> , 4,	30
1862	Probable Rare Case of Cholecystitis After Exposure to Supratherapeutic Doses of Hydralazine. <b>2015</b> , 31, 135-137	O
1861	Current Technology to Maximize Cardiac Resynchronization Therapy Benefit for Patients With Symptomatic Heart Failure. <b>2015</b> , 26, 329-40; quiz 341-2	1
1860	Caregiver coaching program effect: Reducing heart failure patient rehospitalizations and improving caregiver outcomes among African Americans. <b>2015</b> , 44, 466-73	26
1859	A cardiovascular simulator tailored for training and clinical uses. <b>2015</b> , 57, 100-12	25
1858	Impact of lipid disorders on mortality among Saudi patients with heart failure. <b>2015</b> , 27, 91-5	5

1857	Concentraciones plasmbicas de neprilisina: ¿un nuevo marcador pronústico en la însuficiencia cardiaca?. <b>2015</b> , 68, 1053-1055		4
1856	Knowledge and exercise behavior maintenance in cardiac rehabilitation patients receiving educational interventions. <b>2015</b> , 44, 474-80		13
1855	Congestive Heart Failure With Apparently Preserved Left Ventricular Systolic Function: A 10-Year Observational Study. <b>2015</b> , 66, 738-44		1
1854	GYY4137 attenuates remodeling, preserves cardiac function and modulates the natriuretic peptide response to ischemia. <b>2015</b> , 87, 27-37		31
1853	Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. <b>2015</b> , 4,		119
1852	Heart failure with preserved ejection fraction: refocusing on diastole. <b>2015</b> , 179, 430-40		73
1851	Validaci[n de la Barcelona Bio-Heart Failure Risk Calculator en una cohorte de Boston. <b>2015</b> , 68, 80-81		4
1850	Cardiac troponin assays in the management of heart failure. <b>2015</b> , 441, 92-8		8
1849	Vectorcardiographic QRS area as a novel predictor of response to cardiac resynchronization therapy. <b>2015</b> , 48, 45-52		49
1848	Mechanisms and clinical consequences of untreated central sleep apnea in heart failure. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 72-84	15.1	86
1847	Personalized risk assessment of heart failure patients: more perspectives from transforming growth factor super-family members. <b>2015</b> , 443, 94-9		13
1846	Validation of the Barcelona Bio-Heart Failure Risk Calculator in a cohort from Boston. <b>2015</b> , 68, 80-1		2
1845	Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. <b>2015</b> , 48, 223-35		8o
1844	Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. <b>2015</b> , 17, 109-18		35
1843	Stage B heart failure: is it more common than we think?. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 267-9	15.1	4
1842	Simultaneous use of intravenous fluids and diuretics in patients hospitalized with heart failure: when the left hand does not know what the right hand is doing. <b>2015</b> , 3, 134-5		
1841	Correlations between serum intact parathyroid hormone (PTH) and N-terminal-probrain natriuretic peptide levels in elderly patients with chronic heart failure (CHF). <b>2015</b> , 60, 359-65		2
1840	Therapeutic potential of sildenafil in patients with chronic heart failure after cardiac surgery. <b>2015</b> , 5, 1-8		

1839	Effects of exercise training on neurovascular control and skeletal myopathy in systolic heart failure. <b>2015</b> , 308, H792-802		24
1838	Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. <b>2015</b> , 182, 168-70		54
1837	Reference Values for Right Ventricular Strain in Patients without Cardiopulmonary Disease: A Prospective Evaluation and Meta-Analysis. <b>2015</b> , 32, 787-96		68
1836	Critical impact of fitness in the prevention and treatment of heart failure. <b>2015</b> , 169, 194-6		6
1835	Revascularization in severe left ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 615-24	15.1	29
1834	Advance directives among hospitalized patients with heart failure. <b>2015</b> , 3, 112-21		57
1833	Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. <b>2015</b> , 131, 34-42		534
1832	The vulnerable phase after hospitalization for heart failure. <b>2015</b> , 12, 220-9		129
1831	Serum brain-derived neurotropic factor level predicts adverse clinical outcomes in patients with heart failure. <b>2015</b> , 21, 300-6		21
1830	Prognostic effect of carbohydrate antigen 125-guided therapy in patients recently discharged for acute heart failure (CHANCE-HF). Study design. <b>2015</b> , 68, 121-8		2
1829	Cardiorenal syndrome: misgivings about treatment options, clarity on prognosis. <b>2015</b> , 21, 116-8		1
1828	Efecto pron©stico de una estrategia terapŪtica guiada por los valores del antgeno carbohidrato 125 (CHANCE-HF). Dise <del>0</del> del estudio. <b>2015</b> , 68, 121-128		5
1827	Strain, strain rate, torsion, and twist: echocardiographic evaluation. <b>2015</b> , 17, 568		20
1826	Cardiotoxicity due to chemotherapy: role of cardiac imaging. <b>2015</b> , 17, 564		5
1825	Exercise-based rehabilitation for heart failure: systematic review and meta-analysis. <b>2015</b> , 2, e000163		145
1824	G-protein-coupled receptor kinase 2-mediated desensitization of adiponectin receptor 1 in failing heart. <b>2015</b> , 131, 1392-404		34
1823	NT-proBNP is superior to BNP for predicting first cardiovascular events in the general population: the Heinz Nixdorf Recall Study. <b>2015</b> , 183, 155-61		27
1822	Echocardiography and heart failure: a glimpse of the right heart. <b>2015</b> , 32 Suppl 1, S95-107		18

1821	Failure Treatment. <b>2015</b> , 128, 776-83.e4		52	
1820	Left ventricular non-compaction cardiomyopathy associated with epidermolysis bullosa simplex with muscular dystrophy and PLEC1 mutation. <b>2015</b> , 25, 165-8		22	
1819	Hyponatremia in acute decompensated heart failure: depletion versus dilution. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 480-92	15.1	91	
1818	Long-Term Mortality Rates in Acute De Novo Versus Acute-on-Chronic Heart Failure: From the Heart Function Assessment Registry Trial in Saudi Arabia. <b>2015</b> , 66, 837-44		16	
1817	Therapeutic adjustments in stage D heart failure: challenges and strategies. <b>2015</b> , 12, 15-23		2	
1816	The ratio of early transmitral flow velocity (E) to early mitral annular velocity (Em) predicts improvement in left ventricular systolic and diastolic function 1 year after catheter ablation for atrial fibrillation. <b>2015</b> , 17, 1051-8		9	
1815	A reappraisal of loop diuretic choice in heart failure patients. <b>2015</b> , 169, 323-33		62	
1814	Use of different types of angiotensin converting enzyme inhibitors and mortality in systolic heart failure. <b>2015</b> , 182, 90-6		6	
1813	Progression of cardiac involvement in patients with limb-girdle type 2 and Becker muscular dystrophies: a 9-year follow-up study. <b>2015</b> , 182, 403-11		27	
1812	Multiple biomarker strategy based on parathyroid hormone and natriuretic peptides testing for improved prognosis of chronic heart failure. <b>2015</b> , 64, 24-8		9	
1811	Evaluation and management of left ventricular noncompaction cardiomyopathy. 2015, 12, 61-7		6	
1810	Cardiovascular prevention in the cancer survivor. <b>2015</b> , 17, 484		6	
1809	Racial and Ethnic Differences in Heart Failure Etiology, Prognosis, and Management. <b>2015</b> , 9, 1		2	
1808	Diastolische Herzinsuffizienz. <b>2015</b> , 9, 315-328			
1807	Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure. <b>2015</b> , 22, 229-45		37	
1806	Current practice in patient selecting for long-term mechanical circulatory support. <b>2015</b> , 12, 120-9		6	
1805	Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west. <b>2015</b> , 131, 7-10		20	
1804	Full-Body MRI in Patients With an Implantable Cardioverter-Defibrillator: Primary Results of a Randomized Study. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 2581-2588	15.1	50	

1803	Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. <b>2015</b> , 8, 709-16	7
1802	VE/VCO slope and its prognostic value in patients with chronic heart failure. <b>2015</b> , 9, 1407-1412	14
1801	Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. <b>2015</b> , 36, 3227-37	135
1800	Soluble ST2 in Ventricular Dysfunction. <b>2015</b> , 69, 139-59	4
1799	Nutritional Risk Index predicts mortality in hospitalized advanced heart failure patients. <b>2015</b> , 34, 1385-9	46
1798	Risk factors for heart failure during pregnancy among Chinese women with cardiac disease. <b>2015</b> , 130, 266-9	4
1797	Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction. <b>2015</b> , 36, 2733-41	39
1796	The role of metabolic syndrome in heart failure. <b>2015</b> , 36, 2630-4	66
1795	Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of Bo. <b>2015</b> , 8, 862-70	64
1794	Quality Improvement Implementation: Improving Reproducibility in the Echocardiography Laboratory. <b>2015</b> , 28, 959-68	33
1793	Regional differences in use and outcomes of left ventricular assist devices: Insights from the Interagency Registry for Mechanically Assisted Circulatory Support Registry. <b>2015</b> , 34, 912-20	9
1792	Task Force 7: Pediatric Cardiology Fellowship Training in Pulmonary Hypertension, Advanced Heart Failure, and Transplantation. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 732-9	6
1791	Subclinical Cardiotoxicity Associated With Cancer Therapy: Early Detection and Future Directions.  Journal of the American College of Cardiology, <b>2015</b> , 65, 2523-5	17
1790	Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure. <b>2015</b> , 3, 629-36	55
1789	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 278-307	128
1788	Beta-Blockers in Acute Heart Failure: Do They Cause Harm?. <b>2015</b> , 3, 654-6	3
1787	Current and emerging modalities for detection of cardiotoxicity in cardio-oncology. 2015, 11, 471-84	12
1786	Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries. <b>2015</b> , 3, 579-90	42

1785	TĒnicas de imagen en la insuficiencia cardiaca aguda. <b>2015</b> , 68, 612-623	1
1784	Quality of medical care for persons with serious mental illness: A comprehensive review. <b>2015</b> , 165, 227-35	90
1783	End-of-life Heart Failure Care in the United States. <b>2015</b> , 11, 615-23	10
1782	Echocardiographic Findings Predict In-Hospital and 1-Year Mortality in Left-Sided Native Valve Staphylococcus aureus Endocarditis: Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study. <b>2015</b> , 8, e003397	27
1781	Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction. <b>2015</b> , 128, 1102-1108.e6	19
1780	How to differentiate the etiology of LV dysfunction as to whether it is "ischemic cardiomyopathy" or "dilated non-ischemic cardiomyopathy"? Invasive coronary and myocardial assessment is the approach of first choice. <b>2015</b> , 22, 953-6	1
1779	Soluble CD146, a new endothelial biomarker of acutely decompensated heart failure. <b>2015</b> , 199, 241-7	30
1778	Pulmonary Hypertension in Heart Failure. Epidemiology, Right Ventricular Function, and Survival. <b>2015</b> , 192, 1234-46	148
1777	Future of Sleep-Disordered Breathing Therapy Using a Mechanistic Approach. 2015, 31, 880-8	2
1776	2015 ACC Health Policy Statement on Cardiovascular Team-Based Care and the Role of Advanced Practice Providers. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 2118-36	57
1775	Comparison of three diuretic treatment strategies for patients with acute decompensated heart failure. <b>2015</b> , 40, 1115-20	13
1774	Cardiac resynchronization therapy is appropriate for all patients requiring chronic right ventricular pacing: the pro perspective. <b>2015</b> , 7, 433-44	1
1773	Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. <b>2015</b> , 117, 207-19	373
1772	[Key messages for the initial management of the elderly patient with acute heart failure]. <b>2015</b> , 50, 185-94	5
1771	Team-based Care for Cardiac Rehabilitation and Exercise Training in Heart Failure. <b>2015</b> , 11, 431-49	4
1770	Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 2691-8	66
1769	Evolution of the American College of Cardiology/American Heart Association Clinical Guidelines.  Journal of the American College of Cardiology, 2015, 65, 2726-34	17
1768	Why is heart failure so important in the 21st century?. <b>2015</b> , 17, 122-4	8

1767	Improving Outcomes for Breast Cancer Survivors. <b>2015</b> ,	7
1766	Subcutaneous implantable cardioverter-defibrillator: First single-center experience with other cardiac implantable electronic devices. <b>2015</b> , 12, 2230-8	33
1765	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium. <b>2015</b> , 36, 1851-77	26
1764	Team-based Care for Patients Hospitalized with Heart Failure. <b>2015</b> , 11, 359-70	5
1763	Team-Based Care for Managing Cardiac Comorbidities in Heart Failure. <b>2015</b> , 11, 407-17	6
1762	2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American	71
1761	Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. <b>2015</b> , 21, 741-50	22
1760	Iron deficiency and cardiovascular disease. <b>2015</b> , 12, 659-69	147
1759	QRS morphology as a predictor of the response to cardiac resynchronisation therapy: fact or fashion?. <b>2015</b> , 101, 1441-3	2
1758	Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure. <b>2015</b> , 8, 880-6	82
1757	Intravenous home inotropic use is safe in pediatric patients awaiting transplantation. 2015, 8, 64-70	16
1756	Impact of cardiovascular treatments and systolic dysfunction on nutritional risk in patients with ischemic and valvular heart disease. <b>2015</b> , 34, 159-66	4
1755	Digoxin withdrawal worsens clinical status in stable patients with heart failure receiving optimal contemporaneous therapya randomized controlled trial. <b>2015</b> , 21, 779-81	4
1754	Team-Based Care for Outpatients with Heart Failure. <b>2015</b> , 11, 379-405	19
1753	Vinculin network-mediated cytoskeletal remodeling regulates contractile function in the aging heart. <b>2015</b> , 7, 292ra99	63
1752	End-of-Life Care and Treatment Preferences Among Adults with Congenital Heart Disease. <b>2015</b> , 119-129	
1751	Guilt by AssociationA Closer Look at Calcium, Heart Failure, and Mortality. <b>2015</b> , 21, 628-9	1
1750	Heart Failure with Preserved Ejection Fraction. <b>2015</b> , 4, 283-296	

1749	Congestive Heart Failure. <b>2015</b> , 33, 553-62	9
1748	Thyroid function on admission and outcome in patients hospitalized for acute decompensated heart failure. <b>2015</b> , 66, 205-11	23
1747	The perils of surrogate endpoints. <b>2015</b> , 36, 2212-8	41
1746	Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure. <b>2015</b> , 16, 4226-49	16
1745	Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study. <b>2015</b> , 79, 937-45	22
1744	Biomarkers in acute heart failure. <b>2015</b> , 68, 514-25	11
1743	Changes in Drug Utilization and Outcome With Cardiac Resynchronization Therapy: A MADIT-CRT Substudy. <b>2015</b> , 21, 541-7	7
1742	Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality. <b>2015</b> , 184, 512-513	3
1741	The International ST2 Consensus Panel: Introduction. <b>2015</b> , 115, 1B-2B	4
1740	Evolving role of galectin-3 as a cardiac biomarker: heart failure with preserved ejection fraction and renal function, important pieces of the puzzle. <b>2015</b> , 3, 253-6	10
1739	Testosterone may influence left ventricular diastolic function depending on previous myocardial infarction and smoking. <b>2015</b> , 186, 67-71	5
1738	Biomarcadores en la insuficiencia cardiaca aguda. <b>2015</b> , 68, 514-525	24
1737	Heart failure with preserved ejection fraction in the elderly: scope of the problem. 2015, 83, 73-87	94
1736	Long-term outcomes of catheter ablation of atrial fibrillation in dilated cardiomyopathy. <b>2015</b> , 190, 227-32	9
1735	Effect of Chronic Heart Rate Reduction by I(f) Current Inhibitor Ivabradine on Left Ventricular Remodeling and Systolic Performance in Middle-Aged Rats With Postmyocardial Infarction Heart Failure. <b>2015</b> , 20, 299-312	6
1734	Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. <b>2015</b> , 16, 535.e1-12	181
1733	Increased cardiovascular stiffness and impaired age-related functional status. <b>2015</b> , 70, 545-53	8
1732	Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity. <b>2015</b> , 13, 519-27	10

1731	A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk. <b>2015</b> , 17, 38		10
1730	The importance of sleep-disordered breathing in cardiovascular disease. <b>2015</b> , 104, 705-18		84
1729	ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. <b>2015</b> , 115, 70B-5B		62
1728	Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. <b>2015</b> , 115, 901-6		66
1727	Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. <b>2015</b> , 445, 155-60		80
1726	The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure. <b>2015</b> , 21, 233-9		13
1725	Serial ST2 testing in hospitalized patients with acute heart failure. <b>2015</b> , 115, 32B-7B		26
1724	Aplicaciones de la telemedicina en el seguimiento de insuficiencia card <b>i</b> ca: experiencia en una unidad integral. <b>2015</b> , 22, 188-195		
1723	Metabolite profiles in heart failure: looking for unique signatures in a heterogeneous syndrome. Journal of the American College of Cardiology, <b>2015</b> , 65, 1521-4	15.1	13
1722	Dietary sodium adherence is poor in chronic heart failure patients. <b>2015</b> , 21, 323-9		24
1721	Addition of angiotensin-converting enzyme inhibitors to beta-blockers has a distinct effect on hispanics compared with african americans and whites with heart failure and reduced ejection fraction: a propensity score-matching study. <b>2015</b> , 21, 448-56		5
1720	Patient selection in heart failure with preserved ejection fraction clinical trials. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1668-1682	15.1	89
1719	Epigenetics of the failing heart. <b>2015</b> , 20, 435-59		14
1718	Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure. <b>2015</b> , 12, 7-14		10
1717	Small steps for idiopathic giant cell myocarditis. <b>2015</b> , 12, 263-8		10
1716	Sleep-disordered breathing as a modifiable risk factor for cardiovascular disease. <b>2015</b> , 4, 34-41		
1715	The Presentation of Respiratory Failure in Elderly Individuals. <b>2015</b> , 4, 166-173		0
1714	[Heart failure with preserved ejection fraction (HFpEF)]. <b>2015</b> , 157, 45-8		

1713 Natriuretic Peptide Goal-Directed Therapy: Are We There Yet?. **2015**, 3, 80-88

1712	ST2 in Heart Failure: Where Does This New Marker Fit in?. <b>2015</b> , 3, 55-61		
1711	COCATS 4 Task Force 12: Training in Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1866-76	15.1	10
1710	Managing comorbidities in patients with chronic heart failure: first, do no harm. <b>2015</b> , 15, 171-84		10
1709	Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials. <b>2015</b> , 13, 10		22
1708	Multi-state models for investigating possible stages leading to bipolar disorder. <b>2015</b> , 3, 5		7
1707	Pharmacotherapy of heart failure with preserved ejection fraction. <b>2015</b> , 35, 351-60		17
1706	Targeting the sarcomere to correct muscle function. <b>2015</b> , 14, 313-28		76
1705	Discoveries in peripartum cardiomyopathy. <b>2015</b> , 25, 401-6		8
1704	Assessing the use of international classification of diseases-10th revision codes from the emergency department for the identification of acute heart failure. <b>2015</b> , 3, 386-391		25
1703	Adiponectin is independently associated with NT-proBNP: The Multi-Ethnic Study of Atherosclerosis. <b>2015</b> , 25, 780-6		6
1702	Heart failure risk prediction in childhood cancer survivors: where is our crystal ball?. <b>2015</b> , 33, 379-80		
1701	Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. <b>2015</b> , 21, 519-34		195
1700	The Combined Incremental Prognostic Value of LVEF, Late Gadolinium Enhancement, and Global Circumferential Strain Assessed by CMR. <b>2015</b> , 8, 540-549		56
1699	Association of indoxyl sulfate with heart failure among patients on hemodialysis. <b>2015</b> , 10, 111-9		66
1698	Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1231-1248	15.1	252
1697	The impact of telemedicine in cardiac critical care. <b>2015</b> , 31, 305-17		9
1696	Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. <b>2015</b> , 104, 491-9		42

1695	[New therapy concepts for heart failure with preserved ejection fraction]. 2015, 40, 194-205	1
1694	ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. <b>2015</b> , 115, 26B-31B	54
1693	Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure. <b>2015</b> , 3, 214-23	14
1692	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <b>2015</b> , 385, 2067-76	551
1691	Medical Treatment of Heart Failure and Coronary Heart Disease. <b>2015</b> , 533-560	
1690	Digoxin-associated mortality: a systematic review and meta-analysis of the literature. <b>2015</b> , 36, 1831-8	164
1689	State of the Art: Newer biomarkers in heart failure. <b>2015</b> , 17, 559-69	116
1688	Prediction of elevated left ventricular filling pressures in patients with preserved ejection fraction using longitudinal deformation indices of the left ventricle. <b>2015</b> , 16, 1154-61	5
1687	Regular exercise improves weight stability in patients with advanced heart failure. <b>2015</b> , 9, 297-304	2
1686	Quantitative assessment of cardiac mechanical dyssynchrony and prediction of response to cardiac resynchronization therapy in patients with nonischaemic dilated cardiomyopathy using gated myocardial perfusion SPECT. <b>2015</b> , 36, 494-501	16
1685	Comparison of metolazone versus chlorothiazide in acute decompensated heart failure with diuretic resistance. <b>2015</b> , 33, 42-9	24
1684	Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis. <b>2015</b> , 31, 792-9	20
1683	Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. <b>2015</b> , 21, 240-9	37
1682	LCZ696 : a new paradigm for the treatment of heart failure?. <b>2015</b> , 16, 435-46	24
1681	Symptom perceptions and self-care behaviors in patients who self-manage heart failure. <b>2015</b> , 30, E1-7	26
1680	The role of biventricular pacing in the prevention and therapy of pacemaker-induced cardiomyopathy. <b>2015</b> , 20, 224-39	10
1679	BNP in children with congenital cardiac disease: is there now sufficient evidence for its routine use?. <b>2015</b> , 25, 424-37	31
1678	Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure Study. <b>2015</b> , 147, 637-645	54

1677	Left ventricular non-compaction cardiomyopathy. <b>2015</b> , 386, 813-25		276
1676	Evolving therapies for myocardial ischemia/reperfusion injury. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1454-71	15.1	548
1675	One-point carotid wave intensity predicts cardiac mortality in patients with congestive heart failure and reduced ejection fraction. <b>2015</b> , 31, 1369-78		5
1674	Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review. <b>2015</b> , 20, 643-53		50
1673	Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). <b>2015</b> , 200, 15-9		11
1672	An Update on Inpatient Hypertension Management. <b>2015</b> , 17, 94		13
1671	Chronic Inotropic Therapy in the Current Era: Old Wines With New Pairings. 2015, 8, 843-6		14
1670	Implantable Cardioverter-Defibrillator Use in Older Adults: Proceedings of a Hartford Change AGEnts Symposium. <b>2015</b> , 8, 437-46		19
1669	Admission hypoxia-inducible factor 1\(\textit{Hevels}\) and in-hospital mortality in patients with acute decompensated heart failure. <b>2015</b> , 15, 79		6
1668	Impaired fasting glucose and left ventricular diastolic dysfunction in middle-age adults: a retrospective cross-sectional analysis of 2971 subjects. <b>2015</b> , 14, 119		17
1667	Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2092-2100	15.1	31
1666	Prognostic Value of Estimated Plasma Volume in Heart Failure. <b>2015</b> , 3, 886-93		66
1665	Analytical and clinical evaluation of a rapid quantitative lateral flow immunoassay for measurement of soluble ST2 in human plasma. <b>2015</b> , 451, 310-5		23
1664	Inequalities in the Access to Advanced Therapy in Heart Failure. <b>2015</b> , 11, 523-8		O
1663	Diagnostic utility of BNP, corin and furin as biomarkers for cardiovascular complications in type 2 diabetes mellitus patients. <b>2015</b> , 20, 460-9		20
1662	Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology. <b>2015</b> , 17, 60		12
1661	Heart Failure in Post-Acute and Long-Term Care: Evidence and Strategies to Improve Transitions, Clinical Care, and Quality of Life. <b>2015</b> , 16, 825-31		8
1660	Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP. <b>2015</b> , 68, 1075-84		12

Predictors of lack of improvement in the left ventricular ejection fraction in patients with 1659 congestive heart failure 18 months after commencement of a disease management program: A prospective observational study. 2015, 27, 164-169 Evaluating the Effects of an Interdisciplinary Practice Model with Pharmacist Collaboration on HIV 1658 14 Patient Co-Morbidities. 2015, 29, 445-53 Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist 41 Therapy in Patients With Heart Failure. 2015, 314, 1973-5 Plasma Neprilysin Concentrations: A New Prognostic Marker in Heart Failure?. 2015, 68, 1053-5 Herzinsuffizienz als Risikofaktor filden akuten ischinischen Schlaganfall Eine Kombination mit 1655 vergleichsweise schlechter Prognose. 2015, 13, 110-114 1654 Current Approach to Decongestive Therapy in Acute Heart Failure. 2015, 12, 367-78 24 Psychometric Evaluation of Two Appetite Questionnaires in Patients With Heart Failure. 2015, 21, 954-8 11 The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis 1652 30 and management. 2015, 13, 1017-30 Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations 28 1651 From the Heart Failure Society of America Guideline Committee. 2015, 21, 674-93 1650 Digoxin: its role in contemporary medicine. 2015, 91, 514-8 13 Incremental large and small muscle mass exercise in patients with heart failure: evidence of 1649 15 preserved peripheral haemodynamics and metabolism. 2015, 213, 688-99 Heart failure symptom clusters and functional status - a cross-sectional study. 2015, 71, 1274-87 1647 Primary Prevention of Heart Failure in Older Adults. 2015, 3, 529-530 2 1646 Prevention and Treatment of Cardiac Dysfunction in Breast Cancer Survivors. 2015, 862, 213-30 Duration of Heart Failure Is an Important Predictor of Outcomes After Mechanical Circulatory 1645 15 Support. 2015, 8, 953-9 1644 Gender Differences in Cardiovascular Drugs. **2015**, 29, 403-10 24 Usefulness of N-Terminal Pro-Brain Natriuretic Peptide to Predict Mortality in Adults With 1643 23 Congenital Heart Disease. 2015, 116, 1425-30 1642 MitraClip and Transcatheter Aortic Valve Implantation (TAVI): State of the Art 2015. 2015, 12, 379-88

## (2015-2015)

1641	Emergence of Nonobstructive Coronary Artery Disease: A Woman's Problem and Need for Change in Definition on Angiography. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 1918-33	15.1	199
1640	Multidisciplinary management of chronic heart failure: principles and future trends. <b>2015</b> , 37, 2225-33		24
1639	Biomarkers for Heart Failure in Asia. <b>2015</b> , 11, 551-61		2
1638	Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. <b>2015</b> , 351, h4984		33
1637	Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?. <b>2015</b> , 17, 64		12
1636	Identification of Emergency Department Patients With Acute Heart Failure at Low Risk for 30-Day Adverse Events: The STRATIFY Decision Tool. <b>2015</b> , 3, 737-47		52
1635	Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: Results From the ROADMAP Study. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 1747-1761	15.1	228
1634	Automatically finding relevant citations for clinical guideline development. 2015, 57, 436-45		7
1633	Translational aspects of cardiac cell therapy. <b>2015</b> , 19, 1757-72		20
1632	Diastolic dysfunction in spontaneous type 2 diabetes rhesus monkeys: a study using echocardiography and magnetic resonance imaging. <b>2015</b> , 15, 59		19
1631	Prognostic and Therapeutic Implications of Frailty in Older Adults with Heart Failure. <b>2015</b> , 17, 92		20
1630	Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. <b>2015</b> , 21, 4048-54		36
1629	Skeletal muscle electrical stimulation improves baroreflex sensitivity and heart rate variability in heart failure rats. <b>2015</b> , 193, 92-6		10
1628	Hyponatremia during hospitalization and in-hospital mortality in patients hospitalized from heart failure. <b>2015</b> , 15, 88		15
1627	Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. <b>2015</b> , 101, 1881-8		85
1626	New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. <b>2015</b> , 66, 731-8		46
1625	The Genetic Challenges and Opportunities in Advanced Heart Failure. <b>2015</b> , 31, 1338-50		6
1624	Most Heart Failure Patients Die from Pump Failure: Implications for Therapy. <b>2015</b> , 15, 387-93		5

1623	Serelaxin a novel treatment for acute heart failure. <b>2015</b> , 8, 549-57		3
1622	Cost-effectiveness of home versus clinic-based management of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized trial cohort - The WHICH? study (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care). 2015,		34
1621	Pharmacogenomics of hypertension and heart disease. <b>2015</b> , 17, 586		15
1620	Cardiorenal syndrome. <b>2015</b> , 17, 36-45		
1619	A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model. <b>2015</b> , 12, 2069-77		52
1618	Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure: Findings From Get With The Guidelines-Heart Failure Registry. Journal of the American College of Cardiology, <b>2015</b> , 66, 917-26	15.1	101
1617	Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure: Awaiting the Uptick. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 927-9	15.1	2
1616	Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 905-14	15.1	253
1615	Inherited cardiomyopathiesNovel therapies. <b>2015</b> , 155, 36-48		13
1614	Estimated pulmonary artery systolic pressure and self-reported physical function in patients on hemodialysis. <b>2015</b> , 41, 313-9		2
1613	Identifying cancer patients at risk for cardiotoxicity. <b>2015</b> , 11, 2077-91		4
1612	Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. <b>2015</b> , 8, 1121-1129		38
1611	Unsolved challenges in diuretic therapy for acute heart failure: a focus on diuretic response. <b>2015</b> , 13, 1075-8		7
1610	Expanding the role of cardiac biomarkersnatriuretic peptides and troponinsfurther in pre-Stage A. <b>2015</b> , 38, 11-2		
1609	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <b>2015</b> , 351, h4451		172
1608	Consider safety when managing co-morbid conditions in heart failure patients. <b>2015</b> , 31, 397-401		
1607	Candidate biomarkers in heart failure with reduced and preserved ejection fraction. <b>2015</b> , 20, 258-65		5
1606	Adherence to clinical guidelines in heart failure (HF) outpatients: Impact of an interprofessional HF team on evidence-based medication use. <b>2015</b> , 29, 483-7		6

1605	Management of Heart Failure. <b>2015</b> ,	1	
1604	Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis. <b>2015</b> , 10, 1119-27	19	
1603	Can cardio-oncology deliver better care internationally?. <b>2015</b> , 11, 2259-62	1	
1602	Heart failure: new approaches to an old problem. <b>2015</b> , 37, 2151-2		
1601	Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management. <b>2015</b> , 50, 787-99	34	
1600	Socioeconomic Inequalities in Heart Failure. <b>2015</b> , 11, 507-13	29	
1599	Are Hospitalizations for Heart Failure the Great Equalizer?. <b>2015</b> , 3, 539-541	5	
1598	Tackling Early Heart Failure Deaths and Readmissions by Estimating Congestion. <b>2015</b> , 3, 894-5	6	
1597	What's Harder: Seeing a Doctor or Reducing Readmissions?. <b>2015</b> , 3, 774-6		
1596	Improving outcomes in heart failure: a personal perspective. <b>2015</b> , 36, 3467-70	25	
1595	Evolving health care strategy: A look into the future. <b>2015</b> , 78, 633-4		
1594	[Update of treatment in chronic heart failure]. 2015, 145, 545-50	1	
1593	Understanding Heart Failure. <b>2015</b> , 7, 557-75	14	
1592	Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip. <b>2015</b> , 46, 3340-7	57	
1591	Clinical Update on Nursing Home Medicine: 2015. <b>2015</b> , 16, 911-22	1	
1590	Exercise limitation associated with asymptomatic left ventricular impairment: analogy with stage B heart failure. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 257-66	34	
1589	Hospital readmission in heart failure, a novel analysis of a longstanding problem. <b>2015</b> , 20, 251-8	24	
1588	Heart failure: mitochondrial dysfunction and oxidative stress in CHF. <b>2015</b> , 12, 6-8	63	

1587	Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials. <b>2015</b> , 28, 576-85	24
1586	Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. <b>2015</b> , 3, 50-58	62
1585	Roadmap to inpatient heart failure management. <b>2015</b> , 65, 26-31	3
1584	Prognostic value of estimating functional capacity with the use of the duke activity status index in stable patients with chronic heart failure. <b>2015</b> , 21, 44-50	28
1583	Effect of renal function on prognosis in chronic heart failure. <b>2015</b> , 115, 62-8	15
1582	Understanding physical activity and exercise behaviors in patients with heart failure. <b>2015</b> , 44, 2-8	17
1581	Relation of dyspnea severity on admission for acute heart failure with outcomes and costs. <b>2015</b> , 115, 75-81	30
1580	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. <b>2015</b> , 443, 29-38	58
1579	Novedades en el tratamiento farmacol⊡gico de la insuficiencia card⊞ca avanzada. <b>2015</b> , 50, 12-16	O
1578	Early management of patients with acute heart failure: state of the art and future directionsa consensus document from the SAEM/HFSA acute heart failure working group. <b>2015</b> , 22, 94-112	30
1577	Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. <b>2015</b> , 29, 241-6	19
1576	Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction?. <b>2015</b> , 443, 9-16	17
1575	Do Intravenous Nitrates Improve Dyspnea in Acute Heart Failure Syndromes More Than Alternative Pharmacologic Interventions?. <b>2015</b> , 66, 27-9	3
1574	Galectin-3 and heart failure: prognosis, prediction & clinical utility. <b>2015</b> , 443, 48-56	46
1573	Hospital nurses' comfort in and frequency of delivering heart failure self-care education. <b>2015</b> , 14, 431-40	13
1572	Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. <b>2015</b> , 443, 17-24	63
1571	The war against heart failure: the Lancet lecture. <b>2015</b> , 385, 812-24	478
1570	Lack of evidence for intravenous vasodilators in ED patients with acute heart failure: a systematic review. <b>2015</b> , 33, 133-41	38

## (2016-2015)

1569	consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group. <b>2015</b> , 21, 27-43	55
1568	Soluble ST2 in heart failure. <b>2015</b> , 443, 57-70	88
1567	Mitochondrial oxidative metabolism and uncoupling proteins in the failing heart. <b>2015</b> , 20, 227-49	77
1566	A 70-year-old woman with heart failure with preserved ejection fraction. <b>2015</b> , 187, 510-511	2
1565	Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials. <b>2015</b> , 20, 69-80	27
1564	Prognostic Significance of Frontal QRS-T Angle in Patients with Idiopathic Dilated Cardiomyopathy. <b>2016</b> , 129, 1904-11	6
1563	Effectiveness of Ultrafiltration in Patients with Congestive Heart Failure. 2016,	
1562	Caregiver experiences of providing care to adult individuals living with a left ventricular assist device: a qualitative systematic review protocol. <b>2016</b> , 14, 44-54	
1561	Intratherapy Cardiology Evaluation. <b>2016</b> , 379-395	
1560	Prognostic Value of Pulmonary Vascular Resistance by Magnetic Resonance in Systolic Heart Failure. <b>2016</b> , 106, 226-35	6
1559	The Clinical Hillian of Circulatine Missessatisles Massacranes in Heart Failure Debiants 2015 04	
	The Clinical Utility of Circulating Microparticles Measurement in Heart Failure Patients. <b>2016</b> , 04,	
1558	Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart failure management. <b>2016</b> , 57, 354-9	9
1558 1557	Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart	9
	Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart failure management. <b>2016</b> , 57, 354-9	
1557	Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart failure management. <b>2016</b> , 57, 354-9  Management of Congestion and Diuretic Resistance in Heart Failure. <b>2016</b> , 2, pocj.5000200	3
1557 1556	Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart failure management. <b>2016</b> , 57, 354-9  Management of Congestion and Diuretic Resistance in Heart Failure. <b>2016</b> , 2, pocj.5000200  The Danish Heart Failure Registry. <b>2016</b> , 8, 497-502  Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme	3
1557 1556 1555	Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart failure management. 2016, 57, 354-9  Management of Congestion and Diuretic Resistance in Heart Failure. 2016, 2, pocj.5000200  The Danish Heart Failure Registry. 2016, 8, 497-502  Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?. 2016, 2, 47-50	3 19 3

1551	Heart Failure Epidemic: an Expected Phenomenon. <b>2016</b> , 46, 610-612	4
1550	Real-Time Assessment of Autonomic Nerve Activity During Adaptive Servo-Ventilation Support or Waon Therapy. <b>2016</b> , 57, 511-4	6
1549	Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure?. <b>2016</b> , 2, 35-39	7
1548	Troponin elevations in patients with chronic cardiovascular disease: An analysis of current evidence and significance. <b>2016</b> , 19, 321-7	6
1547	Pursuing early catheter ablation to treat atrial fibrillation in the congestive heart failure population: significance of the AATAC trial results. <b>2016</b> , 8, 1913-5	
1546	Listen to patient's complaints more than ECHO. <b>2016</b> , 8, E1688-E1690	
1545	The role of coronary artery bypass grafting in patients with ischemic cardiomyopathy in the current era. <b>2016</b> , 8, E1032-E1033	1
1544	Integrated Care for Heart Failure in Primary Care. <b>2016</b> ,	
1543	The association between cognitive function and objective adherence to dietary sodium guidelines in patients with heart failure. <b>2016</b> , 10, 233-41	16
1542	The Modification Effect of Influenza Vaccine on Prognostic Indicators for Cardiovascular Events after Acute Coronary Syndrome: Observations from an Influenza Vaccination Trial. <b>2016</b> , 2016, 4097471	5
1541	Electrocardiography as the First Step for the Further Examination of Cardiac Involvement in Myasthenia Gravis. <b>2016</b> , 2016, 8058946	7
1540	Role of Neutrophil Gelatinase-Associated Lipocalin in the Diagnosis and Early Treatment of Acute Kidney Injury in a Case Series of Patients with Acute Decompensated Heart Failure: A Case Series. <b>2016</b> , 2016, 3708210	11
1539	Diagnostic Utility of ANG in Coronary Heart Disease Complicating Chronic Heart Failure: A Cross-Sectional Study. <b>2016</b> , 2016, 2740826	4
1538	The Current Approach to Diagnosis and Management of Left Ventricular Noncompaction Cardiomyopathy: Review of the Literature. <b>2016</b> , 2016, 5172308	40
1537	Molecular Imaging for Comparison of Different Growth Factors on Bone Marrow-Derived Mesenchymal Stromal Cells' Survival and Proliferation In Vivo. <b>2016</b> , 2016, 1363902	8
1536	Cardiac 123I-MIBG Parameters at 4 Hours Derived from Earlier Acquisition Times. <b>2016</b> , 2, 21-29	2
1535	Pathophysiology of Heart Failure and an Overview of Therapies. <b>2016</b> , 271-339	1
1534	Chronic Heart Failure and Comorbid Renal Dysfunction - A Focus on Type 2 Cardiorenal Syndrome. <b>2016</b> , 12, 186-94	10

1533	Depressive Symptoms among Patients with Heart Failure in Korea: An Integrative Review. <b>2016</b> , 4,	3
1532	Prevalence of Heart Failure and Adherence to Process Indicators: Which Socio-Demographic Determinants are Involved?. <b>2016</b> , 13, 238	17
1531	Evaluating the scripts and thresholds of general practitioners for diagnosing heart failure in elderly people. <b>2016</b> , 17, 86	
1530	Heart Failure as a Comorbidity of Diabetes: Role of Dipeptidyl Peptidase 4. <b>2016</b> , 23, 147-54	9
1529	Copeptin in Heart Failure. <b>2016</b> , 73, 29-64	14
1528	Interventions to improve evidence-based prescribing in heart failure. 2016,	
1527	Baseline Characteristics and Prescription Patterns of Standard Drugs in Patients with Angiographically Determined Coronary Artery Disease and Renal Failure (CAD-REF Registry). <b>2016</b> , 11, e0148057	6
1526	Financial Burden and Impoverishment Due to Cardiovascular Medications in Low and Middle Income Countries: An Illustration from India. <b>2016</b> , 11, e0155293	4
1525	Metrics of High-Density Lipoprotein Function and Hospital Mortality in Acute Heart Failure Patients. <b>2016</b> , 11, e0157507	19
1524	Comorbid Depression and Heart Failure: A Community Cohort Study. <b>2016</b> , 11, e0158570	23
1523	The Pathophysiology of Heart Failure in Children: The Basics. <b>2016</b> , 12, 99-103	8
1522	Relationship between Statin Utilization and Socioeconomic Deprivation in Hungary. 2016, 7, 66	16
1521	Nutrition and Cardiovascular Disease: Finding the Perfect Recipe for Cardiovascular Health. <b>2016</b> , 8,	51
1520	Heart Failure: Diagnosis, Management and Utilization. <b>2016</b> , 5,	148
1519	EFFECT OF TRIPTOLIDE ON PROLIFERATION AND APOPTOSIS OF ANGIOTENSIN II-INDUCED CARDIAC FIBROBLASTS A PRELIMINARY STUDY. <b>2017</b> , 14, 145-154	2
1518	The Mechanism of Action of LCZ696. <b>2016</b> , 2, 40-46	30
1517	Health Care Costs for Patients with Heart Failure Escalate Nearly 3-Fold in Final Months of Life. <b>2016</b> , 22, 1446-1456	15
1516	A Cycle Ergometer Exercise Program Improves Exercise Capacity and Inspiratory Muscle Function in Hospitalized Patients Awaiting Heart Transplantation: a Pilot Study. <b>2016</b> , 31, 389-395	6

1515	Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date. <b>2016</b> , 10, 1627-39	11
1514	Impact of Exercise Training on Peak Oxygen Uptake and its Determinants in Heart Failure with Preserved Ejection Fraction. <b>2016</b> , 2, 95-101	20
1513	Antineutrophil Cytoplasmic Antibodies Associated With Infective Endocarditis. 2016, 95, e2564	29
1512	Effective Strategies in Reducing Rehospitalizations in Patients With Heart Failure. <b>2016</b> , 23, e799-804	7
1511	Treatment of Heart Failure With Reduced Ejection Fraction-Recent Developments. 2016, 23, e531-49	1
1510	Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Chronic Heart Failure. <b>2016</b> , 17, S20-34	15
1509	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <b>2016</b> , 23, 922-31	7
1508	Patient-centered care for left ventricular assist device therapy: current challenges and future directions. <b>2016</b> , 31, 313-20	12
1507	In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). <b>2016</b> , 41, 424-31	15
1506	A remote monitoring program evaluation: a retrospective study. <b>2016</b> , 22, 978-984	1
1505	A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. <b>2016</b> , 17 Suppl 1, S93-S104	31
1504	Addition of beta-blockers to digoxin is associated with improved 1- and 10-year survival of patients hospitalized due to decompensated heart failure. <b>2016</b> , 221, 198-204	5
1503	Heart Failure After Myocardial Infarction is Associated With Increased Risk of Cancer. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 265-271	85
1502	Putting Together the Pieces of the Natriuretic Peptide Puzzle. <b>2016</b> , 4, 670-3	5
1501	Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION. <b>2016</b> , 4, 617-24	7
1500	Angiotensin-receptor-neprilysin inhibition. <b>2016</b> , 11, 5-8	
1499	European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. <b>2016</b> , 18, 613-25	316
1498	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice	45

1497	Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. <b>2016</b> , 22, 670-1	О
1496	A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate . <b>2016</b> , 37, 3130-3134	3
1495	BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure. <b>2016</b> , 105, 1021-1029	13
1494	Cardiovascular complications of anorexia nervosa: A systematic review. <b>2016</b> , 49, 238-48	94
1493	Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center. <b>2016</b> , 36, 174-86	27
1492	Serum Sclerostin as an Independent Marker of Peripheral Arterial Stiffness in Renal Transplantation Recipients: A Cross-Sectional Study. <b>2016</b> , 95, e3300	26
1491	Clinical Usefulness of a Mobile Application for the Appropriate Selection of the Antiarrhythmic Device in Heart Failure. <b>2016</b> , 39, 696-702	7
1490	Temporal trends in nitrate utilization for acute heart failure in elderly emergency patients: A single-centre observational study. <b>2016</b> , 109, 449-56	4
1489	2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 525-568	38
1488	Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 189-99	60
1487	Decongestion in Acute Heart Failure: Does the End Justify the Means?. <b>2016</b> , 4, 589-590	4
1486	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <b>2016</b> , 18, 306-13	26
1485	Genetic Variants in the Vicinity of LGALS-3 Gene and LGALS-3 mRNA Expression in Advanced Carotid Atherosclerosis: An Exploratory Study. <b>2016</b> , 30, 1150-1157	8
1484	Preliminary investigation of multiparametric strain Z-score (MPZS) computation using displacement encoding with simulated echoes (DENSE) and radial point interpretation method (RPIM). <b>2016</b> , 44, 993-1002	7
1483	Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction. <b>2016</b> , 34, 172-9	2
1482	Home-based cardiac rehabilitation for people with heart failure: A systematic review and meta-analysis. <b>2016</b> , 221, 963-9	55
1481	The prognostic combined role of B-type natriuretic peptide, blood urea nitrogen and congestion signs persistence in patients with acute heart failure. <b>2016</b> , 17, 818-27	12

1479	T-peak to T-end Interval Predicts Appropriate Shocks in Patients with Heart Failure Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prophylaxis. <b>2016</b> ,	6
1478	Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits. <b>2016</b> , 70, 537-53	6
1477	Heart Rate and VID2 Concordance in Continuous-Flow Left Ventricular Assist Devices. <b>2016</b> , 48, 363-7	9
1476	PARP inhibition and postinfarction myocardial remodeling. <b>2016</b> , 217 Suppl, S52-9	12
1475	Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection Fraction. <b>2016</b> , 1, 207-221	27
1474	End of the Road for Vagus Nerve Stimulation?. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 159-60	
1473	Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent. <b>2016</b> , 24, 41-7	10
1472	Cardiac Abnormalities in Adult Patients With Polymyositis or Dermatomyositis as Assessed by Noninvasive Modalities. <b>2016</b> , 68, 1012-20	31
1471	Cardiovascular Health Status and Incidence of Heart Failure in the Framingham Offspring Study. <b>2016</b> , 9, e002416	33
1470	Optimising self-care support for people with heart failure and their caregivers: development of the Rehabilitation Enablement in Chronic Heart Failure (REACH-HF) intervention using intervention mapping. <b>2016</b> , 2, 37	32
1469	Relationships among achieved heart rate, I-blocker dose and long-term outcomes in patients with heart failure with atrial fibrillation. <b>2016</b> , 3, e000520	6
1468	Subgroup analyses of randomized clinical trials in heart failure: facts and numbers. <b>2016</b> , 3, 152-157	6
1467	Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review. <b>2016</b> , 3, e000449	12
1466	Comparative Effectiveness of Renin-Angiotensin System Antagonists in Maintenance Dialysis Patients. <b>2016</b> , 41, 873-885	2
1465	A Physician Advisory System for Chronic Heart Failure management based on knowledge patterns. <b>2016</b> , 16, 604-618	19
1464	Intravenous enalaprilat for treatment of acute hypertensive heart failure in the emergency department. <b>2016</b> , 9, 28	7
1463	Planning for Deactivation of Implantable Cardioverter Defibrillators at the End of Life in Patients With Heart Failure. <b>2016</b> , 36, 24-31	9
1462	Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes. <b>2016</b> , 4, 935-946	55

1461 Turning Failure into Success: Trials of the Heart Failure	Clinical Research Network. <b>2016</b> , 18, 121	
1460 The cardiac consult for patients undergoing non-cardia	c surgery. <b>2016</b> , 102, 1322-32	
1459 Cardiovascular diseases in Paralympic athletes. <b>2016</b> , 5	0, 1075-80	
Clinical effects of a standardized Chinese herbal remediates heart failure: systematic review and meta-analysis. <b>201</b>		
High-Intensity Interval Training Versus Moderate-Inten Prevention/Management of Cardiovascular Disease. <b>20</b>		
1456 Drug-induced long QT syndrome. <b>2016</b> , 11, 5-10	1	
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLO ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTI PATIENTS WITH OBESITY. <b>2016</b> , 22 Suppl 3, 1-203		
Are Two Heads Better Than One or Do Too Many Cooks 1454 Physician Division of Labor and Patient Continuity of Co Conditions. <b>2016</b> , 51, 2176-2205		
1453 Current Approach to Heart Failure. <b>2016</b> ,		
Comparison of Neuropsychological Patterns in Nigerian <b>2017</b> , 32, 280-288	ns with different Heart Failure Phenotypes.	
Effect of short-term exercise intervention on cardiovas heart failure patients: A meta-analysis. <b>2016</b> , 14, 67-75	cular functions and quality of life of chronic	
A Phase I, Single Ascending Dose Study of Cimaglermin Systolic Dysfunction and Heart Failure. <b>2016</b> , 1, 576-586		
Response to Comment on Ferrannini et al. Diabetes Ca Mudaliar et al. Diabetes Care 2016;39:1115-1122. <b>2016</b>		
1448 Dilated Cardiomyopathy. <b>2016,</b> 75-89	3	
Therapeutic effects of intravenous urapidil in elderly per decompensated heart failure: A pilot clinical trial. <b>2016</b>		
1446 Speckle Tracking Echocardiographic Imaging in Metabo	lic Cardiomyopathies. <b>2016</b> , 9, 1	
Diagnostic significance of serum galectin-3 levels in hea <b>2016</b> , 71, 191-197	art failure with preserved ejection fraction.	
Cardiovascular Protection From Severe OSA: The Pickw <b>2016</b> , 150, 1410-1411	ickian Paradox: Is Bigger Really Better?.	

1443 WITHDRAWN: Percutaneous left ventricular restoration in chronic heart failure. **2016**,

1442	Home-based versus centre-based cardiac rehabilitation: abridged Cochrane systematic review and meta-analysis. <b>2016</b> , 3, e000463	74
1441	Prevalence and socio-economic burden of heart failure in an aging society of South Korea. <b>2016</b> , 16, 215	36
1440	Interactive Digital e-Health Game for Heart Failure Self-Management: A Feasibility Study. <b>2016</b> , 5, 366-374	22
1439	Absorbent products use and symptom distress in women who have urinary incontinence and heart failure. <b>2016</b> , 70, 1019-1026	О
1438	Fine Tuning Adenylyl Cyclase as a (Gene) Therapy for Heart Failure. <b>2016</b> , 1, 630-632	1
1437	The clinical dilemma of heart failure with preserved ejection fraction: an update on pathophysiology and management for physicians. <b>2016</b> , 92, 346-55	5
1436	Initial central venous pressure could be a prognostic marker for hemodynamic improvement of polymyxin B direct hemoperfusion: a retrospective cohort study. <b>2016</b> , 4, 64	2
1435	Aufbau und Organisation von Herzinsuffizienz-Netzwerken (HF-NETs) und Herzinsuffizienz-Einheiten (Heart Failure Units[IHFUs) zur Optimierung der Behandlung der akuten und chronischen Herzinsuffizienz. <b>2016</b> , 10, 222-235	25
1434	Meeting the Unmet Needs of Aging Heart Failure Patients: A Role for Palliative Care. <b>2016</b> , 10, 1	1
1433	Cardiopulmonary exercise testing in the MRI environment. <b>2016</b> , 37, N11-25	9
1432	Digoxin: The good and the bad. <b>2016</b> , 26, 585-95	66
1431	[Cochrane Corner: Intra-aortic balloon pump in patients with cardiogenic shock following myocardial infarction]. <b>2016</b> , 35, 229-31	1
1430	From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure. <b>2016</b> , 35, 714-21	9
1429	CapEulo 5. Estructura y funcionamiento del hospital de dEl. <b>2016</b> , 23, 25-27	
1428	Secondary Prevention Recommendation Attainment with Cardiac Rehabilitation: Is There a Gender Disparity?. <b>2016</b> , 26, 278-87	8
1427	Laboratory medicine and mobile health technologies at crossroads: Perspectives for the management of chronic diseases. <b>2016</b> , 53, 352-7	2
1426	Pulsatile Load Components, Resistive Load and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA). <b>2016</b> , 22, 988-995	17

1425	Racial Differences in the Prevalence and Outcomes of Atrial Fibrillation in Patients Hospitalized With Heart Failure. <b>2016</b> , 117, 1468-73	11
1424	Comparison of Length of Stay, 30-Day Mortality, and 30-Day Readmission Rates in Medicare Patients With Heart Failure and With Reduced Versus Preserved Ejection Fraction. <b>2016</b> , 118, 79-85	34
1423	Hemodiafiltration affects NT-proBNP but not ST2 serum concentration in end-stage renal disease patients. <b>2016</b> , 49, 1159-1163	9
1422	Readmission rates and related factors in heart failure patients: A study in Lebanon. <b>2016</b> , 23, 61-8	14
1421	CapBulo 15. Seguimiento al paciente con dispositivos de estimulaciEn cardiaca. <b>2016</b> , 23, 62-64	
1420	Pathogen-driven treatment strategy in new onset dilated cardiomyopathy. Impact on ventricular function and clinical outcome. <b>2016</b> , 209, 15-6	5
1419	CapBulo 6. SelecciEn de los candidatos para el ingreso a las clBicas de falla cardiaca. <b>2016</b> , 23, 28-30	
1418	Pptidos natriurEicos: consenso y uso necesarios. <b>2016</b> , 69, 817-819	7
1417	Skeletal Muscle Mitochondrial Content, Oxidative Capacity, and Mfn2 Expression Are Reduced in Older Patients With Heart Failure and Preserved Ejection Fraction and Are Related to Exercise Intolerance. <b>2016</b> , 4, 636-45	87
1416	Home Inotropes and Other Palliative Care. <b>2016</b> , 12, 437-48	6
1415	Normal echocardiographic measurements in Indian adults: How different are we from the western populations? A pilot study. <b>2016</b> , 68, 772-775	6
1414	Heart failure with preserved ejection fraction in hypertension. <b>2016</b> , 31, 410-6	23
1413	Cap⊞ulo 1. Introducci⊡n. <b>2016</b> , 23, 4-5	1
1412	The Prognostic Value of Peripheral Artery Disease in Heart Failure: Insights from a Meta-analysis. <b>2016</b> , 25, 1195-1202	5
1411	New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. <b>2016</b> , 216, 46-51	19
1410	The role of pharmacotherapy in the prevention of sudden cardiac death in patients with heart failure. <b>2016</b> , 21, 415-31	4
1409	Dystrophin-Deficient Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2533-46 15.1	166
1408	Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease?. <b>2016</b> , 4, 689-97	31

1407	Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1474-1475	15.1	2
1406	A Suprainstitutional Network for Remote Extracorporeal Life Support: A Retrospective Cohort Study. <b>2016</b> , 4, 698-708		46
1405	Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. <b>2017</b> , 38, 104-112		76
1404	Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. <b>2016</b> , 17, 1435-48		21
1403	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology,	15.1	452
1402	Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. <b>2016</b> , 37, 2096		5
1401	Serelaxin for the treatment of heart failure. <b>2016</b> , 14, 667-75		2
1400	Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. <b>2016</b> , 374, 1511-20		444
1399	Role of low-level laser therapy on the cardiac remodeling after myocardial infarction: A systematic review of experimental studies. <b>2016</b> , 151, 109-114		5
1398	Heart Failure After CABG. <b>2016</b> , 189-197		
1397	CapEulo 12. Dispositivos de asistencia ventricular: una realidad en Colombia. <b>2016</b> , 23, 49-54		
1396	Consensus document and recommendations on the use of natriuretic peptides in clinical practice. <b>2016</b> , 216, 313-22		12
1396 1395			12
	<b>2016</b> , 216, 313-22		
1395	Prognostic value of angiopoietin-2 in patients with chronic heart failure. 2016, 212, 364-8		
1395 1394	Prognostic value of angiopoietin-2 in patients with chronic heart failure. 2016, 212, 364-8  Perspectives on Nuclear Medicine for Molecular Diagnosis and Integrated Therapy. 2016,  Myocardial Strain Is Associated with Adverse Clinical Cardiac Events in Patients Treated with Anthracyclines. 2016, 29, 522-527.e3  Knowledge Gaps in Cardiovascular Care of the Older Adult Population: A Scientific Statement From	15.1	21
1395 1394 1393	Prognostic value of angiopoietin-2 in patients with chronic heart failure. 2016, 212, 364-8  Perspectives on Nuclear Medicine for Molecular Diagnosis and Integrated Therapy. 2016,  Myocardial Strain Is Associated with Adverse Clinical Cardiac Events in Patients Treated with Anthracyclines. 2016, 29, 522-527.e3  Knowledge Gaps in Cardiovascular Care of the Older Adult Population: A Scientific Statement From the American Heart Association, American College of Cardiology, and American Geriatrics Society.	15.1	<ul><li>21</li><li>53</li></ul>

Measuring therapeutic efficacy in the treatment of central sleep apnoea in patients with heart failure. **2016**, 206 Suppl, S16-21

Cochrane Corner: Intra-aortic balloon pump in patients with cardiogenic shock following myocardial infarction **2016**, 35, 229-231

1388	Cochrane Corner: Intra-aortic balloon pump in patients with cardiogenic shock following myocardial infarction. <b>2016</b> , 35, 229-231	1
1387	Cardiovascular Disease in Women: Clinical Perspectives. <b>2016</b> , 118, 1273-93	435
1386	Pulmonary arterial hypertension and associated conditions. <b>2016</b> , 62, 379-402	5
1385	Importance of Calibration Method in Central Blood Pressure for Cardiac Structural Abnormalities. <b>2016</b> , 29, 1070-6	30
1384	Impact of the Timing of Metoprolol Administration During STEMI on Infarct Size and Ventricular Function. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2093-2104	60
1383	Digoxin Toxicity and Use of Digoxin Immune Fab: Insights From a National Hospital Database. <b>2016</b> , 4, 357-64	25
1382	Sex Differences in Mitral Regurgitation Before and After Mitral Valve Surgery. <b>2016</b> , 9, 397-9	7
1381	Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence. <b>2016</b> , 9, e002837	14
1380	Pharmacotherapy of Vasospastic Angina. <b>2016</b> , 21, 439-51	13
1379	A randomized, double-blind, multicenter, placebo-controlled clinical study on the efficacy and safety of Shenmai injection in patients with chronic heart failure. <b>2016</b> , 186, 136-142	49
1378	Digoxin for Worsening Chronic Heart Failure: Underutilized and Underrated. <b>2016</b> , 4, 365-7	4
1377	Surgical ventricular reconstruction for ischaemic heart failure: state of the art. <b>2016</b> , 18, E8-E14	11
1376	[Length of stay in patients admitted for acute heart failure]. <b>2016</b> , 30, 191-200	7
1375	Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera. <b>2016</b> , 4, 403-403	9
1374	B-Type Natriuretic Peptide Testing in the Era of Neprilysin Inhibition: Are the Winds of Change Blowing?. <b>2016</b> , 62, 663-5	7
1373	Patient and medication-related factors associated with hospital-acquired hyponatremia in patients hospitalized from heart failure. <b>2016</b> , 38, 848-54	3
1372	Neprilysin Inhibition in the Time of Precision Medicine. <b>2016</b> ,	6

1371	Heart Failure Therapies for End-Stage Chemotherapy-Induced Cardiomyopathy. <b>2016</b> , 22, 439-48	20
1370	QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction. <b>2016</b> , 4, 477-86	24
1369	B-Type Cardiac Natriuretic Peptides in the Neonatal and Pediatric Intensive Care Units. <b>2016</b> , 5, 189-197	2
1368	Effect of Neurohormonal Blockade Drug Therapy on Outcomes and Left Ventricular Function and Structure After Left Ventricular Assist Device Implantation. <b>2016</b> , 117, 1765-70	13
1367	Heart Failure in Older Adults. 2016, 32, 1140-7	56
1366	Changes in Thirst Intensity During Optimization of Heart Failure Medical Therapy by Nurses at the Outpatient Clinic. <b>2016</b> , 31, E17-24	7
1365	Reference values of galectin-3 and cardiac troponins derived from a single cohort of healthy blood donors. <b>2016</b> , 456, 19-23	19
1364	Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. <b>2016</b> , 127, 820-8	84
1363	Heart failure medications prescribed at discharge for patients with left ventricular assist devices. <b>2016</b> , 179, 99-106	6
1362	Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction. <b>2017</b> , 243, 447-464	2
1361	Clinical Case 1: Patient with Essential Hypertension and Systolic Dysfunction. 2016, 1-21	
1360	Relationship between different doses of beta-blockers and prognosis in elderly patients with reduced ejection fraction. <b>2016</b> , 220, 219-25	3
1359	Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND. <b>2016</b> , 222, 385-390	9
1358	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. <b>2016</b> , 4, 840-9	108
1357	Troponin-Guided Heart Failure Therapy: Are We There Yet?. <b>2016</b> , 4, 200-205	
1356	Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial. <b>2016</b> , 182, 80-88	83
1355	Current Perspectives on Left Ventricular Geometry in Systemic Hypertension. <b>2016</b> , 59, 235-246	30
1354	Women and heart disease, the underrecognized burden: sex differences, biases, and unmet clinical and research challenges. <b>2016</b> , 130, 551-63	63

Data. 2016, 1, 1014-1020

Where's the "Label" for Beet Juice: The Value of the Food and Drug Administration. 2016, 4, 438-40 Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional 1352 36 Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. 2016, 4, 860-869 Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for 62 1351 Exercise Tolerance and Outcomes. 2016, 9, e002826 Giant cell myocarditis: still a conundrum. The need for a worldwide registry. 2016, 18, 1459-1461 1350 9 1349 Hyperkalemia in Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1575-89 15.1 60 1348 What You See Is What You Get: Real-Time CMR to Guide Endomyocardial Biopsy. 2016, 1, 384-385 Current treatment of heart failure with reduction of left ventricular ejection fraction. 2016, 9, 1619-1631 5 [Optimization of the management of acute heart failure. New concept of fast-track]. 2016, 65, 330-333 1345 Sunshine Heart C-Pulse: device for NYHA Class III and ambulatory Class IV heart failure. 2016, 12, 521-31 3 Meta-Analysis of Association Between Mediastinal Radiotherapy and Long-Term Heart Failure. 1344 11 2016, 118, 1685-1691 Left ventricular scar impact on left ventricular synchronization parameters and outcomes of cardiac 5 1343 resynchronization therapy. **2016**, 222, 665-670 Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute 1342 myocardial infarction propensity-score matching analysis. 2016, 225, 50-59 1341 Contemporary Controversies in Digoxin Use in Systolic Heart Failure. 2016, 13, 197-206 5 "Usual" Yet Not Uniform Care Limits Our Understanding of Trials of Self-Management Interventions 1340 in Heart Failure. 2016, 22, 872-874 Heart deformation analysis for automated quantification of cardiac function and regional myocardial motion patterns: A proof of concept study in patients with cardiomyopathy and healthy 14 subjects. 2016, 85, 1811-1817 1338 Personalized Computer Simulation of Diastolic Function in Heart Failure. 2016, 14, 244-52 5 Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. 2016, 16, 116 1337 33 Comparison of Approaches for Heart Failure Case Identification From Electronic Health Record 1336 44

1335	Improving performance of an accountable care organization on a quality measure assessing Improving performance of an accountable care organization on a quality measure assessing Improving performance of an accountable care organization on a quality measure assessing Improving performance of an accountable care organization on a quality measure assessing	3
1334	Marital status and living condition as predictors of mortality and readmissions among African Americans with heart failure. <b>2016</b> , 222, 313-318	32
1333	Rethinking Thirty-Day Hospital Readmissions: Shorter Intervals Might Be Better Indicators Of Quality Of Care. <b>2016</b> , 35, 1867-1875	66
1332	Usefulness of late gadolinium enhancement MRI combined with stress imaging in predictive significant coronary stenosis in new-diagnosed left ventricular dysfunction. <b>2016</b> , 224, 337-342	5
1331	Variations on a Precision Medicine Theme: One Size Fits Some. <b>2016</b> , 9,	О
1330	Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. <b>2016</b> , 5,	101
1329	Reframing the association and significance of co-morbidities in heart failure. <b>2016</b> , 18, 744-58	116
1328	Hypertension and Comorbidities. 2016,	2
1327	Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?. <b>2016</b> , 219, 111-4	17
1326	Exercise And Heart Failure: Advancing Knowledge And Improving Care. <b>2016</b> , 12, 110-5	22
1325	Frequency of Methamphetamine Use as a Major Contributor Toward the Severity of Cardiomyopathy in Adults Bo Years. <b>2016</b> , 118, 585-9	36
1324	Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. <b>2016</b> , 18, 1072-81	30
1323	A meta-analysis of low-dose dopamine in heart failure. <b>2016</b> , 222, 1003-1011	8
1322	Clinical Case 5: Patient with Essential Hypertension and Congestive Heart Failure. <b>2016</b> , 81-99	
1321	Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. <b>2016</b> , 12, 1	7
1320	Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA. <b>2016</b> , 18, 1211-1219	20
1319	Identifying evidence of cardio-renal syndrome in patients with Duchenne muscular dystrophy using cystatin C. <b>2016</b> , 26, 637-642	16
1318	Guideline-Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program. <b>2016</b> , 39, 145-9	18

1317	The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics. <b>2016</b> , 18, 71-80	85
1316	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <b>2016</b> , 18, 54-65	57
1315	Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. <b>2016</b> , 18, 1193-202	135
1314	Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. <b>2016</b> , 18, 976	1
1313	Is Heart Rate a Norepiphenomenon in Heart Failure?. <b>2016</b> , 18, 91	
1312	Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature Review. <b>2016</b> , 34, 152-60	16
1311	Increased Body Mass Index Is Associated with Congestive Heart Failure and Mortality in Adult Fontan Patients. <b>2016</b> , 11, 71-9	24
1310	Intra-abdominal Hypertension: An Important Consideration for Diuretic Resistance in Acute Decompensated Heart Failure. <b>2016</b> , 39, 37-40	10
1309	□adrenergic receptor signalling and its functional consequences in the diseased heart. <b>2016</b> , 46, 362-74	71
1308	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <b>2016</b> , 37, 2768-2801	1249
1308	auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and	1249
	auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <b>2016</b> , 37, 2768-2801	
1307	auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <b>2016</b> , 37, 2768-2801  Decision-Making Experiences of Patients with Implantable Cardioverter Defibrillators. <b>2016</b> , 39, 1061-1069  Effects of rhBNP after PCI on non-invasive hemodynamic in acute myocardial infarction patients	12
1307	auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <b>2016</b> , 37, 2768-2801  Decision-Making Experiences of Patients with Implantable Cardioverter Defibrillators. <b>2016</b> , 39, 1061-1069  Effects of rhBNP after PCI on non-invasive hemodynamic in acute myocardial infarction patients with left heart failure. <b>2016</b> , 9, 791-5  Heart failure across Asia: Same healthcare burden but differences in organization of care. <b>2016</b> ,	9
1307 1306 1305	auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). 2016, 37, 2768-2801  Decision-Making Experiences of Patients with Implantable Cardioverter Defibrillators. 2016, 39, 1061-1069  Effects of rhBNP after PCI on non-invasive hemodynamic in acute myocardial infarction patients with left heart failure. 2016, 9, 791-5  Heart failure across Asia: Same healthcare burden but differences in organization of care. 2016, 223, 163-167	12 9 64
1307 1306 1305	auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). 2016, 37, 2768-2801  Decision-Making Experiences of Patients with Implantable Cardioverter Defibrillators. 2016, 39, 1061-1069  Effects of rhBNP after PCI on non-invasive hemodynamic in acute myocardial infarction patients with left heart failure. 2016, 9, 791-5  Heart failure across Asia: Same healthcare burden but differences in organization of care. 2016, 223, 163-167  The Relationship of Plasma NT-proBNP to Age and Outcomes in Heart Failure. 2016, 4, 746-8  Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease.	12 9 64 7
1307 1306 1305 1304	auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). 2016, 37, 2768-2801  Decision-Making Experiences of Patients with Implantable Cardioverter Defibrillators. 2016, 39, 1061-1069  Effects of rhBNP after PCI on non-invasive hemodynamic in acute myocardial infarction patients with left heart failure. 2016, 9, 791-5  Heart failure across Asia: Same healthcare burden but differences in organization of care. 2016, 223, 163-167  The Relationship of Plasma NT-proBNP to Age and Outcomes in Heart Failure. 2016, 4, 746-8  Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease. 2016, 5,	12 9 64 7 41

1299	Use of Electronic Health Data to Estimate Heart Failure Events in a Population-Based Cohort with CKD. <b>2016</b> , 11, 1954-1961		2
1298	Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. <b>2016</b> , 105, 873-9		55
1297	Self-efficacy and depression predicting the health-related quality of life of outpatients with chronic heart failure in Singapore. <b>2016</b> , 32, 148-155		16
1296	The Potential Impact of Expanding Cardiac Rehabilitation in Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 977-8	15.1	5
1295	Exercise-based cardiac rehabilitation in heart transplant recipients. 2016,		72
1294	A cost analysis of remote monitoring in a heart failure program. <b>2016</b> , 35, 112-122		5
1293	Prognostic Utility of Galectin-3 for Recurrent Cardiovascular Events During Long-term Follow-up in Patients with Stable Coronary Heart Disease: Results of the KAROLA Study. <b>2016</b> , 62, 1372-9		16
1292	Relation of Echocardiographic Characteristics of the Right-Sided Heart With Incident Heart Failure and Mortality in Patients With Sleep-Disordered Breathing and Preserved Left Ventricular Ejection Fraction. <b>2016</b> , 118, 1268-1273		8
1291	Hypochloremia and Diuretic Resistance in Heart Failure: Mechanistic Insights. 2016, 9,		59
1290	Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: new challenges and perspectives. <b>2016</b> , 12, 573-84		8
1289	Pulse contour cardiac output monitoring in acute heart failure patients: Assessment of hemodynamic measurements. <b>2016</b> , 128, 864-869		5
1288	Can Big Data Simplify the Complexity of Modern Medicine?: Prediction of Right Ventricular Failure After Left Ventricular Assist Device Support as a Test Case. <b>2016</b> , 4, 722-5		5
1287	Clinical and socio-demographic determinants of self-care behaviours in patients with heart failure and diabetes mellitus: A multicentre cross-sectional study. <b>2016</b> , 63, 18-27		40
1286	Handbook of Consult and Inpatient Gynecology. <b>2016</b> ,		
1285	Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial. <b>2016</b> , 17, 530		5
1284	Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2425-2436	15.1	190
1283	Optimal Use of Beta-Blockers for Congestive Heart Failure. <b>2016</b> , 80, 565-71		11
1282	The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2348-2364	15.1	164

1281 Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure. 2016, 463, 158-164 26 1280 Management of mild hypertension in adults. 2016, 355, i5719 17 Influence of heart failure on the prognosis of patients with acute myocardial infarction in 1279 5 southwestern China. 2016, 11, 2127-2138 Optimized management of heart failure patients aged 80 years or more improves outcomes versus 1278 usual care: The HF80 randomized trial. 2016, 109, 667-678 Prognostic Impact of New-Onset Atrial Fibrillation in Patients With Chronic Heart Failure - A Report 24 From the CHART-2 Study. 2016, 80, 157-67 Relationship of Left Ventricular Diastolic Function to Obesity and Overweight in a Japanese 11 Population With Preserved Left Ventricular Ejection Fraction. 2016, 80, 1951-6 Correlation of Pre- and In-Hospital Systolic Blood Pressure in Acute Heart Failure Patients and the Prognostic Implications - Report From the Tokyo Cardiac Care Unit Network Emergency Medical 10 Service Database. 2016, 80, 2473-2481 1274 Cost-effectiveness of Intensive Blood Pressure Management. 2016, 1, 872-879 32 Outcomes With Left Bundle Branch Block and Mildly to Moderately Reduced Left Ventricular 1273 47 Function. 2016, 4, 897-903 2016 ESC and ACC/AHA/HFSA heart failure quideline update - what is new and why is it important?. 1272 27 2016, 13, 623-8 Temporal trends and factors associated with diabetes mellitus among patients hospitalized with 1271 72 heart failure: Findings from Get With The Guidelines-Heart Failure registry. 2016, 182, 9-20 Gender Disparities Across the Spectrum of Advanced Cardiac Therapies: Real or Imagined?. 2016, 1270 10 18, 108 Depression in heart failure: Intricate relationship, pathophysiology and most updated evidence of 1269 40 interventions from recent clinical studies. 2016, 224, 170-177 1268 Sleep-Disordered Breathing-Do We Have to Change Gears in Heart Failure?. 2016, 13, 255-265 The C of CHADS: Historical perspective and clinical applications for anticoagulation in patients with 1267 3 non valvular atrial fibrillation and congestive heart failure. 2016, 224, 431-436 1266 Cardiac Troponin: Myocardial Infarction and More. **2016**, 5, 492-506 Ischemic Heart Disease in New-Onset Heart Failure, or Finding Waldo: Where's Waldo?. Journal of 1265 15.1 1 the American College of Cardiology, 2016, 68, 459-460 1264 Comprehensive therapeutic approach for patients with heart failure and comorbidity. 2016, 216, 323-330

1263	Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance. <b>2016</b> , 36, 852-60		19
1262	Revascularizaci[h quirfgica en pacientes con disfunci[h ventricular severa. <b>2016</b> , 23, 383-388		
1261	Cardiorenal Interactions. <b>2016</b> , 12, 335-47		9
1260	Milrinone for cardiac dysfunction in critically ill adult patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. <b>2016</b> , 42, 1322-35		19
1259	Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study. <b>2016</b> , 48, 787-96		64
1258	Underutilization of Coronary Artery Disease Testing Among Patients Hospitalized With New-Onset Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 450-458	15.1	38
1257	Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. <b>2016</b> , 4, 808-815		46
1256	Advances in Echocardiographic Imaging in Heart Failure With Reduced and Preserved Ejection Fraction. <b>2016</b> , 119, 357-74		43
1255	Influence of Sacubitril/Valsartan (LCZ696) ´on ´30-Day Readmission After Heart Failure Hospitalization. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 241-248	15.1	81
1254	Coenzyme Q10 - A new player in the treatment of heart failure?. <b>2016</b> , 68, 1015-9		22
1253	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I). <b>2016</b> , 9,		37
1253 1252	the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I).		<ul><li>37</li><li>5</li></ul>
	the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I). <b>2016</b> , 9,  Vasopressin type 1A receptor deletion enhances cardiac contractility, Dadrenergic receptor		
1252	the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I).  2016, 9,  Vasopressin type '1A receptor deletion enhances cardiac contractility, I-adrenergic receptor sensitivity and acute cardiac injury-induced dysfunction. 2016, 130, 2017-2027  Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?. 2016,	15.1	5
1252	the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I).  2016, 9,  Vasopressin type '1A receptor deletion enhances cardiac contractility, I-adrenergic receptor sensitivity and acute cardiac injury-induced dysfunction. 2016, 130, 2017-2027  Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?. 2016, 175, 577-587  Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection	15.1	5
1252 1251 1250	the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I). 2016, 9,  Vasopressin type '1A receptor deletion enhances cardiac contractility, I-adrenergic receptor sensitivity and acute cardiac injury-induced dysfunction. 2016, 130, 2017-2027  Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?. 2016, 175, 577-587  Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2016, 68, 1823-1834  The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. Journal of the American College of Cardiology, 2016, 68, 1898-1907		5 11 69
1252 1251 1250 1249	the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I). 2016, 9,  Vasopressin type '1A receptor deletion enhances cardiac contractility, I-adrenergic receptor sensitivity and acute cardiac injury-induced dysfunction. 2016, 130, 2017-2027  Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?. 2016, 175, 577-587  Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2016, 68, 1823-1834  The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. Journal of the American College of Cardiology, 2016, 68, 1898-1907		<ul><li>5</li><li>11</li><li>69</li><li>53</li></ul>

1245	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2217-2228	15.1	157
1244	Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. <b>2016</b> , 16, 199		25
1243	Contextual risk: a study of fish out of water. <b>2016</b> , 18, 1506-1507		
1242	Recipient age impact on outcome after cardiac transplantation: should it still be considered in organ allocation?. <b>2016</b> , 23, 573-9		7
1241	Cardiac Biomarkers. <b>2016</b> ,		1
1240	Genetic Predispositions to Heart Failure. <b>2016</b> , 10, 1		
1239	Functional Mitral Regurgitation: Appraising the Evidence Behind Recommended Treatment Strategies. <b>2016</b> , 18, 128		
1238	Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. <b>2016</b> , 13, 319-328		17
1237	Pharmacogenomics of heart failure: a systematic review. <b>2016</b> , 17, 1817-1858		8
1236	Main group metal-ligand cooperation of N-heterocyclic germylene: an efficient catalyst for hydroboration of carbonyl compounds. <b>2016</b> , 52, 13799-13802		69
1235	Biomarkers in Heart Failure: ST2. <b>2016</b> , 251-268		
1234	The predictive value of plasma catestatin for all-cause and cardiac deaths in chronic heart failure patients. <b>2016</b> , 86, 112-117		14
1233	Biomarker-based risk prediction in the community. <b>2016</b> , 18, 1342-1350		16
1232	A Change of Heart. <b>2016</b> , 14, 1193-1196		
1231	Endocardial Remodeling in Heart Failure Patients with Impaired and Preserved Left Ventricular Systolic FunctionA Magnetic Resonance Image Study. <b>2016</b> , 6, 20868		4
1230	Educating Home Healthcare Nurses About Heart Failure Self-Care. <b>2016</b> , 34, 500-6		3
1229	Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. <b>2016</b> , 6, e014010		11
1228	Association of HbA1c with hospitalization and mortality among patients with heart failure and diabetes. <b>2016</b> , 16, 99		11

1227	Identification of volume overload hospitalizations among hemodialysis patients using administrative claims: a validation study. <b>2016</b> , 17, 173	13
1226	Functional mitral regurgitation in patients with heart failure and depressed ejection fraction. <b>2016</b> , 31, 483-92	5
1225	Discharge planning for heart failure patients in a tertiary hospital in Shanghai: a best practice implementation project. <b>2016</b> , 14, 322-36	2
1224	Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers. <b>2016</b> , 5, 6	12
1223	Implementing Electronic Tablet-Based Education of Acute Care Patients. <b>2016</b> , 36, 60-70	11
1222	Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction. <b>2016</b> , 28, 576-582	1
1221	Bioelectrical impedance vector analysis and clinical outcomes in patients with acute heart failure. <b>2016</b> , 17, 283-90	17
1220	Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies. <b>2016</b> , 17 Suppl 1, S64-75	18
1219	Why is polypharmacy increasing in aged care facilities? The views of Australian health care professionals. <b>2016</b> , 22, 677-82	21
1218	Neprilysin and Natriuretic Peptide Regulation in Heart Failure. <b>2016</b> , 13, 151-7	20
1217	Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure. <b>2016</b> , 129, 1067-73	34
1216	Pulmonary Artery Pressure-Guided Heart Failure Management Reduces 30-Day Readmissions. <b>2016</b> , 9,	50
1215	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <b>2016</b> , 22, 618-27	1
1214	The Established Therapies: HF-PEF and HF-REF. <b>2016</b> , 1-27	
1213	The Diagnosis and Evaluation of Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2996-3010	217
1212	Peripartum cardiomyopathy: challenges in diagnosis and management. <b>2016</b> , 14, 1035-41	8
1211	Trastuzumab-Related Cardiotoxic Effects in Taiwanese Women: A Nationwide Cohort Study. <b>2016</b> , 2, 1317-1325	22
1210	How peptide technology has improved costs and outcomes in patients with heart failure. <b>2016</b> , 16, 371-82	2

## (2016-2016)

1209	Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. <b>2016</b> , 4, 419-27	34
1208	Coenzyme Q10 and Utility in Heart Failure: Just Another Supplement?. <b>2016</b> , 13, 190-5	12
1207	Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on left ventricular mass index and ejection fraction in hemodialysis patients: A meta-analysis with trial sequential analysis of randomized controlled trials. <b>2016</b> , 219, 350-7	5
1206	Predicting Heart Failure Readmissions. <b>2016</b> , 31, 114-20	5
1205	Focused cardiopulmonary ultrasound for assessment of dyspnea in a resource-limited setting. <b>2016</b> , 8, 7	24
1204	Health-related quality of life in children with heart failure as perceived by children and parents. <b>2016</b> , 26, 885-93	19
1203	Current and future developments in the field of central sleep apnoea. <b>2016</b> , 18, 1123-34	16
1202	Usefulness of Geriatric Nutritional Risk Index for Assessing Nutritional Status and Its Prognostic Impact in Patients Aged <b>8</b> 5 Years With Acute Heart Failure. <b>2016</b> , 118, 550-5	66
1201	Cap⊞ulo 8. Educaci⊡n al paciente y su familia. <b>2016</b> , 23, 34-37	1
1200	CapEulo 11. Paciente candidato a trasplante cardiaco. <b>2016</b> , 23, 44-48	
1199	Natriuretic Peptides: Consensus Call for Use. <b>2016</b> , 69, 817-9	1
1198	Mitral regurgitation. Timing of surgery or interventional treatment. <b>2016</b> , 41, 3-9	2
1197	Left Ventricular Ejection Fraction: What Is "Normal"?. <b>2016</b> , 4, 511-3	10
1196	Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure. <b>2016</b> , 22, 692-9	9
1195	Impacto clīlico de un programa de falla cardiaca. <b>2016</b> , 23, 260-264	5
1194	To Supplement or Not: A Role for Antioxidant Vitamins in the Management of Heart Failure?. <b>2016</b> , 129, 767-8	5
1193	Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection	17
	fraction. <b>2016</b> , 457, 99-105	

1191	Clinical Characteristics and Outcomes of Patients with Amphetamine-Associated Cardiomyopathy in South Auckland, New Zealand. <b>2016</b> , 25, 1087-1093	7
1190	Consensus document and recommendations on the use of natriuretic peptides in clinical practice. <b>2016</b> , 216, 313-322	
1189	The Impact of Race on the Prognosis of Preclinical Diastolic Dysfunction: A Large Multiracial Urban Population Study. <b>2016</b> , 129, 222.e1-10	4
1188	Temporal changes of left ventricular synchronization parameters and outcomes of cardiac resynchronization therapy. <b>2016</b> , 4, 105-112	
1187	Pharmacologic Trends of Heart Failure. <b>2016</b> ,	
1186	A Comprehensive Transition of Care Plan for a Patient Admitted with Acute Decompensated Heart Failure. <b>2016</b> , 73-124	
1185	Therapeutic targeting of autophagy in myocardial infarction and heart failure. 2016, 14, 1007-19	25
1184	A proposal for monitoring patients with heart failure via "smart phone technology"-based electrocardiograms. <b>2016</b> , 49, 699-706	14
1183	Oxygen Therapy in Patients With Acute Heart Failure: Friend or Foe?. <b>2016</b> , 4, 783-790	42
1182	Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. <b>2016</b> , 18, 433-41	19
1181	A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction. <b>2016</b> , 56, 936-47	3
1180	Epigenetics in heart failure phenotypes. <b>2016</b> , 6, 31-7	32
1179	Evaluation of mortality and readmissions following hospitalization with heart failure. <b>2016</b> , 32, 1745-1755	5
1178	Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients. <b>2016</b> , 220, 56-60	18
1177	Development of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. <b>2016</b> , 59, 52-8	10
1176	Driveline Infection Risk with Utilization of a Temporary External Anchoring Suture After Implantation of a Left Ventricular Assist Device. <b>2016</b> , 62, 291-6	4
1175	Diagnosing Acute Heart Failure in the Emergency Department: A Systematic Review and Meta-analysis. <b>2016</b> , 23, 223-42	142
1174	Elastic properties of ascending aorta in women with previous pregnancy complicated by early- or late-onset pre-eclampsia. <b>2016</b> , 47, 316-23	27

1173	Malnutrition and Cachexia in Heart Failure. <b>2016</b> , 40, 475-86		109
1172	Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact?. <b>2016</b> , 5, 534-548		26
1171	Systematic review of trial-based analyses reporting the economic impact of heart failure management programs compared with usual care. <b>2016</b> , 15, 82-90		9
1170	Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure. <b>2016</b> , 9, e002453		45
1169	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. <b>2016</b> , 21, 455-62		21
1168	Lessons learned from a clinical trial: Design, rationale, and insights from The Cardiovascular Improvements with Minute Ventilation-targeted Adaptive Sero-Ventilation (ASV) Therapy in Heart Failure (CAT-HF) Study. <b>2016</b> , 47, 158-64		14
1167	Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype?. <b>2016</b> , 29, 46-57		2
1166	Contemporary Treatment of Acute Heart Failure. <b>2016</b> , 58, 367-78		17
1165	Renal insufficiency and mortality in coronary artery disease with reduced ejection fraction. <b>2016</b> , 29, 78-87		1
1164	The Value of Left Ventricular Relative Wall Thickness in Predicting Ventricular Arrhythmia and Related Death. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 313-5	;.1	3
1163	Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome. <b>2016</b> , 6, 83-98		28
1162	A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 330-7	;.1	35
1161	Statins and oxidative stress in chronic heart failure. <b>2016</b> , 35, 41-57		30
1160	Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study. <b>2016</b> , 4, 129-136		60
1159	Long-term outcome of patients with and without super-response to CRT-D. <b>2016</b> , 105, 341-8		11
1158	Quantitative assessment of cardiac mechanical dyssynchrony and prediction of response to cardiac resynchronization therapy in patients with non-ischaemic dilated cardiomyopathy using equilibrium radionuclide angiography. <b>2016</b> , 18, 851-7		7
1157	Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population. <b>2016</b> , 4, 78-87		61
1156	Controversies Among the Hypertension Guidelines. <b>2016</b> , 29, 5-14		3

1155	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <b>2016</b> , 117, 404-11	38
1154	Comorbidity of atrial fibrillation and heart failure. <b>2016</b> , 13, 131-47	88
1153	Evaluation of a provocative dyspnea severity score in acute heart failure. <b>2016</b> , 172, 34-41	9
1152	Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. <b>2016</b> , 452, 50-7	22
1151	Heart Failure in Africa, Asia, the Middle East and South America: The INTER-CHF study. <b>2016</b> , 204, 133-41	72
1150	Critical appraisal of international guidelines on chronic heart failure: Can China AGREE?. <b>2016</b> , 203, 111-4	6
1149	Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. <b>2016</b> , 6, 20-28	32
1148	Moving From Disease-Centered to Patient Goals-Directed Care for Patients With Multiple Chronic Conditions: Patient Value-Based Care. <b>2016</b> , 1, 9-10	120
1147	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1444-1455	142
1146	The effect of adaptive servo ventilation (ASV) on objective and subjective outcomes in Cheyne-Stokes respiration (CSR) with central sleep apnea (CSA) in heart failure (HF): A systematic review. <b>2016</b> , 45, 199-211	8
1145	Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction. <b>2016</b> , 4, 86-94	30
1144	C⊡mo iniciar una unidad de insuficiencia card⊞ca multidisciplinar paso a paso. <b>2016</b> , 51, 111-118	
1143	Cardiac structural and functional profile of patients with delayed QRS transition zone and sudden cardiac death. <b>2017</b> , 19, 629-635	7
1142	Mending the Broken Heart: A Neprilysin Inhibitor for Heart Failure. <b>2016</b> , 12, e111-e114	1
1141	Clinical Characteristics, Management, and Outcomes of Hospitalized Heart Failure in a Chinese Population-The Hong Kong Heart Failure Registry. <b>2016</b> , 22, 600-8	23
1140	64-Year-Old-Woman With Chest Pressure and Shortness of Breath. <b>2016</b> , 91, e61-5	
1139	Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): A multidisciplinary position statement. <b>2016</b> , 212, 1-10	32
1138	Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 780-9	104

1137	2015 The American Association for Thoracic Surgery Consensus Guidelines: Ischemic mitral valve regurgitation. <b>2016</b> , 151, 940-56	33
1136	Effect of Coronary Atherosclerosis and Myocardial Ischemia on Plasma Levels of High-Sensitivity Troponin T and NT-proBNP in Patients With Stable Angina. <b>2016</b> , 36, 757-64	26
1135	Impact of Physical Inactivity on Mortality in Patients With Heart Failure. <b>2016</b> , 117, 1135-43	44
1134	Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring. <b>2016</b> , 4, 333-44	82
1133	Variable Contribution of Heart Failure to Quality of Life in Ambulatory Heart Failure With Reduced, Better, or Preserved Ejection Fraction. <b>2016</b> , 4, 184-93	28
1132	One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction. <b>2016</b> , 4, 428-37	113
1131	Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. <b>2016</b> , 209, 310-6	19
1130	Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. <b>2016</b> , 4, 348-56	25
1129	Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. <b>2016</b> , 102, 390-6	59
1128	A Machine Without an Owner's Manual. <b>2016</b> , 4, 218-9	
1127	[Rehabilitation standards for follow-up treatment and rehabilitation of patients with ventricular assist device (VAD)]. <b>2016</b> , 11 Suppl 1, 2-49	13
1126	Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients. <b>2016</b> , 67, 854-9	16
1125	Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis. <b>2016</b> , 10, 329-42	24
1124	Heterogeneity of the prognostic significance of B-type natriuretic peptide levels on admission in patients hospitalized for acute heart failure syndromes. <b>2016</b> , 31, 41-9	4
1123	The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction. <b>2016</b> , 13, 47-59	34
1122	Complex Care Options for Patients With Advanced Heart Failure Approaching End of Life. <b>2016</b> , 13, 20-9	13
1121	Pathophysiological mechanism and therapeutic role of S100 proteins in cardiac failure: a systematic review. <b>2016</b> , 21, 463-73	22
1120	The Effectiveness of a Nurse-Led Cognitive-Behavioral Therapy on the Quality of Life, Self-Esteem and Mood Among Filipino Patients Living With Heart Failure: a Randomized Controlled Trial. <b>2016</b> , 31, 86-93	22

1119	Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine. <b>2016</b> , 129, 560-7	38
1118	Prevention, Detection, and Management of Chemotherapy-Related Cardiac Dysfunction. <b>2016</b> , 32, 891-9	13
1117	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. <b>2016</b> , 9, e002843	84
1116	Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity. <b>2016</b> , 12, 855-70	18
1115	Cardiovascular Serenade: Listening to the Heart. <b>2016</b> , 87-100	
1114	Polypharmacy in heart failure - Is reducing medication safe?. <b>2016</b> , 214, 529-30	4
1113	Absence of coronary sinus tributaries in ischemic cardiomyopathy: An insight from multidetector computed tomography cardiac venographic study. <b>2016</b> , 10, 156-61	7
1112	Nouveaux mdicaments dans linsuffisance cardiaque aigu <b>2016</b> , 25, 145-154	
1111	Prevalent diabetes mellitus in patients with heart failure and disease determinants in sub-Saharan Africans having diabetes with heart failure: a protocol for a systematic review and meta-analysis. <b>2016</b> , 6, e010097	5
1110	Ambulatory Blood Pressure Monitoring in Coronary Artery Disease and Heart Failure. <b>2016</b> , 299-321	
1109	The fibrosis-cell death axis in heart failure. <b>2016</b> , 21, 199-211	144
1108	Patient Selection for Long-Term Mechanical Circulatory Support: Is It Ever too Early for the NYHA Class III Patient?. <b>2016</b> , 13, 13-9	4
1107	Decision Support Systems in Healthcare. <b>2016</b> , 75-93	1
1106	Effect of intravenous l-carnitine in Chinese patients with chronic heart failure. <b>2016</b> , 18, A27-A36	6
1105	Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. <b>2016</b> , 133, 1115-24	115
1104	Obesity and Cardiovascular Disease: a Risk Factor or a Risk Marker?. <b>2016</b> , 18, 21	143
1103	Diagnosing Sleep Apnea in Patients Hospitalized With Heart Failure: A Role for Advanced Practice Nurses. <b>2016</b> , 27, 15-20	
1102	Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease. <b>2016</b> , 50, 475-85	6

## (2016-2016)

1101	Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study. <b>2016</b> , 23, 1421-8	25
1100	Sudden death prediction by C-reactive protein, electrocardiographic findings, and myocardial fatty acid uptake in haemodialysis patients: analysis of a multicentre prospective cohort sub-study. <b>2016</b> , 17, 1394-1404	5
1099	ErbB4 Gene Polymorphism Is Associated With the Risk and Prognosis of Congestive Heart Failure in a Northern Han Chinese Population. <b>2016</b> , 22, 700-9	1
1098	Comprehensive therapeutic approach for patients with heart failure and comorbidity. <b>2016</b> , 216, 323-30	4
1097	A method for the development of disease-specific reference standards vocabularies from textual biomedical literature resources. <b>2016</b> , 68, 47-57	11
1096	Heart Failure With Preserved Ejection Fraction. <b>2016</b> , 41, 145-88	80
1095	Sleep apnea in total joint arthroplasty patients and the role for cardiac biomarkers for risk stratification: an exploration of feasibility. <b>2016</b> , 10, 265-300	6
1094	Embolic Stroke in Cardiomyopathy: Should Patients be Anticoagulated?. <b>2016</b> , 34, 215-24	1
1093	Gaps in Adherence to Guideline-Directed Medical Therapy Before Defibrillator Implantation.  Journal of the American College of Cardiology, <b>2016</b> , 67, 1070-1073	8
1092	Cardiac Outcomes in Survivors of Pediatric and Adult Cancers. <b>2016</b> , 32, 871-80	23
	Cardiac Outcomes in Survivors of Pediatric and Adult Cancers. <b>2016</b> , 32, 871-80  Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. <b>2016</b> , 22, 545-7	23
1091		
1091	Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. <b>2016</b> , 22, 545-7	1
1091 1090 1089	Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. <b>2016</b> , 22, 545-7  Statins and oxidative stress in chronic heart failure. <b>2016</b> , 35, 41-57  Long-term low-level laser therapy promotes an increase in maximal oxygen uptake and exercise	1
1091 1090 1089	Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. 2016, 22, 545-7  Statins and oxidative stress in chronic heart failure. 2016, 35, 41-57  Long-term low-level laser therapy promotes an increase in maximal oxygen uptake and exercise performance in a dose-dependent manner in Wistar rats. 2016, 31, 241-8	1 15 8
1091 1090 1089	Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. 2016, 22, 545-7  Statins and oxidative stress in chronic heart failure. 2016, 35, 41-57  Long-term low-level laser therapy promotes an increase in maximal oxygen uptake and exercise performance in a dose-dependent manner in Wistar rats. 2016, 31, 241-8  Dietary Salt Restriction in Heart Failure: Where Is the Evidence?. 2016, 58, 401-6	1 15 8 8
1091 1090 1089 1088 1087	Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. 2016, 22, 545-7  Statins and oxidative stress in chronic heart failure. 2016, 35, 41-57  Long-term low-level laser therapy promotes an increase in maximal oxygen uptake and exercise performance in a dose-dependent manner in Wistar rats. 2016, 31, 241-8  Dietary Salt Restriction in Heart Failure: Where Is the Evidence?. 2016, 58, 401-6  Monocyte Subsets and Inflammatory Cytokines in Acute Decompensated Heart Failure. 2016, 22, 358-65  Long-term Risk of Heart Failure and Myocardial Dysfunction After Thoracic Radiotherapy: A	1 15 8 8 18

1083	Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. <b>2016</b> , 22, 853-858	5
1082	Heart failure family-based education: a systematic review. <b>2016</b> , 99, 326-338	14
1081	A comparative study of fluid management education before hospital discharge. <b>2016</b> , 45, 21-8	3
1080	Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. <b>2016</b> , 4, 152-158	73
1079	New-onset left bundle branch block-associated idiopathic nonischemic cardiomyopathy and left ventricular ejection fraction response to guideline-directed therapies: The NEOLITH study. <b>2016</b> , 13, 933-42	24
1078	Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis. <b>2016</b> , 205, 65-71	20
1077	Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. <b>2016</b> , 9, e002370	59
1076	Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. <b>2016</b> , 315, 36-46	366
1075	Dietary Sodium Restriction in Heart Failure: A Recommendation Worth its Salt?. <b>2016</b> , 4, 36-8	5
1074	The Uncertainty of Sodium Restriction in Heart Failure: We Can Do Better Than This. <b>2016</b> , 4, 39-41	7
1073	Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. <b>2016</b> , 31, 1650-8	24
1072	Impact of Dietary Sodium Restriction on Heart Failure Outcomes. <b>2016</b> , 4, 24-35	65
1071	Heart Failure Management: The Neural Pathways. <b>2016</b> ,	
1070	Sacubitril/valsartan (LCZ696) for the treatment of heart failure. <b>2016</b> , 14, 145-53	15
1069	Validation of the Get With The Guideline-Heart Failure risk score in Japanese patients and the potential improvement of its discrimination ability by the inclusion of B-type natriuretic peptide level. <b>2016</b> , 171, 33-9	54
1068	Serelaxin and acute heart failure. <b>2016</b> , 102, 95-9	20
1067	Beta-blockers treatment in heart failure with atrial fibrillationWho should we believe?. <b>2016</b> , 203, 60-1	3
1066	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <b>2016</b> , 13, e136-221	58

1065	Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Journal of the American College</i>	15.1	246	
1064	of Cardiology, <b>2016</b> , 67, e27-e115  Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. <b>2016</b> , 37, 1642-50		163	
1063	Mechanical circulatory assistance: A growing and expanding field in cardiac surgery. <b>2016</b> , 151, e9-10			
1062	Ultrastructural morphometric findings of cardiomyocytes in patients with impaired ventricular functiona comparative clinicopathological study. <b>2016</b> , 25, 25-32		3	
1061	Serum alkaline phosphatase as a predictor of worsening renal function in patients with acute decompensated heart failure. <b>2016</b> , 67, 412-7		15	
1060	Effects of renin-angiotensin-aldosterone system inhibitors on mortality, hospitalization, and diastolic function in patients with HFpEF. A meta-analysis of 13 randomized controlled trials. <b>2016</b> , 41, 76-86		14	
1059	Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. <b>2016</b> , 42, 147-63		113	
1058	Pathophysiology and clinical evaluation of acute heart failure. <b>2016</b> , 13, 28-35		86	
1057	Risk assessment in the prevention of cardiovascular disease in low-resource settings. <b>2016</b> , 68, 391-8		16	
1056	Impact of Digoxin on Mortality in Patients With Atrial Fibrillation Stratified by Heart Failure: Findings From Gulf Survey of Atrial Fibrillation Events in the Middle East. <b>2016</b> , 21, 273-9		11	
1055	Predictors of exercise capacity following exercise-based rehabilitation in patients with coronary heart disease and heart failure: A meta-regression analysis. <b>2016</b> , 23, 683-93		57	
1054	Estimation of Myocardial Strain and Contraction Phase From Cine MRI Using Variational Data Assimilation. <b>2016</b> , 35, 442-55		3	
1053	The Efficacy and Safety of Iron Supplementation in Patients With Heart Failure and Iron Deficiency: A Systematic Review and Meta-analysis. <b>2016</b> , 32, 151-9		35	
1052	Arginine vasopressin receptor signaling and functional outcomes in heart failure. <b>2016</b> , 28, 224-233		28	
1051	Editor's Choice- Call to action: Initiation of multidisciplinary care for acute heart failure begins in the Emergency Department. <b>2016</b> , 5, 141-9		12	
1050	European Society of Cardiology-Acute Cardiovascular Care Association Position paper on acute heart failure: A call for interdisciplinary care. <b>2017</b> , 6, 81-86		34	
1049	The Self-care Educational Intervention for Patients With Heart Failure: A Study Protocol. <b>2017</b> , 32, 165-1	70	12	
1048	Normal range and usefulness of right ventricular systolic strain to detect subtle right ventricular systolic abnormalities in patients with heart failure: a multicentre study. <b>2017</b> , 18, 212-223		70	

1047	Agents with vasodilator properties in acute heart failure. 2017, 38, 317-325	36
1046	Editor's Choice-The role of the emergency department in the management of acute heart failure: An international perspective on education and research. <b>2017</b> , 6, 421-429	20
1045	Preliminary effects of renal denervation with saline irrigated catheter on cardiac systolic function in patients with heart failure: A Prospective, Randomized, Controlled, Pilot Study. <b>2017</b> , 89, E153-E161	28
1044	Worsening heart failure in 'real-world' clinical practice: predictors and prognostic impact. <b>2017</b> , 19, 987-995	9
1043	Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects. <b>2017</b> , 42, 309-318	15
1042	Long-term functional outcomes and quality of life in adult survivors of childhood extremity sarcomas: a report from the St. Jude Lifetime Cohort Study. <b>2017</b> , 11, 1-12	33
1041	New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction. 2017, 30, 541-548	
1040	Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients With Left Ventricular Systolic Dysfunction: A Meta-Analysis. <b>2017</b> , 68, 19-28	9
1039	HE4 Serum Levels Are Associated with Heart Failure Severity in Patients With Chronic Heart Failure. <b>2017</b> , 23, 12-19	31
1038	Asistencias ventriculares percutīleas, una herramienta cada vez mā al alcance de muchos hospitales. <b>2017</b> , 52, 120-123	
1037	Impact of Platelet-to-Lymphocyte Ratio on Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction. <b>2017</b> , 68, 346-353	15
1036	Role of Neprilysin Inhibitors in Heart Failure. <b>2017</b> , 24, e737-e743	3
1035	Prognostic significance of serial high-sensitivity troponin I measurements following acute cardiac decompensation-correlation with longer-term clinical outcomes and reverse remodelling. <b>2017</b> , 232, 199-207	6
1034	Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach. <b>2017</b> , 10,	56
1033	Downregulation of the []1 adrenergic receptor in the myocardium results in insensitivity to metoprolol and reduces blood pressure in spontaneously hypertensive rats. <b>2017</b> , 15, 703-711	6
1032	A Fixed-Dose Combination of Bisoprolol and Amlodipine for Hypertension: A Potential Benefit to Selected Patients. <b>2017</b> , 6, 6-8	2
1031	Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. <b>2017</b> , 19, 1014-1022	52
1030	Precision Phenotyping in Heart Failure and Pattern Clustering of Ultrasound Data for the Assessment of Diastolic Dysfunction. <b>2017</b> , 10, 1291-1303	50

1029	Obesity and Heart Failure: Focus on the Obesity Paradox. <b>2017</b> , 92, 266-279	137
1028	Race-Related Differences in Left Ventricular Structural and Functional Remodeling in Response to Increased Afterload: The ARIC Study. <b>2017</b> , 5, 157-165	24
1027	Valvular Heart Disease. <b>2017</b> , 13, e195-e198	1
1026	Short Stay Management of Acute Heart Failure. <b>2017</b> ,	
1025	Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. <b>2017</b> , 70, 225-231	26
1024	Evaluation of the predictors of readmission in Korean patients with heart failure. <b>2017</b> , 42, 51-57	3
1023	A Phase Ib open label, randomized, safety study of SANGUINATEIIn patients with sickle cell anemia. <b>2017</b> , 39, 20-27	38
1022	Effect of heart failure reversal treatment as add-on therapy in patients with chronic heart failure: A randomized, open-label study. <b>2017</b> , 69, 299-304	4
1021	Fluid status and outcome in patients with heart failure and preserved ejection fraction. 2017, 230, 476-481	15
1020	Value of serum N-terminal B-type natriuretic peptide in asymptomatic structural heart disease in Taiwanese population: Comparisons with current ESC Guidelines. <b>2017</b> , 231, 195-200	5
1019	Inspiratory muscle weakness in patients with Chagas heart disease: Echocardiographic and functional predictors. <b>2017</b> , 14, 21-25	3
1018	New guidelines, new recommendations! But what is really new? A pragmatic interpretation of the 2016 European guidelines for the management of chronic heart failure. <b>2017</b> , 110, 1-6	2
1017	Functional outcome in chronic heart failure after exercise training: Possible predictive value of heart rate variability. <b>2017</b> , 60, 87-94	9
1016	Stress echo 2020: the international stress echo study in ischemic and non-ischemic heart disease. <b>2017</b> , 15, 3	59
1015	Haemoconcentration as a treatment goal in heart failure: ready for prime time?. 2017, 19, 237-240	1
1014	Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions. <b>2017</b> , 5, 194-203	35
1013	Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. <b>2017</b> , 10,	13
1012	Heart Failure Complicated by Atrial Fibrillation: Don't Bury the Beta-Blockers Just Yet. <b>2017</b> , 5, 107-109	11

1011	Exo-organoplasty interventions: A brief review of past, present and future directions for advance heart failure management. <b>2017</b> , 88, 162-172	7
1010	Comparison of Echocardiography, Cardiac Magnetic Resonance, and Computed Tomographic Imaging for the Evaluation of Left Ventricular Myocardial Function: Part 2 (Diastolic and Regional Assessment). <b>2017</b> , 19, 6	10
1009	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. <b>2017</b> , 5, 391-402	42
1008	Association between obesity and heart failure symptoms in male and female patients. <b>2017</b> , 7, 77-85	12
1007	Prognostic impact of disseminated intravascular coagulation score in acute heart failure patients referred to a cardiac intensive care unit: a retrospective cohort study. <b>2017</b> , 32, 872-879	10
1006	Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis. <b>2017</b> , 35, e12253	8
1005	Acute Effects of Multisite Biventricular Pacing on Dyssynchrony and Hemodynamics in Canines With Heart Failure. <b>2017</b> , 23, 304-311	4
1004	Integrating palliative care into routine care of patients with heart failure: models for clinical collaboration. <b>2017</b> , 22, 517-524	19
1003	Association between reduced arterial stiffness and preserved diastolic function of the left ventricle in middle-aged and elderly patients. <b>2017</b> , 19, 620-626	9
1002	Palliative Care in Older Adults with Cardiovascular Disease: Addressing Misconceptions to Advance Care. <b>2017</b> , 11, 1	1
1001	Cardio-Onco-Hematologii en la priitica cliica. Documento de consenso y recomendaciones. <b>2017</b> , 70, 474-486	58
1000	The influence of aetiology on the benefits of exercise training in patients with heart failure. <b>2017</b> , 24, 365-372	14
999	What is the association between left ventricular diastolic dysfunction and 6-minute walk test in hypertensive patients?. <b>2017</b> , 11, 158-164	5
998	YiQiFuMai Powder Injection attenuates coronary artery ligation-induced myocardial remodeling and heart failure through modulating MAPKs signaling pathway. <b>2017</b> , 202, 67-77	24
997	Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival. <b>2017</b> , 235, 162-168	27
996	Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. <b>2017</b> , 19, 893-900	68
995	Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. <b>2017</b> , 19, 595-602	141
994	Fast left ventricle tracking using localized anatomical affine optical flow. <b>2017</b> , 33, e2871	15

993	Exercise-induced B-lines identify worse functional and prognostic stage in heart failure patients with depressed left ventricular ejection fraction. <b>2017</b> , 19, 1468-1478		54
992	Microparticles in Chronic Heart Failure. <b>2017</b> , 81, 1-41		9
991	Neprilysin Inhibitors in Cardiovascular Disease. <b>2017</b> , 19, 16		2
990	Orexin: a Missing Link Between Sleep Disorders and Heart Failure?. <b>2017</b> , 14, 100-105		3
989	The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials. <b>2017</b> , 22, 447-457		22
988	Imaging-Guided Cardioprotective Treatment in a Community Elderly Population of Stage B Heart Failure. <b>2017</b> , 10, 217-226		16
987	Perspective on precision medicine in paediatric heart failure. <b>2017</b> , 131, 439-448		5
986	Heart Rhythm Society: expert consensus statements-part 1. <b>2017</b> , 40, 177-185		1
985	2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <b>2017</b> , 14, e155-e217		74
984	2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant): A	15.1	14
983	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Journal of the American College of Cardiology</i> ,	15.1	154
982	<b>2017</b> , 70, e39-e110  Sleep-Disordered Breathing and Arrhythmia in Heart Failure Patients. <b>2017</b> , 12, 229-241		13
981	A randomized trial of heart failure disease management in skilled nursing facilities (SNF Connect): Lessons learned. <b>2017</b> , 14, 308-313		2
980	Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis. <b>2017</b> , 7, 27		58
979	Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT study. <b>2017</b> , 235, 124-132		23
978	Nutritional Status in Advanced Heart Failure and Heart Transplant Patients. <b>2017</b> , 70, 626-628		2
977	Atrial Arrhythmias and Electroanatomical Remodeling in Patients With Left Ventricular Assist Devices. <b>2017</b> , 6,		26
976	Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?. <b>2017</b> , 22, 305-316		1

975	Effect of carperitide on in-hospital mortality of patients admitted for heart failure: propensity score analyses. <b>2017</b> , 32, 916-925	7
974	Role of the Pharmacist for Improving Self-care and Outcomes in Heart Failure. <b>2017</b> , 14, 78-86	17
973	Diuretic Strategies in Acute Decompensated Heart Failure. <b>2017</b> , 14, 127-133	8
972	Cirug∃ coronaria en pacientes con disfunci⊡n ventricular severa. Resultados a medio plazo. <b>2017</b> , 24, 287-292	
971	Hemodynamic phenotyping based on exercise catheterization predicts outcome in patients with heart failure and reduced ejection fraction. <b>2017</b> , 36, 880-889	10
970	A Multisensor Algorithm Predicts Heart Failure Events in Patients With Implanted Devices: Results From the MultiSENSE Study. <b>2017</b> , 5, 216-225	139
969	Automatic segmentation and quantification of the cardiac structures from non-contrast-enhanced cardiac CT scans. <b>2017</b> , 62, 3798-3813	20
968	Randomized controlled trial of family-based education for patients with heart failure and their carers. <b>2017</b> , 73, 857-870	30
967	Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients. <b>2017</b> , 13, 473-481	1
966	Comparison of Echocardiography, Cardiac Magnetic Resonance, and Computed Tomographic Imaging for the Evaluation of Left Ventricular Myocardial Function: Part 1 (Global Assessment). <b>2017</b> , 19, 9	15
965	Cardiac diastolic and autonomic dysfunction are aggravated by central chemoreflex activation in heart failure with preserved ejection fraction rats. <b>2017</b> , 595, 2479-2495	28
964	Outpatient Emergencies: Acute Heart Failure. <b>2017</b> , 101, 507-519	3
963	Heart failure with preserved ejection fraction and skeletal muscle physiology. <b>2017</b> , 22, 141-148	7
962	Comparison of Clinical and Electrocardiographic Predictors of Ischemic and Nonischemic Cardiomyopathy During the Initial Evaluation of Patients With Reduced (图0%) Left Ventricular Ejection Fraction. <b>2017</b> , 119, 1650-1655	2
961	Evaluation of prokinetic agents used in the treatment of gastroparesis. 2017, 6, 6-9	9
960	Engaging patients with heart failure into the design of health system interventions: Impact on research methods. <b>2017</b> , 38, 342-346	2
959	Can Functional Testing for Ischemia and Viability Guide Revascularization?. 2017, 10, 354-364	13
958	Evaluation of remote dielectric sensing (ReDS) technology-guided therapy for decreasing heart failure re-hospitalizations. <b>2017</b> , 240, 279-284	61

Nuclear Cardiology for the Prediction of Response to Cardiac Resynchronization Therapy. 2017, 10, 1 957 2016 update to The American Association for Thoracic Surgery (AATS) consensus guidelines: 956 Ischemic mitral valve regurgitation. 2017, 153, e97-e114 Focus on the Patient With Known Cardiac Disease. 2017, 363-368 955 Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. 954 71 **2017**, 5, 287-296 Heart Transplant and Mechanical Circulatory Support in Patients With Advanced Heart Failure. 2017 6 953 .70.371-381 Natriuretic Peptides in Older Patients With Heart Failure: A Look Into the Seeds of Time. 2017, 65, 691-692 952 Altered myocyte contractility and calcium homeostasis in alpha-myosin heavy chain point 5 951 mutations linked to familial dilated cardiomyopathy. 2017, 615, 53-60 The renal and cardiovascular effects of natriuretic peptides. 2017, 41, 179-185 950 45 Cardio-Oncology. 2017, 1 949 Electronic Health Records and Drugs Prescribed for Off-label Indications. 2017, 92, 683-684 948 Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders. 2017, 243, 537-560 8 947 Troponin Testing in Patients Without Chest Pain or Electrocardiographic Ischemic Changes. 2017, 946 11 130, 1205-1210 Renin-Angiotensin System Inhibitor is Associated with Lower Risk of Ensuing Chronic Kidney 945 33 Disease after Functional Recovery from Acute Kidney Injury. 2017, 7, 46518 Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients. 2017, 7, 46642 16 944 Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience. 2017, 15 943 64, e26562 Potential palliative care quality indicators in heart disease patients: A review of the literature. 2017 942 13 , 70, 335-341 Development of a BNP1-32 Immunoassay That Does Not Cross-React with proBNP. 2017, 63, 1110-1117 941 15 Cardiac magnetic resonance imaging in heart failure: where the alphabet begins!. 2017, 22, 385-399 940 17

939	The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus. <b>2017</b> , 17, 38	31
938	The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure. <b>2017</b> , 22, 731-739	14
937	Screening and Monitoring for Cardiotoxicity During Cancer Treatment. 2017, 43-80	2
936	Management of Chemotherapy-Associated Cardiomyopathy. <b>2017</b> , 81-104	
935	Contemporary Approaches to Patients with Heart Failure. <b>2017</b> , 35, 261-271	15
934	Palliative care in heart failure: facts and numbers. <b>2017</b> , 4, 81-87	51
933	The clinical epidemiology of fatigue in newly diagnosed heart failure. <b>2017</b> , 17, 122	19
932	Salt Taste Recognition in a Heart Failure Cohort. <b>2017</b> , 23, 538-544	4
931	Renal response to intravascular volume expansion in euvolemic heart failure patients with reduced ejection fraction: Mechanistic insights and clinical implications. <b>2017</b> , 243, 318-325	4
930	The impact of carperitide usage on the cost of hospitalization and outcome in patients with acute heart failure: High value care vs. low value care campaign in Japan. <b>2017</b> , 241, 243-248	17
929	Achieving a Maximally Tolerated Blocker Dose in Heart Failure Patients: Is There Room for 1mprovement?. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2542-2550	23
928	Palliative Care in Heart Failure: What Triggers Specialist Consultation?. <b>2017</b> , 60, 215-225	16
927	Percutaneous Interventions for Structural Heart Disease. 2017,	
926	The State of the Science on Integrating Palliative Care in Heart Failure. <b>2017</b> , 20, 592-603	31
925	A multidimensional sight on cardiac failure: uncovered from structural to molecular level. <b>2017</b> , 22, 357-370	5
924	Prognostic Implications of Moderate Aortic Stenosis in Patients With Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2383-2392	61
923	Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2428-2445	50
922	Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure. <b>2017</b> , 37, 662-672	15

921	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). <b>2017</b> , 120, 98-105	9
920	Using Biomarkers to Guide Heart Failure Therapy. <b>2017</b> , 63, 954-957	6
919	Heart Failure Guidelines on Pharmacotherapy. <b>2017</b> , 243, 109-129	6
918	Uric acid predicts mortality and ischaemic stroke in subjects with diastolic dysfunction: the Troms   Study 1994-2013. <b>2017</b> , 4, 154-161	12
917	Plasma Catecholamine Levels on the Morning of Surgery Predict Post-Operative Atrial Fibrillation. <b>2017</b> , 3, 1456-1465	6
916	Invasive Hemodynamic Assessment of Patients with Heart Failure and Pulmonary Hypertension. <b>2017</b> , 19, 40	1
915	Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. <b>2017</b> , 5, e665-e672	148
914	Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure. <b>2017</b> , 6, 346-352	5
913	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. <b>2017</b> , 19, 800-809	91
912	The Role of Positive Inotropic Drugs in the Treatment of Older Adults with Heart Failure and Reduced Ejection Fraction. <b>2017</b> , 13, 527-534	1
911	Metabolic Syndrome Modulates Association between Endothelial Lipase and Lipid/Lipoprotein Plasma Levels in Acute Heart Failure Patients. <b>2017</b> , 7, 1165	7
910	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <b>2017</b> , 38, 2364-2373	72
909	Galectin-3 in acute coronary syndrome. <b>2017</b> , 50, 797-803	56
908	Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. <b>2017</b> , 5, 388-392	5
907	Right Ventricular Failure. <b>2017</b> , 711-725	
906	Expert consensus document: Echocardiography and lung ultrasonography for the assessment and management of acute heart failure. <b>2017</b> , 14, 427-440	84
905	2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant): A	2
904	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <b>2017</b> , 23, 628-651	378

903	Sympathetic modulation of electrical activation in normal and infarcted myocardium: implications for arrhythmogenesis. <b>2017</b> , 312, H608-H621	39
902	Metabolic profiles in heart failure due to non-ischemic cardiomyopathy at rest and under exercise. <b>2017</b> , 4, 178-189	22
901	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Journal of the</i>	1064
900	American College of Cardiology, 2017, 70, 776-803  Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure. 2017, 19, 502-511	13
899	Progression to Stage D Heart Failure Among Outpatients With Stage C Heart Failure and Reduced Ejection Fraction. <b>2017</b> , 5, 528-537	29
898	Patient Perceptions on Facilitating Follow-Up After Heart Failure Hospitalization. 2017, 10,	7
897	Precision Medicine for Heart Failure: Lessons From Oncology. <b>2017</b> , 10,	8
896	Cuidado paliativo en falla cardiaca. <b>2017</b> , 24, 286-296	O
895	How Trialists and Pharmaceutical Sponsors Have Failed Us by Thinking That Acute Heart Failure Is a 48-Hour Illness. <b>2017</b> , 120, 505-508	13
894	Late In-Hospital Management of Patients Hospitalized with Acute Heart Failure. <b>2017</b> , 60, 198-204	2
893	Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. <b>2017</b> , 47, 678-682	18
892	Central-acting therapeutics alleviate respiratory weakness caused by heart failure-induced ventilatory overdrive. <b>2017</b> , 9,	13
891	Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction. <b>2017</b> , 5, 483-493	28
890	Not Illness Trajectory but Bayesian-Estimated Rate Model Should Be Appropriately Explained When Discussing Palliative Care in Heart Disease. <b>2017</b> , 20, 580-581	
889	Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides. <b>2017</b> , 19, 1166-1175	21
888	Ground Hog Day: Do We Need Another Analysis of Diuretic Dose and Outcomes in Heart Failure Patients?. <b>2017</b> , 23, 594-596	
887	Palliative Care Interventions before Left Ventricular Assist Device Implantation in Both Bridge to Transplant and Destination Therapy. <b>2017</b> , 20, 977-983	33
886	Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management. <b>2017</b> , 19, 50	3

## (2017-2017)

885	Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. <b>2017</b> , 35, 178-187	1	18
884	Serial Heart Rates, Guideline-Directed Beta Blocker Use, and Outcomes in Patients With Chronic Heart Failure With Reduced Ejection Fraction. <b>2017</b> , 120, 803-808	3	;
883	Perceived social support and self-care in patients hospitalized with heart failure. <b>2017</b> , 16, 753-761	1	15
882	National Trends in Use and Outcomes of Pulmonary Artery Catheters Among Medicare Beneficiaries, 1999-2013. <b>2017</b> , 2, 908-913	3	34
881	Upcoming Challenges in Multidisciplinary Heart Failure Management: Active Role of Future Clinical Pharmacists. <b>2017</b> , 102, 180-182	1	[
880	Evaluation for Heart Transplant Candidacy. <b>2017</b> , 21-35		
879	Differences in Repolarization Heterogeneity Among Heart Failure With Preserved Ejection Fraction Phenotypic Subgroups. <b>2017</b> , 120, 601-606	1	10
878	Depression and health behaviors in women with Peripartum Cardiomyopathy. 2017, 46, 363-368	1	[1
877	Natriuretic peptides: degradation, circulating forms, dosages and new therapeutic approaches. <b>2017</b> , 75, 259-267	2	2
876	Left Ventricular Assist Devices for Lifelong Support. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2845-2861	5.1 E	58
875	Heart Failure. <b>2017</b> ,	4	ļ
874	Pulmonary congestion evaluated by lung ultrasound predicts decompensation in heart failure outpatients. <b>2017</b> , 240, 271-278	4	<b>1</b> 6
873	"We are all there for the same purpose": Support for an integrated community exercise program for older adults with HF and COPD. <b>2017</b> , 46, 308-312	6	5
872	Management of heart failure in the elderly. <b>2017</b> , 32, 217-223	6	6
871	Diabetes Mellitus and Heart Failure. <b>2017</b> , 130, S40-S50	7	7
870	Thyroid hormone biosynthesis machinery is altered in the ischemic myocardium: An epigenomic study. <b>2017</b> , 243, 27-33	1	<b>4</b>
869	Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. <b>2017</b> , 243, 389-395	2	21
868	Clinical features of extremely elderly patients with heart failure. <b>2017</b> , 17, 2194-2199	2	2

867	Inhaled Pulmonary Vasodilator Therapy for Management of Right Ventricular Dysfunction after Left Ventricular Assist Device Placement and Cardiac Transplantation. <b>2017</b> , 37, 944-955		24
866	Heart Failure Complicating Acute Mtyocardial Infarction. <b>2017</b> , 13, 513-525		4
865	Impact of a Multidisciplinary Heart Failure Postdischarge Management Clinic on Medication Adherence. <b>2017</b> , 39, 1200-1209		5
864	Incremental prognostic value of a complex left ventricular remodeling classification in asymptomatic for heart failure hypertensive patients. <b>2017</b> , 11, 412-419		16
863	Multidisciplinary Heart Failure Clinics Are Associated With Lower Heart Failure Hospitalization and Mortality: Systematic Review and Meta-analysis. <b>2017</b> , 33, 1237-1244		45
862	The Swing of ⊡Blockers: Time for a System Reboot. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2721-2724	15.1	9
861	Heart Failure with Myocardial Recovery - The Patient Whose Heart Failure Has Improved: What Next?. <b>2017</b> , 60, 226-236		16
860	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <b>2017</b> , 19, 821-836		147
859	Aspirin in heart failure: don't throw the baby (aspirin) out with the bathwater. <b>2017</b> , 19, 1089-1094		3
858	Agreement between heart failure patients and providers in assessing New York Heart Association functional class. <b>2017</b> , 46, 293-299		9
857	A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure. <b>2017</b> , 44, 31-38		34
856	Omega-3 supplementation on inflammatory markers in patients with chronic Chagas cardiomyopathy: a randomized clinical study. <b>2017</b> , 16, 36		9
855	How to Use Beta-Blockers in Heart Failure With Reduced Ejection Fraction and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2897-2900	15.1	9
854	Invited Commentary: Searching for the Perfect Measure of Diastolic Dysfunction-A Futile Exercise?. <b>2017</b> , 185, 1228-1230		1
853	Transcatheter Mitral Valve Repair With MitraClip for Symptomatic Functional Mitral Valve Regurgitation. <b>2017</b> , 120, 708-715		17
852	Diabetes Mellitus and Heart Failure. <b>2017</b> , 120, S37-S47		98
851	Diagnosis and Management of Heart Failure in Older Adults. <b>2017</b> , 13, 427-444		7
850	Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults. <b>2017</b> , 13, 467-483		2

849	Heart Failure with Preserved Ejection Fraction in Older Adults. <b>2017</b> , 13, 485-502	38
848	Use of Diuretics in the Treatment of Heart Failure in Older Adults. <b>2017</b> , 13, 503-512	4
847	Arrhythmic risk stratification in non-ischemic dilated cardiomyopathy: Where do we stand after DANISH?. <b>2017</b> , 27, 542-555	9
846	Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention. <b>2017</b> , 19, 1067-1078	8
845	Comparison of Predictors of Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Preclinical Left Ventricular Diastolic Dysfunction. <b>2017</b> , 119, 1815-1820	19
844	Management of Ventricular Arrhythmias in Patients With Advanced Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1842-1860	58
843	Effect of Milrinone Infusion on Pulmonary Vasculature and Stroke Work Indices: A Single-Center Retrospective Analysis in 69 Patients Awaiting Cardiac Transplantation. <b>2017</b> , 17, 335-342	4
842	Heart failurepathophysiology and inpatient management. <b>2017</b> , 17, 151-160	4
841	Risk of Stroke in Patients With Heart Failure: A Population-Based 30-Year Cohort Study. <b>2017</b> , 48, 1161-1168	58
840	Exercise-based cardiac rehabilitation in heart transplant recipients. <b>2017</b> , 4, CD012264	38
839	Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial. <b>2017</b> , 186, 130-138	21
838	Secondary Hyperparathyroidism in Heart Failure. <b>2017</b> , 354, 335-338	8
837	Prognostic value of VE/VCO2 and interleukin-6 in chronic heart failure subjects. 2017, 14, 65-66	
836	Reply: Routine Ischemic Work-Up for Patients With New-Onset Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 364-365	
835	Discordance of Patient-Reported and Clinician-Ordered Resuscitation Status in Patients Hospitalized With Acute Decompensated Heart Failure. <b>2017</b> , 53, 745-750	8
834	Assessment of cardiovascular impairment in obese patients: Limitations and troubleshooting of available imaging tools. <b>2017</b> , 36, 247-253	O
833	Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions. <b>2017</b> , 17, 283-298	6
832	SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. <b>2017</b> , 22, 518-525	25

831	Baroflex Activation Therapy for Refractory Congestive Heart Failure: Anesthetic Implications. <b>2017</b> , 31, 1103-1108	1
830	Nurses' attitudes toward family importance in heart failure care. <b>2017</b> , 16, 256-266	21
829	Routine Ischemic Work-Up for Patients With New-Onset Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 363-364	Ĺ
828	Response to Endurance Exercise Training in Older Adults with Heart Failure with Preserved or Reduced Ejection Fraction. <b>2017</b> , 65, 1698-1704	28
827	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <b>2017</b> , 33, 768-776	8
826	Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1683-1691	1 27
825	Systematic Evaluation of Endothelin 1 Measurement Relative to Traditional and Modern Biomarkers for Clinical Assessment and Prognosis in Patients With Chronic Systolic Heart Failure: Serial Measurement and Multimarker Testing. <b>2017</b> , 147, 461-472	13
824	Tensor Factorization for Precision Medicine in Heart Failure with Preserved Ejection Fraction. <b>2017</b> , 10, 305-312	21
823	Length of stay and risk of very early readmission in acute heart failure. <b>2017</b> , 42, 61-66	15
822	□Blockers, Cocaine, and the Unopposed ⊞timulation Phenomenon. <b>2017</b> , 22, 239-249	33
821	Hospice Enrollment in Patients With Advanced Heart Failure Decreases Acute Medical Service Utilization. <b>2017</b> , 10,	15
820	True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. <b>2017</b> , 188, 99-108	40
819	Comparison of Frequency of Cardiovascular Events and Mortality in Patients With Heart Failure Using Versus Not Using Cocaine. <b>2017</b> , 119, 2030-2034	13
818	Stop the Next Readmission for Heart Failure With Gap Time and a Natriuretic Peptide?. <b>2017</b> , 23, 390-391	
817	The Effect of Trabeculae Carneae on Left Ventricular Diastolic Compliance: Improvement in Compliance With Trabecular Cutting. <b>2017</b> , 139,	15
816	Perioperative NT-proBNP level: Potential prognostic markers in children undergoing congenital heart disease surgery. <b>2017</b> , 154, 631-640	23
815	Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). <b>2017</b> , 19, 1586-1596	82
814	Clinical utility of sympathetic blockade in cardiovascular disease management. <b>2017</b> , 15, 277-288	7

813	Advances in heart failure: a review of biomarkers, emerging pharmacological therapies, durable mechanical support and telemonitoring. <b>2017</b> , 131, 553-566	11
812	Heart Failure-Induced Brain Injury. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1609-1616 15.1	55
811	Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1577-1587	77
810	Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit. <b>2017</b> , 51, 529-542	2
809	A Change of Heart: the New Era of Heart Failure Management. <b>2017</b> , 5, 21-27	
808	Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure. <b>2017</b> , 240, 265-270	50
807	Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations. 2017, 70, 474-486	31
806	Effect of long-term remote ischaemic conditioning on platelet function and fibrinolysis in patients with chronic ischaemic heart failure. <b>2017</b> , 153, 40-46	19
805	Lvad pump speed increase is associated with increased peak exercise cardiac output and vo, postponed anaerobic threshold and improved ventilatory efficiency. <b>2017</b> , 230, 28-32	32
804	2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death:  A Report of the American College of Cardiology/American Heart Association Task Force on 15.1  Performance Measures. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 712-744	18
803	Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study. <b>2017</b> , 197, 1251-1257	14
802	Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. <b>2017</b> , 14, 238-250	322
801	Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. <b>2017</b> , 19, 1119-1127	66
800	Acute Heart Failure in the Emergency Department: Just a One Night Stand?. <b>2017</b> , 24, 385-387	5
799	Metabolic Modulators in Heart Disease: Past, Present, and Future. 2017, 33, 838-849	86
798	Prognostic value of malnutrition assessed by Controlling Nutritional Status score for long-term mortality in patients with acute heart failure. <b>2017</b> , 230, 529-536	73
797	Nutritional preconditioning by marine omega-3 fatty acids in patients with ST-segment elevation myocardial infarction: A METOCARD-CNIC trial substudy. <b>2017</b> , 228, 828-833	4
796	Natriuretic Peptides and Analytical Barriers. <b>2017</b> , 63, 50-58	25

795	Application of Cardiac Troponin in Cardiovascular Diseases Other Than Acute Coronary Syndrome. <b>2017</b> , 63, 223-235		54
794	Using coronary calcification to exclude an ischemic etiology for cardiomyopathy: A validation study and systematic review. <b>2017</b> , 230, 518-522		5
793	Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients. <b>2017</b> , 230, 378-383		5
792	Advanced refractory heart failure: conservative or interventional approach?. <b>2017</b> , 47, 193-194		
791	Healthcare Costs Among Patients with Heart Failure: A Comparison of Costs between Matched Decedent and Survivor Cohorts. <b>2017</b> , 34, 261-276		7
790	Increasing Cardiac Rehabilitation Participation From 20% to 70%: A Road Map From the Million Hearts Cardiac Rehabilitation Collaborative. <b>2017</b> , 92, 234-242		181
789	Perioperative Hypertension and Diastolic Dysfunction. 2017, 31, 1487-1496		3
788	Soluble ST2 predicts 1-year outcome in patients undergoing transcatheter aortic valve implantation. <b>2017</b> , 47, 149-157		19
787	An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands. <b>2017</b> , 20, 388-396		20
786	Recent advancements in the molecular genetics of left ventricular noncompaction cardiomyopathy. <b>2017</b> , 465, 40-44		19
785	Oleuropein attenuates the progression of heart failure in rats by antioxidant and antiinflammatory effects. <b>2017</b> , 390, 245-252		24
784	Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. <b>2017</b> , 35, 870-877		207
783	Palliative Care in Heart Failure: Architects Needed. <b>2017</b> , 23, 201-203		1
782	Cardiac contractility modulation in heart failure patients: Randomized comparison of signal delivery through one vs. two ventricular leads. <b>2017</b> , 69, 326-332		12
781	An emerging epidemic: cancer and heart failure. <b>2017</b> , 131, 113-121		13
780	Ontology-based systematical representation and drug class effect analysis of package insert-reported adverse events associated with cardiovascular drugs used in China. <b>2017</b> , 7, 13819		9
779	Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 2378-2388	15.1	72
778	The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 2393-2410	15.1	65

777	Refining Classification of Heart Failure Based on Ejection Fraction. 2017, 5, 808-809		16
776	Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients With Heart Failure. <b>2017</b> , 5, 810-819		33
775	Clinical Implications of Echocardiographic Phenotypes of Patients With Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1704-1716	15.1	70
774	Evolutional change in epicardial fat and its correlation with myocardial diffuse fibrosis in heart failure patients. <b>2017</b> , 11, 1421-1431		51
773	Utility of Growth Differentiation Factor-15, A'Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. <b>2017</b> , 5, 724-734		49
772	Comparison of Incidence of Left Ventricular Systolic Dysfunction Among Patients With Left Bundle Branch Block Versus Those With Normal QRS Duration. <b>2017</b> , 120, 1990-1997		21
771	Palliative Care in Heart Failure: Rationale, Evidence, and Future Priorities. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1919-1930	15.1	125
770	Two different methods of determining B-type natriuretic peptide, either from fingertip\(\mathbb{I}\) capillary blood or antecubital vein; A comparison regarding diagnostic accuracy in patients with chronic heart failure in NYHA class I-III. <b>2017</b> , 6, 4		
769	Pharmacogenomics and Cardiovascular Disease. <b>2017</b> , 161-174		
768	Cardiac Resynchronization Therapy in Heart Failure. <b>2017</b> , 385-402		
767	Emergency Department Therapy of Acute Heart Failure. <b>2017</b> , 165-183		
766	Education Elements in the Observation Unit for Heart Failure Patients. <b>2017</b> , 211-222		
765	Cardiac Surveillance Whilst Listed for Renal Transplantation. 2017, 251-258		
764	A Quality Improvement Project to Identify Patients With Advanced Heart Failure for Potential Palliative Care Referral in Telemetry and Cardiac Intensive Care Units. <b>2017</b> , 10, 17-23		O
763	Epidemiology of Heart Failure. <b>2017</b> , 93-102		
762	Ischemic Cardiomyopathy. <b>2017</b> , 119-133		
761	Health-Economic Aspects of MCS Therapy. <b>2017</b> , 595-603		
760	Techniques and Devices. <b>2017</b> , 133-151		

759	PharmacotherapyFirst: A Multimedia Learning Resource. 2017,	
758	The Use of Cardiac Resynchronization Therapy in Cancer Patients with Heart Failure. 2017, 3,	
757	Ambulatory Heart Failure Monitoring: A Systemic Review. <b>2017</b> , 9, e1174	5
756	Left lateral decubitus position on patients with atrial fibrillation and congestive heart failure. 2017,	
755	Chronic Heart Failure. <b>2017</b> ,	
754	Radiation-Related Heart Disease: Up-to-Date Developments.	
753	Stress Induced Cardiomyopathy Triggered by Acute Myocardial Infarction: A Case Series Challenging the Mayo Clinic Definition. <b>2017</b> , 18, 931-936	
75²	Heart Failure with Preserved Ejection Fraction in the Elderly: Challenges and Management. <b>2018</b> , 263-272	
75 <sup>1</sup>	Lay Consultations in Heart Failure Symptom Evaluation. <b>2017</b> , 3,	O
75°	eplerenone on the dynamics of the structural-functional state of the myocardium in patients with non Q-wave myocardial infarction after 3 and 6 months of treatment. <b>2018</b> , 24, 17-23	
749	OBSOLETE: Sex and Gender Differences in Cardiovascular Disease. 2018,	
748	Medical Management of Left Ventricular Assist Devices. <b>2018</b> , 328-330	
747	OBSOLETE: Medical Management of Left Ventricular Assist Devices. 2018,	
746	Pro-NT-Brain natriuretic peptide. <b>2018</b> , 1-2	
745	Diuretics in Heart Failure. <b>2018</b> , 53-70	
744	Is Cardiac Troponin I Valuable to Detect Low-Level Myocardial Damage in Congestive Heart Failure?. <b>2019</b> , 53, 172-178	O
743	Valvular Disease and Heart Failure: Mitral Regurgitation. <b>2018</b> , 43-50	
742	Brain natriuretic peptide. <b>2018</b> , 1-2	

Cardiovascular Disease in Elderly an Early Care. 2018, 175-193 741 Gender Differences in Cardiovascular Drugs. 2018, 287-302 740 Palliative Care in Advanced Heart Failure. 2018, 1-7 739 738 Acute and Chronic Heart Failure. 2018, 237-252 OBSOLETE: Echocardiography in Heart Failure. 2018, 737 OBSOLETE: Palliative Care in Advanced Heart Failure. 2018, 736 Ultrafiltration for the Treatment of Acute Decompensated Heart Failure. 2018, 600-605 735 OBSOLETE: Obesity and The Obesity Paradox in Heart Failure. 2018, 734 Cardiac Disease in Older Adults. 2018, 1-21 733 Atrial Fibrillation as a Cause of Incident Heart Failure: A Discrete Clinical Phenotype. 2018, 10, 1807 732 1 Association of change in 5-year N-terminal fragment of the prohormone brain-type natriuretic 731 3 peptide with left ventricular structure and function in stable coronary disease. 2018, 19, 67-72 Giant Cell Myocarditis: Case Review. 2018, In Press, 730 Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP Circulating 729 Levels in a Canine Model of RAAS Activation. The Added Value of In-Hospital Tracking of the Efficacy of Decongestion Therapy and Prognostic Value of a Wearable Thoracic Impedance Sensor in Acutely Decompensated Heart Failure With 728 Volume Overload: Prospective Cohort Study (Preprint). Cardiovascular Damage in Clinical Trials. 2019, 205-217 727 726 [A novel agent in the treatment of heart failure with depressed systolic function]. 2018, 88, 287-297 End-Stage Heart Disease and Indications for Heart Transplantation. 2019, 195-203 725 The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) 724 inhibition. 2018, 7, 212549

723	ICDs, VADs, and Total Artificial Heart Implantation. <b>2019</b> , 215-224	
722	The evolution of PCI registries: implementing a sustainable future for health systems and clinicians. <b>2018</b> , 14, 1076-1079	O
721	THE IMPORTANCE OF THE DIASTOLIC DYSFUNCTION IN THE CARDIOVASCULAR RISK STRATIFICATION OF NON-CARDIAC SURGICAL INTERVENTION. <b>2018</b> , 5, 18-25	
720	The effect of progressive muscle relaxation on the quality of life among patients with heart failure. <b>2018</b> , 28, 297-306	O
719	Dilated Cardiomyopathy. <b>2019</b> , 97-106	
718	Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy. <b>2018</b> , 12, CD012738	5
717	. <b>2018</b> , 58, 47-57	
716	The Cost-Effectiveness of Digital Health Interventions on the Management of Cardiovascular Diseases: Systematic Review (Preprint).	
715	Acute Decompensated Heart Failure. <b>2019</b> , 309-324	
714	HEART FAILURE - MEDICAL, ECONOMIC AND SOCIAL PROBLEM. <b>2019</b> , 72, 284-290	
714 713	HEART FAILURE - MEDICAL, ECONOMIC AND SOCIAL PROBLEM. <b>2019</b> , 72, 284-290  . <b>2019</b> , 59, 84-92	1
		1
713	. <b>2019</b> , 59, 84-92	1
713 712	. 2019, 59, 84-92  Pharmacogenomics and Cardiovascular Disease. 2019, 184-197	1
713 712 711	. 2019, 59, 84-92  Pharmacogenomics and Cardiovascular Disease. 2019, 184-197  [Functional recovery of the cardio-respiratory patient]. 2019, 36, 38-43  Equilibrium Radionuclide Angiography in Evaluation of Left Ventricular Mechanical Dyssynchrony in Patients with Dilated Cardiomyopathy: Comparison with Electrocardiographic Parameters and	1
713 712 711 710	. 2019, 59, 84-92  Pharmacogenomics and Cardiovascular Disease. 2019, 184-197  [Functional recovery of the cardio-respiratory patient]. 2019, 36, 38-43  Equilibrium Radionuclide Angiography in Evaluation of Left Ventricular Mechanical Dyssynchrony in Patients with Dilated Cardiomyopathy: Comparison with Electrocardiographic Parameters and Speckle-Tracking Echocardiography. 2019, 34, 88-95	1 O
713 712 711 710 709	. 2019, 59, 84-92  Pharmacogenomics and Cardiovascular Disease. 2019, 184-197  [Functional recovery of the cardio-respiratory patient]. 2019, 36, 38-43  Equilibrium Radionuclide Angiography in Evaluation of Left Ventricular Mechanical Dyssynchrony in Patients with Dilated Cardiomyopathy: Comparison with Electrocardiographic Parameters and Speckle-Tracking Echocardiography. 2019, 34, 88-95  Advances in New Marker ST2 for Heart Failure. 2019, 09, 451-455  A mini review of inhaled beta 2 agonists in acute decompensated heart failure requiring respiratory	

705	Current Management and Treatment. <b>2019</b> , 199-215	
704	Guidelines for Cardiovascular Magnetic Resonance. <b>2019</b> , 582-584.e1	
703	Patterns of Treatment in Patients with Heart Failure with Preserved Ejection Fraction: the REasons for Geographic And Racial Differences in Stroke study.	
702	Brain natriuretic peptide. <b>2019</b> , 481-482	
701	Cardiovascular Disease in Elderly an Early Care. <b>2019</b> , 455-473	
700	Left Ventricular Remodeling Patterns in Primary Healthcare. <b>2020</b> , 114, 59-65	Ο
699	Acute Cardiorenal Syndrome: Which Diagnostic Criterion to Use And What is its Importance for Prognosis?. <b>2020</b> , 115, 127-133	Ο
698	Patient-Centered Approach to Heart Failure Management: Transforming Care Delivery. <b>2019</b> , 75-92	
697	Heart Failure with Preserved Ejection Fraction. <b>2019</b> , 397-408	
696	CHOLESTEROL AND CHLORIDE IN ACUTE HEART FAILURE. <b>2019</b> , 58, 195-201	O
696 695	CHOLESTEROL AND CHLORIDE IN ACUTE HEART FAILURE. <b>2019</b> , 58, 195-201  The Kidney in Diastolic Dysfunction. <b>2019</b> , 718-721.e1	Ο
		2
695	The Kidney in Diastolic Dysfunction. <b>2019</b> , 718-721.e1  Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for	2
695 694	The Kidney in Diastolic Dysfunction. <b>2019</b> , 718-721.e1  Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. <b>2020</b> , 23, 160-168	2
695 694 693	The Kidney in Diastolic Dysfunction. 2019, 718-721.e1  Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. 2020, 23, 160-168  Noncardiac co Imorbidities in elderly patients with heart failure. 2019, 16, 72	2
695 694 693	The Kidney in Diastolic Dysfunction. 2019, 718-721.e1  Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. 2020, 23, 160-168  Noncardiac co Emorbidities in elderly patients with heart failure. 2019, 16, 72  Pro-NT-Brain natriuretic peptide. 2019, 1961-1962	2
695 694 693 692	The Kidney in Diastolic Dysfunction. 2019, 718-721.e1  Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. 2020, 23, 160-168  Noncardiac co Imorbidities in elderly patients with heart failure. 2019, 16, 72  Pro-NT-Brain natriuretic peptide. 2019, 1961-1962  Current Listing System. 2019, 1-16  Biventricular pacing for treating heart failure in children: A case report and review of the literature.	O 2

687	Levo-transposition of the Great Arteries in an Adult Patient: Management Considerations and Treatment Strategy. <b>2019</b> , 11, e4306	
686	Effect of coronary artery bypass surgery on ventricular functions in patients with poor left ventricular function.	1
685	Clinical Impact and Associated Factors of Delayed Ambulation in Patients With Acute Heart Failure. <b>2020</b> , 1, 179-186	2
684	Anemia in Patients with Heart Failure: Current State of the Problem. <b>2019</b> , 8, 68-73	1
683	Genetic determinants of lipids and cardiovascular disease outcomes: a wide-angled Mendelian randomization investigation.	1
682	MitraClip Deployed via Left Femoral Vein in an 85-Year-Old Woman with Mitral Regurgitation. <b>2019</b> , 46, 195-198	
681	Hemodynamic Insights to Cardio-Renal Syndrome: A View Looking Back to See Forward. <b>2020</b> , 11-20	
680	Akut anterior ST segment miyokard infarktsonras-GRACE risk skorunun sol ventrik[lejeksiyon fraksiyonundaki prediktif deëri. <b>2019</b> , 44, 819-828	
679	Postoperative Antibiotic Prophylaxis Following Cardiac Implantable Electronic Device Placement. <b>2019</b> , 10, 3777-3784	3
678	Prescription Selection and Dosing. <b>2020</b> , 169-175	
677	Flash Pulmonary Edema: Staying Afloat in the Flash Flood. <b>2020</b> , 225-238	
676	The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus. <b>2019</b> , 98-111	3
675	Impact of left ventricular assist devices and heart transplant on acute myocardial infarction and heart failure mortality and readmission measures.	
674	Digoxin Toxicity in a Patient with Pacemaker: A Case Report. <b>2019</b> , 11, e6056	1
673	Mitochondrial DNA copy number and incident heart failure: The Atherosclerosis Risk in Communities (ARIC) study.	
672	Hypotensive Syndromes and Heart Failure. <b>2020</b> , 117-127	
672 671	Hypotensive Syndromes and Heart Failure. <b>2020</b> , 117-127  Anticoagulation in Cardiac Patients. <b>2020</b> , 77-102	

669	Current clinical practice of cardiac resynchronization therapy in Turkey: Reflections from Cardiac Resynchronization Therapy Survey-II. <b>2020</b> , 24, 382-396	1
668	Arrhythmia-Induced Cardiomyopathies. <b>2020</b> , 547-567	
667	Heart Failure and the Obesity Paradox. <b>2020</b> , 427-435	
666	The Heart failure treatment, All at once!. <b>2020</b> , 218, 03037	
665	Unexpected Reduced Biventricular Ejection Fraction in a Healthy Young Male. 2020, 12, e7292	
664	Defining the Role of MitraClip Therapy for Mitral Valve Regurgitation. <b>2020</b> , 47, 130-133	
663	Interpretation of Physiologic and Left Ventricular Assist Device Parameters: Implications for Physical Therapist Decision-Making. <b>2021</b> , 32, 41-51	
662	Old and New Drugs for Treatment of Advanced Heart Failure. <b>2020</b> , 26, 1571-1583	1
661	Heart Failure Drug Class Effects on 30-Day Readmission Rates in Patients with Heart Failure with Preserved Ejection Fraction: A Retrospective Single Center Study. <b>2020</b> , 7,	1
660	Left ventricular systolic dysfunction in patients with unprotected left main coronary artery disease. <b>2021</b> , 46, 262-268	1
659	Characteristics that Predict Response After Cardiac Resynchronization Therapy. <b>2020</b> , 14, 1	1
658	Identification of Target Genes and Transcription Factors in Mice with LMNA-Related Dilated Cardiomyopathy by Integrated Bioinformatic Analyses. <b>2020</b> , 26, e924576	
657	Predictors of Ischemic Cardiomyopathy in Patients with Acute Myocardial Infarction who Underwent Percutaneous Coronary Intervention. <b>2020</b> , 95, 188-200	
656	Role of MicroRNAs in Diagnosis, Prognosis, and Treatment of Acute Heart Failure: Ambassadors from Intracellular Zone. <b>2020</b> , 9, e1818	1
655	Non-Invasive Central Venous Pressure Measurement Using Enclosed-Zone Central Venous Pressure (ezCVP). <b>2020</b> , 84, 1112-1117	0
654	Comparison of Perioperative Outcomes in Heart Failure Patients With Reduced Versus Preserved Ejection Fraction After Noncardiac Surgery. <b>2020</b> ,	1
653	A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction. <b>2020</b> , 15, 644-653	
652	Weight change in heart failure inpatients not associated with 30-day readmission. <b>2020</b> , 16, 289-296	

651	Heart Failure Training and Job Satisfaction: A Survey of Home Care Workers Caring for Adults with Heart Failure in New York City. <b>2020</b> , 30, 575-582		3
650	The Association Between Pneumonia and Heart failure. <b>2020</b> , 27, 125-130		О
649	Endocrine system dysfunction and chronic heart failure: a clinical perspective. 2021, 1		1
648	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, e187-e285	15.1	28
647	Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study. <b>2021</b> ,		2
646	Effect of early cardiac rehabilitation on prognosis in patients with heart failure following acute myocardial infarction. <b>2021</b> , 13, 139		O
645	Harnessing the Potential of Primary Care Pharmacists to Improve Heart Failure Management. <b>2021</b> , 48, 25-25		
644	Mortality among ischemic and nonischemic heart failure patients with a primary implantable cardioverter-defibrillator. <b>2021</b> , 37, 1537-1545		
643	Better CRT Response in Patients Who Underwent Atrioventricular Node Ablation or Upgrade From Pacemaker: A Nomogram to Predict CRT Response. <b>2021</b> , 8, 760195		
642	Concentrations of Mg, Ca, Fe, Cu, Zn, P and anthropometric and biochemical parameters in adults with chronic heart failure. <b>2021</b> , 9, e12207		O
641	Using the Evidence for Palliative Care to Improve Outcomes for Patients With Heart Failure. <b>2021</b> , 30, 479-482		
640	Comparison of haemodynamic response to muscle reflex in heart failure with reduced vs. preserved ejection fraction. <b>2021</b> ,		1
639	Incidence, prognosis, and risk factors of sepsis-induced cardiomyopathy. <b>2021</b> , 9, 9452-9468		1
638	Heart Failure. <b>2020</b> , 201-212		
637	Pharmacologic Support of the Failing Heart. <b>2020</b> , 597-605		
636	Risk Factors for AKI Development in Acute Decompensated Heart Failure. <b>2020</b> , 69-83		
635	Part 1: Disease of the Heart and Liver: A Relationship That Cuts Both Ways. 2020,		
634	Persistent Heart Failure Symptoms at Hospital Discharge Predicts 30-Day Clinical Events. <b>2020</b> , 37,		

## (2020-2020)

633	Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases. <b>2020</b> , 15, e0244231	1
632	Secondary Prevention and Cardiac Rehabilitation. <b>2021</b> , 673-703	
631	Drug-Therapy Problems and Predictors among Hospitalized Heart-Failure Patients: A Prospective Observational Study. <b>2020</b> , 12, 281-291	О
630	In-Hospital acute ischemic stroke following ST-elevation myocardial infarction. <b>2020</b> , 31, 100684	1
629	Prevention of Heart Failure. <b>2021</b> , 489-512	
628	Regional variation in cardiac implantable electronic device implants trends in New Zealand over the past decade (ANZACS-QI 54). <b>2020</b> ,	1
627	Developments in Heart Failure With Reduced Ejection Fraction. 2020, 324, 2214-2215	
626	Serum Copper Level in Patients with Heart Failure and its Related Factors. <b>2020</b> , In Press,	
625	Exercise training modalities for heart transplant recipients: a systematic review and network meta-analysis protocol. <b>2020</b> , 10, e044975	0
624	The Efficacy of Psychological Interventions on Health-Related Quality of Life for Patients with Heart Failure and Depression: A Systematic Review. <b>2020</b> , Publish Ahead of Print,	1
623	The Association of Diurnal Blood Glucose Variability With Subclinical Cardiac Disease in Patients With Type 2 Diabetes Mellitus. <b>2020</b> , 32, 490-497	
622	Can we have a rationalized selection of intra-aortic balloon pump, Impella, and extracorporeal membrane oxygenation in the catheterization laboratory?. <b>2020</b> ,	1
621	Development of a Novel Homogeneous Nanoparticle-Based Assay for Rapid and High-Throughput Quantitation of the sST2 Protein in Human Serum. <b>2020</b> , 15, 10539-10546	O
620	Control of blood pressure in older patients with heart failure and the risk of mortality: a population-based prospective cohort study. <b>2021</b> , 50, 1173-1181	
619	Association between platelet distribution width and prognosis in patients with heart failure. <b>2020</b> , 15, e0244608	3
618	Atherogenic index of plasma and left ventricular ejection fraction in newly diagnosed type 2 diabetes mellitus patients. <b>2021</b> , 10, 73	1
617	The Impact of beta blockade on the cardio-respiratory system and symptoms during exercise <b>2021</b> , 4, 235-242	0
616	Encyclopedia of Systems and Control. <b>2020</b> , 1-13	

615 Selection of Artificial Heart Devices. **2020**, 129-145

614	Quality of Life of Chronic Heart Failure Patients. <b>2020</b> , 10, 831-857	1
613	Cardiogenic Shock in Patients with Advanced Chronic Heart Failure. <b>2020</b> , 16, 22-26	2
612	Cardio-Ankle Vascular Index Predicts Post-Discharge Stroke in Patients with Heart Failure. <b>2021</b> , 28, 766-775	1
611	Novel pharmacotherapies for heart failure. <b>2020</b> , 359-380	
610	Cardiac Disease in Older Adults. <b>2020</b> , 229-249	
609	NT-proBNP Level Predicts Extent of Myonecrosis and Clinical Adverse Outcomes in Patients with ST-Elevation Myocardial Infarction: A Pilot Study. <b>2020</b> , 8,	1
608	Management of Heart Failure in Older Adults with Dementia. <b>2020</b> , 53-76	
607	A myriad of electrocardiographic findings associated with digoxin use. <b>2020</b> , 61, 9-14	2
606	Exercise in Specific Diseases: Heart Transplantation and Left Ventricular Assist Device. <b>2020</b> , 977-1009	
605	Echocardiographic Changes in Newly Diagnosed Type 2 Diabetes Mellitus Patients with and without Hypertension. <b>2020</b> , 26, e918972	2
604	Percutaneous left and right ventricular support devices. <b>2020</b> , 41-54	
603	Clinical and Hospital Factors Affecting Treatment with Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy Patients. <b>2020</b> , 61, 942-950	
602	Inpatient Pain Medicine Considerations in Patients with Heart Failure, Cardiac Arrhythmias, and Other Cardiac Conditions. <b>2020</b> , 57-81	
601	Cardiopulmonary Rehabilitation in Heart Failure. <b>2020</b> , 229-244	
600	Dilated Cardiomyopathy. <b>2020</b> , 77-97	
599	Maternal Cardiomyopathy and Critical Care Medicine. <b>2020</b> , 135-148	
598	Management of Cardiogenic Shock in a Cardiac Intensive Care Unit. <b>2020</b> , 16, 36-42	4

New Onset Heart Failure: Which Side Is It, Right or Left?. **2020**, 21-41

596	Current Listing System. <b>2020</b> , 97-112		
595	Management of Acute Decompensated Heart Failure. <b>2020</b> , 27-34		
594	Marital status and outcomes in chronic heart failure: Does it make a difference of being married, widow or widower?. <b>2021</b> , 8, 63-70		1
593	Pharmacological and Non-pharmacological Strategies for Volume Overload in Acute Decompensated Congestive Heart Failure: A Review Article. <b>2020</b> , 12, e6952		1
592	Diuretic Resistance in Heart Failure. <b>2021</b> , 29, 73-81		2
591	Chronic heart failure: syndrome or disease?. <b>2020</b> , 19, 134-139		4
590	Comparable Efficacy in Ischemic and Non-Ischemic ICD Recipients for the Primary Prevention of Sudden Cardiac Death. <b>2021</b> , 9,		Ο
589	Usefulness of Incorporating Hypochloremia into the Get With The Guidelines-Heart Failure Risk Model in Patients With Acute Heart Failure. <b>2021</b> ,		1
588	The impact of a community-based heart failure multidisciplinary team clinic on healthcare utilization and costs. <b>2021</b> ,		1
587	Exercise Ventricular Reserve Among Women With a History of Peripartum Cardiomyopathy. <b>2021</b> , 3, 1649-1653		
586	Enrollment and Adherence to Early Outpatient and Maintenance Cardiac Rehabilitation Programs. <b>2021</b> , 41, 367-374		1
585	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 2004-2012	15.1	7
584	Heart Failure With Reduced Ejection Fraction: "Guideline-Directed Medical Therapy (GDMT)" Versus "The Art of Medicine". <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 2013-2016	15.1	
583	Contemporary Trends of Clinical Outcomes in Primary Left Ventricular Assist Device Implantation and Postprocedure High-Risk Categories. <b>2021</b> ,		0
582	Euvolemia as a criterion of diuretic therapy efficacy in chronic heart failure: Literature review. <b>2020</b> , 35, 13-25		
581	Pharmacotherapy Update and Review for Family Medicine Residents Using Jeopardy-Style Game. <b>2020</b> , 16, 10941		1
580	Antiarrhythmics, Inotropes, and Vasopressors. 237-252		

579	Left ventricular response after cardiac resynchronization therapy is related to early left atrial volume reduction. <b>2020</b> , 35, 1125-1135	О
578	Is the Obesity Paradox in Heart Failure Dependent on Cardiorespiratory Fitness?. <b>2020</b> , 115, 646-648	O
577	The Role of Adherence to Basic Pharmacotherapy of Heart Failure for Prevention of Late Adverse Events in Patients with Coronary Artery Disease and Left Ventricular Dysfunction After Surgical Revascularization of Myocardium. <b>2020</b> , 16, 678-685	
576	Cardiovascular disease risk and pathophysiology in South Asians: can longitudinal multi-omics shed light?. <b>2020</b> , 5, 255	O
575	All-Cause Mortality Outcomes of Usage of Cardiac Contractility Modulation in Patients With Dilated Cardiomyopathy Ineligible for Cardiac Re-Synchronization Therapy: An Updated Meta-Analysis of Randomized Controlled Trials. <b>2020</b> , 12, e10627	1
574	Cardiomyopathies: Dilated, Restrictive/Infiltrative, and Hypertrophic Cardiomyopathies. 2021, 535-549	
573	Myocarditis and Inflammatory Cardiomyopathy. <b>2021</b> , 551-563	
572	Valid cardiac biochemical markers. Part II. <b>2020</b> , 19, 2588	2
571	LDL/Apo B ratio and Lp (a) Each Predict Coronary Artery Disease in Type2 Diabetes Independent of ASCVD Risk Score: A Case-Cohort Study.	
570	Patient-centered communication and outcomes in heart failure. <b>2020</b> , 26, 425-430	3
569	Serelaxin, a 'breakthrough' investigational intravenous agent for acute heart failure. <b>2013</b> , 38, 606-11	
		2
568	Heart failure with preserved ejection fraction. <b>2013</b> , 10, 369-76	14
568 567	Heart failure with preserved ejection fraction. <b>2013</b> , 10, 369-76  Disparities in medication therapy in patients with heart failure across the State of Hawai'i. <b>2015</b> , 74, 5-8	
567	Disparities in medication therapy in patients with heart failure across the State of Hawai'i. <b>2015</b> , 74, 5-8	14
567 566	Disparities in medication therapy in patients with heart failure across the State of Hawai'i. <b>2015</b> , 74, 5-8  Rationale and Design of the Echocardiographic Study of Hispanics/Latinos (ECHO-SOL). <b>2015</b> , 25, 180-6	14
567 566 565	Disparities in medication therapy in patients with heart failure across the State of Hawai'i. <b>2015</b> , 74, 5-8  Rationale and Design of the Echocardiographic Study of Hispanics/Latinos (ECHO-SOL). <b>2015</b> , 25, 180-6  Left Ventricular Assist Devices for Destination Therapy: A Health Technology Assessment. <b>2016</b> , 16, 1-60	14 14 4

561	Soluble ST2 and Galectin-3: What We Know and Don't Know Analytically. 2016, 27, 224-37	16
560	Evaluation of myocardial viability in old myocardial infarcted patients with CHF: delayed enhancement MRI vs. low-dose dobutamine stress speckle tracking echocardiography. <b>2016</b> , 8, 3731-3743	4
559	Cardiac Resynchronization Therapy in Non-Ischemic Cardiomyopathy. <b>2016</b> , 8, 1362	3
558	Worse Prognosis in Heart Failure Patients with 30-Day Readmission. <b>2016</b> , 32, 698-707	14
557	Branko Furst's Radical Alternative: Is the Heart Moved by the Blood, Rather Than Vice Versa?. <b>2017</b> , 42, 33-39	4
556	DCDS: A Real-time Data Capture and Personalized Decision Support System for Heart Failure Patients in Skilled Nursing Facilities. <b>2016</b> , 2016, 2100-2109	
555	Automating Guidelines for Clinical Decision Support: Knowledge Engineering and Implementation. <b>2016</b> , 2016, 1189-1198	14
554	Identification and Use of Frailty Indicators from Text to Examine Associations with Clinical Outcomes Among Patients with Heart Failure. <b>2016</b> , 2016, 1110-1118	17
553	Stretch-activated channel Piezo1 is up-regulated in failure heart and cardiomyocyte stimulated by AngII. <b>2017</b> , 9, 2945-2955	23
552	The Association between CHADS-VASc Score and Mortality in Patients with Heart Failure with Reduced Ejection Fraction. <b>2017</b> , 33, 429-435	4
551	The Clinical and Economic Burden of Hyperkalemia on Medicare and Commercial Payers. <b>2017</b> , 10, 202-210	27
550	New Heart Failure Medications Aim To Fill Significant Gaps in Treatment. 2017, 42, 764-766	2
549	Effect of Heart Rate-Oriented Therapy on Diastolic Functions in Patients with Heart Failure with Reduced Ejection Fraction. <b>2018</b> , 34, 251-258	4
548	Influenza vaccination in acute coronary syndromes patients in Thailand: the cost-effectiveness analysis of the prevention for cardiovascular events and pneumonia. <b>2018</b> , 15, 413-421	4
547	Repeated measurement of growth-differentiation factor-15 in Chinese Han patients with post-myocardial infarction chronic heart failure. <b>2018</b> , 15, 618-627	2
546	Diagnostic Snapshot: "I Have a Bad Cold". <b>2018</b> , 9, 241-243	
545	Factors affecting medication adherence trajectories for patients with heart failure. <b>2015</b> , 21, e197-205	16
544	Using Feedback Intervention Theory to Guide Clinical Dashboard Design. <b>2018</b> , 2018, 395-403	7

543	The Pharmacist's Role in Medication Optimization for Patients With Chronic Heart Failure. 2017, 34, S10-S15	3
542	Heart Failure in Older Adults: A Geriatrician Call for Action. <b>2018</b> , 35, S23-S29	
541	Clinical characteristics, treatment and prognosis of patients with idiopathic dilated cardiomyopathy: a tertiary center experience. <b>2019</b> , 16, 320-328	1
540	Toward a Clinical Point of Care Tool for Managing Heart Failure. <b>2019</b> , 2019, 819-828	
539	Testing the obesity paradox in patients on long-term milrinone infusion for end-stage heart failure. <b>2019</b> , 9, 59-64	1
538	Endomyocardial biopsy in patients with acute myocarditis, idiopathic dilated cardiomyopathy, and arrhythmogenic right ventricular dysplasia. <b>2018</b> , 11, 4270-4275	1
537	The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population. 2019, 12, 352-361	1
536	Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction. <b>2020</b> , 36, 125-132	2
535	The association between particulate matter 2.5 and hospitalization and mortality rates of heart failure: The CAPACITY study. <b>2019</b> , 15, 253-259	2
534	One-Year Mortality Risk Stratification in Patients Hospitalized for Acute Decompensated Heart Failure: Construction of TSOC-HFrEF Risk Scoring Model. <b>2020</b> , 36, 240-250	
533	Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. <b>2020</b> , 7, L1-L4	1
532	Reply to Letter to the Editor regarding reference limits for echocardiography. 2020,	
531	Prognostic Awareness and Goals of Care Discussions Among Patients With Advanced Heart Failure. <b>2020</b> , 13, e006502	3
530	Geriatric issues in patients with or being considered for implanted cardiac rhythm devices: a case-based review. <b>2020</b> , 17, 710-722	
529	Neurohumoral, cardiac and inflammatory markers in the evaluation of heart failure severity and progression. <b>2021</b> , 18, 47-66	1
528	Beta-blocker therapy in elderly patients with renal dysfunction and heart failure. <b>2021</b> , 18, 20-29	
527	Heart Failure and Malignancy: Implications of Chemotherapy and Radiation in the Pathogenesis of Cardiomyopathy in Cancer Treated Populations. <b>2020</b> , 16,	
526	The relationship between coronary microvascular dysfunction, atrial fibrillation and heart failure with preserved ejection fraction. <b>2021</b> , 11, 29-38	

525	Information Needs of Skilled Nursing Facility Staff to Support Heart Failure Disease Management. <b>2020</b> , 2020, 878-885	1
524	Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets. <b>2020</b> , 3, 82-97	2
523	Combined atrioventricular longitudinal strain rate during isovolumic contraction predicts pulmonary capillary wedge pressure in patients with systolic dysfunction. <b>2021</b> , 11, 530-538	
522	Advances in telemedicine for the management of the elderly cardiac patient. 2021, 18, 759-767	O
521	Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. <b>2021</b> , 8, 754499	3
520	Heart Failure Biomarker Education: An Unmet Need in Cardiovascular Fellowship Training. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 2265-2266	15.1
519	Circumstances surrounding end-of-life in pediatric patients pre- and post-heart transplant: a report from the Pediatric Heart Transplant Society. <b>2021</b> , e14196	O
518	Cardiac Rehabilitation for Patients with Heart failure: Association With Readmission and Mortality Risk. <b>2021</b> ,	O
517	Initiation of Anti-Hypertensive Drugs and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. <b>2021</b> ,	О
516	Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. <b>2021</b> ,	1
515	SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness. <b>2021</b> , 1	О
514	Integration of clinical pharmacists into a heart failure clinic within a safety-net hospital 2021,	1
513	Echocardiography in the diagnostic evaluation and phenotyping of heart failure with preserved ejection fraction. <b>2021</b> ,	О
512	Prescriptions for Potentially Inappropriate Medications from the Beers Criteria Among Older Adults Hospitalized for Heart Failure. <b>2021</b> ,	O
511	The Impact of Clinical, Biochemical, and Echocardiographic Parameters on the Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction. <b>2021</b> , 18,	
510	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <b>2021</b> ,	3
509	A Natural Language Processing-Based Approach for Identifying Hospitalizations for Worsening Heart Failure Within an Integrated Health Care Delivery System. <b>2021</b> , 4, e2135152	2
508	Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. <b>2021</b> , 1	3

507	The Ratio of NT-proBNP to CysC Predicts Heart Failure in Patients With Chronic Kidney Disease. <b>2021</b> , 8, 731864	2
506	Risk factors for asymptomatic echocardiographic abnormalities that predict symptomatic heart failure. <b>2021</b> ,	1
505	Temporal Association of Atrial Fibrillation With Cardiac Implanted Electronic Device Detected Heart Failure Status <b>2022</b> , 8, 182-193	
504	Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature <b>2021</b> , 9, 10382-10391	1
503	Association of tacrolimus time-to-therapeutic range on renal dysfunction and acute cellular rejection after orthotopic heart transplantation in a high use basiliximab population. <b>2021</b> , e14542	
502	Race Differences in Quality of Life following a Palliative Care Intervention in Patients with Advanced Heart Failure: Insights from the Palliative Care in Heart Failure Trial. <b>2021</b> ,	1
501	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines <b>2021</b> ,	6
500	Translation of New and Emerging Therapies for Genetic Cardiomyopathies 2022, 7, 70-83	O
499	Preeclampsia Predicts Risk of Hospitalization for Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, <b>2021</b> , 78, 2281-2290	15.1 5
498	Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results. <b>2021</b> , 22,	2
497	Myocardial mechanics in dilated cardiomyopathy: prognostic value of left ventricular torsion and strain. <b>2021</b> , 23, 136	2
496	Impact of physical performance on exercise capacity in older patients with heart failure with reduced and preserved ejection fraction. <b>2021</b> , 156, 111626	1
495	Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity 2021, 1342, 377-387	
494	Acute Heart Failure in the 2021 ESC Heart Failure Guidelines: a scientific statement from the Association for Acute CardioVascular Care (ACVC) of the European Society of Cardiology <b>2022</b> ,	3
493	Significant vascular complications in percutaneous axillary intra-aortic balloon pump 2022,	О
492	Incidence, Clinical Characteristics and Short-Term Prognosis in Patients With Cardiogenic Shock and Various Left Ventricular Ejection Fractions After Acute Myocardial Infarction <b>2022</b> ,	O
491	An evaluation of torsemide in patients with heart failure and renal disease 2021,	1
490	Serum Galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study <b>2022</b> , 23, 5	O

## (2021-2021)

489	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Journal of the American College of Cardiology, 2021,	15.1	42
488	Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. <b>2020</b> , 7, L1-L4		1
487	Response to Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. <b>2020</b> , 7, L5-L7		
486	A Comparison of Oversampling Methods for Constructing a Prognostic Model in the Patient with Heart Failure. <b>2020</b> ,		3
485	Subclinical anthracycline therapy-related cardiac Dysfunction: an ignored stage B heart failure in an African population. <b>2020</b> , 31, 262-266		О
484	Impact of left ventricular diastolic dysfunction on liver transplantation outcomes based on the latest American Society of Echocardiography/European Association of Cardiovascular Imaging recommendations <b>2021</b> , 7, 390-395		0
483	Does group-based high-intensity aerobic interval training improve the inflammatory status in patients with chronic heart failure? A randomized controlled trial. <b>2021</b> ,		1
482	The Use of Mobile Apps for Heart Failure Self-management: Systematic Review of Experimental and Qualitative Studies <b>2022</b> , 6, e33839		1
481	Living with heart failure: patient experiences and implications for physical activity and daily living <b>2022</b> ,		1
480	Evaluation of the safety and efficacy of Zhenwu decoction as adjuvant therapy for the treatment of heart failure with reduced ejection fraction: A protocol for systematic review and meta-analysis <b>2022</b> , 101, e28672		1
479	Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation <b>2022</b> , 26, 1-128		2
478	NT-pro B-type natriuretic peptide, early menopause, and incident heart failure in postmenopausal women of the ARIC study <b>2022</b> , 29, 309-316		1
477	Nrf2 Signaling in Heart Failure: Expression of Nrf2, Keap1, Antioxidant and Detoxification Genes in Dilated or Ischemic Cardiomyopathy <b>2022</b> ,		1
476	Muscle-Skeletal Abnormalities and Muscle Oxygenation during Isokinetic Strength Exercise in Heart Failure with Preserved Ejection Fraction Phenotype: A Cross-Sectional Study <b>2022</b> , 19,		
475	Association Between Exposure to Effervescent Paracetamol and Hospitalization for Acute Heart Failure: A Case-Crossover Study <b>2022</b> ,		
474	Galectin-3 as an independent prognostic factor after heart transplantation 2022, e14592		
473	Relation of Cardiorenal Syndrome to Mitral and Tricuspid Regurgitation in Acute Decompensated Heart Failure <b>2022</b> ,		
472	Traditional Chinese Medicine Targeting Heat Shock Proteins as Therapeutic Strategy for Heart Failure <b>2021</b> , 12, 814243		

471	One step closer to myocardial physiology: from PV-loop analysis to state-of-the-art myocardial imaging <b>2022</b> , e13759	
470	Left Ventricular Structure is Associated with Postoperative Death After Coronary Artery Bypass Grafting in Patients with Heart Failure with Reduced Ejection Fraction <b>2022</b> , 15, 53-62	Ο
469	Current State of Pediatric Cardio-Oncology: A Review <b>2022</b> , 9,	Ο
468	Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020 <b>2022</b> , 12,	Ο
467	Glycemic Markers and Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA) <b>2022</b> ,	3
466	The role of SGLT2 inhibitors in heart failure. 1, 2	
465	Intracoronary pressures to predict myocardial viability in patients with ischemic left ventricular dysfunction <b>2022</b> ,	
464	Safety and efficacy of renal denervation in patients with heart failure with reduced ejection fraction (HFrEF): A systematic review and meta-analysis <b>2022</b> , 8, e08847	1
463	Junctional AV ablation in patients with atrial fibrillation undergoing cardiac resynchronization therapy (JAVA-CRT): results of a multicenter randomized clinical trial pilot program <b>2022</b> , 1	
462	Role of genetic testing in cardiomyopathies: [þrimer for cardiologists <b>2022</b> , 14, 29-39	1
462 461	Role of genetic testing in cardiomyopathies: [primer for cardiologists 2022, 14, 29-39  Chronic Heart Failure: Clinical Implications of Iron Homeostasis Disturbances Revisited 2022, 14, e21224	1
		1
461	Chronic Heart Failure: Clinical Implications of Iron Homeostasis Disturbances Revisited <b>2022</b> , 14, e21224	
461 460	Chronic Heart Failure: Clinical Implications of Iron Homeostasis Disturbances Revisited 2022, 14, e21224  Effects of Astragaloside IV on the Pharmacokinetics of Metoprolol in Rats and Its Mechanism 2022  Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December	1
461 460 459	Chronic Heart Failure: Clinical Implications of Iron Homeostasis Disturbances Revisited 2022, 14, e21224  Effects of Astragaloside IV on the Pharmacokinetics of Metoprolol in Rats and Its Mechanism 2022,  Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 2022, 327, 331-340  Prevalence and clinical outcome of main echocardiographic and hemodynamic heart failure	1 78
461 460 459 458	Chronic Heart Failure: Clinical Implications of Iron Homeostasis Disturbances Revisited 2022, 14, e21224  Effects of Astragaloside IV on the Pharmacokinetics of Metoprolol in Rats and Its Mechanism 2022  Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 2022, 327, 331-340  Prevalence and clinical outcome of main echocardiographic and hemodynamic heart failure phenotypes in a population of hospitalized patients 70 years old and older 2022, 1  Cardiac cycle time-corrected electromechanical activation time greater than 15% is an independent	1 78
461 460 459 458	Chronic Heart Failure: Clinical Implications of Iron Homeostasis Disturbances Revisited 2022, 14, e21224  Effects of Astragaloside IV on the Pharmacokinetics of Metoprolol in Rats and Its Mechanism 2022  Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 2022, 327, 331-340  Prevalence and clinical outcome of main echocardiographic and hemodynamic heart failure phenotypes in a population of hospitalized patients 70 years old and older 2022, 1  Cardiac cycle time-corrected electromechanical activation time greater than 15% is an independent risk factor for major adverse cardiovascular events in chronic heart failure outpatients 2022, 38, 456-461  European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with	1 78 1

453	Characteristics and long-term prognosis of patients with reduced, mid-range, and preserved ejection fraction: A systemic review and meta-analysis <b>2022</b> ,		О
452	Unraveling and Targeting Myocardial Regeneration Deficit in Diabetes 2022, 11,		О
451	Social Determinants of Health and 30-Day Readmissions Among Adults Hospitalized for Heart Failure in the REGARDS Study. <b>2021</b> , CIRCHEARTFAILURE121008409		О
450	Resistance exercise for cardiac rehabilitation 2022,		1
449	Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure Journal of the American College of Cardiology, <b>2022</b> , 79, 355-368	15.1	1
448	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases <b>2021</b> , 36, 108101		2
447	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 504-510	15.1	0
446	Cardiologists' Perspectives on BiDil and the Use of Race in Drug Prescribing 2022, 1		
445	Prediction of Incident Heart Failure in CKD: The CRIC Study 2022, 7, 708-719		О
444	Food security, diet quality, nutritional knowledge, and attitudes towards research in adults with heart failure during the COVID-19 pandemic <b>2022</b> ,		1
443	Arterial Stiffness and Vascular Load in HFpEF: Differences Among Women and Men 2021,		2
442	The Palliative Approach and Terminal Heart Failure Admissions - Are We Getting it Right?. 2022,		O
441	Heart Transplantation of the Elderly-Old Donors for Old Recipients: Can We Still Achieve Acceptable Results?. <b>2022</b> , 11,		О
440	The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensin-converting enzyme inhibitor in dilated cardiomyopathy <b>2022</b> ,		2
439	Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht Cardiomyopathy registry <b>2022</b> ,		2
438	Evaluation of the effectiveness of the physician education program on primary palliative care in heart failure <b>2022</b> , 17, e0263523		
437	Cheyne-Stokes Breathing as a Predictive Indicator of Heart Failure in Patients With Obstructive Sleep Apnea; A Retrospective Case Control Study Using Continuous Positive Airway Pressure Remote Monitoring Data <b>2022</b> , 9, 790331		О
436	Association of adherence to a 3´month cardiac rehabilitation with long-term clinical outcomes in heart failure patients <b>2022</b> ,		1

435	Determinant of repeat revascularization within 5 years of Percutaneous Coronary Intervention at a tertiary care hospital, Karachi: A matched case-control study <b>2022</b> , 75, 103364	
434	Left ventricular systolic dysfunction predicted by artificial intelligence using the electrocardiogram in Chagas disease patients-The SaMi-Trop cohort. <b>2021</b> , 15, e0009974	Ο
433	Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial <b>2021</b> , 49, 3000605211062770	2
432	Effects of enriched-potassium diet on cardiorespiratory outcomes in experimental non-ischemic chronic heart failure <b>2021</b> , 54, 43	Ο
431	Vitamin D Deficiency Is a Predictor of Mortality in Elderly with Chronic Heart Failure <b>2021</b> , 17, 358-364	1
430	Medical Management of Patients With Heart Failure and Reduced Ejection Fraction <b>2022</b> , 52, 173-197	2
429	Eplerenone novel Mineralocorticoid receptor antagonist for the clinical application. 2022, 7, 1	
428	Macrophages secrete murinoglobulin-1 and galectin-3 to regulate neutrophil degranulation after myocardial infarction <b>2022</b> ,	1
427	Digoxin Impact on Heart Failure Patients with Atrial Fibrillation <b>2022</b> , 76, 23-28	
426	Cardiovascular benefits of digoxin and empagliflozin in patients with chronic heart failure: the DIG trial revisited <b>2022</b> ,	
425	Right atrial pressure represents cumulative cardiac burden in heart failure with preserved ejection fraction <b>2022</b> ,	1
424	Exercise Training Outcomes in Patients with Chronic Heart Failure with Reduced Ejection Fraction Depend on Medications and Disease Conditions: Proposal of SEEM Score to Judge Exercise Suitability.	
423	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism <b>2022</b> , 13, 800490	O
422	An Analysis of Epidemiological Factors in Heart Failure Outcomes <b>2022</b> , 14, e22627	
421	B-type natriuretic peptide is associated with the occurrence of bleeding events in heart failure patients with a history of coronary artery disease <b>2022</b> ,	0
420	Hemoglobin-to-Red-Cell Distribution Width Ratio Is a Novel Predictor of Long-Term Patient Outcomes After Percutaneous Coronary Intervention: A Retrospective Cohort Study <b>2022</b> , 9, 726025	1
419	Impact of baseline left ventricular volume on left ventricular reverse remodelling after cardiac resynchronization therapy <b>2022</b> ,	1
418	Electrophysiological, structural, and functional disorders in patients with inflammatory cardiomyopathy secondary to inflammatory myopathy <b>2022</b> , e12938	

417	Management of Obstructive Sleep Apnea in Patients With Heart Failure 2022, 9, 803388	O
416	Validaci[n de constructo de la escala Zung en pacientes con falla card∃ca. 23,	
415	Lack of Association between Inadequate Micronutrient Intake and Prognosis in Outpatients with Heart Failure <b>2022</b> , 14,	
414	Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure <b>2022</b> , 132,	3
413	A low-cost, paper fluidic platform to detect B-type Natriuretic Peptide (BNP) for Congestive Heart Failure (CHF). <b>2022</b> ,	
412	Variability in Coronary Artery Disease Testing for Patients With New-Onset Heart Failure <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 849-860	15.1 0
411	Population-Level Impact of the Guidelines Update on Patient Selection and Outcomes After Cardiac Resynchronization Therapy <b>2022</b> , 8, 651-661	0
410	Heart failure in childhood cancer survivors-a systematic review protocol <b>2022</b> , 11, 54	
409	Effectiveness of Motivational Interviewing on contribution to self-care, self-efficacy, and preparedness in caregivers of patients with heart failure: a secondary outcome analysis of the MOTIVATE-HF randomized controlled trial <b>2022</b> ,	0
408	Human Immunodeficiency Virus Infection and Variation in Heart Failure Risk by Age, Sex, and Ethnicity: The HIV HEART Study <b>2021</b> ,	1
407	DYRK1B-STAT3 Drives Cardiac Hypertrophy and Heart Failure by Impairing Mitochondrial Bioenergetics <b>2022</b> ,	0
406	Effect of omega-3 polyunsaturated fatty acids on left ventricular remodeling in chronic heart failure: a systematic review and meta-analysis <b>2022</b> , 1-35	2
405	The Cardiomyocyte in Heart Failure with Preserved Ejection Fraction-Victim of Its Environment?. <b>2022</b> , 11,	
404	Unloading left heart with a shunt device shows no benefits in heart failure with preserved ejection fraction but supports the importance of phenotyping patients in clinical trials 2022,	1
403	Top Ten Tips Palliative Care Clinicians Should Know About Solid Organ Transplantation 2022,	
402	Differential Effects of Reperfusion on Cardiac Mitochondrial Subpopulations in a Preclinical Porcine Model of Acute Myocardial Infarction <b>2022</b> , 10, 843733	1
401	Management of Cardiac Diseases in Liver Transplant Recipients: Comprehensive Review and Multidisciplinary Practice-Based Recommendations <b>2022</b> ,	2
400	Medical Therapy During Hospitalization for Heart Failure with Reduced Ejection Fraction: The VICTORIA Registry: Medical Therapy During Hospitalization for HFrEF <b>2022</b> ,	1

399	The Peritoneal Membrane-A Potential Mediator of Fibrosis and Inflammation among Heart Failure Patients on Peritoneal Dialysis <b>2022</b> , 12,	O
398	Re-analysis of the effect of coronary artery bypass surgery in patients with left ventricular dysfunction <b>2022</b> ,	
397	Sex Differences in Therapies for Heart Failure 2022,	
396	Fluid and Salt Balance and the Role of Nutrition in Heart Failure 2022, 14,	1
395	Evaluation of diastole by echocardiography for detecting early cardiac dysfunction: an outcome study <b>2022</b> ,	1
394	Reduction of Hospitalization and Mortality by Echocardiography-Guided Treatment in Advanced Heart Failure <b>2022</b> , 9,	
393	Optimal effectiveness of heart failure management - an umbrella review of meta-analyses examining the effectiveness of interventions to reduce (re)hospitalizations in heart failure <b>2022</b> , 1	2
392	Relation Between Frailty and 1-Year Outcomes After Implantation of a Left Ventricular Assist Device <b>2022</b> ,	O
391	Clinical characteristics, predictors, and outcomes of heart failure with improved ejection fraction <b>2022</b> ,	О
390	Development of Advanced Heart Failure: A Population-Based Study <b>2022</b> , CIRCHEARTFAILURE121009218	1
389	Clinical Implications of Heart Rate Control in Heart Failure With Atrial Fibrillation: Multi-Center Prospective Observation Registry (CODE-AF Registry) <b>2022</b> , 9, 787869	
388	Detection Efficiency of Ag Nanoparticle Labels for a Heart Failure Marker Using Linear and Square-Wave Anodic Stripping Voltammetry <b>2022</b> , 12,	1
387	General Rehabilitation Program after Knee or Hip Replacement Significantly Influences Erythrocytes Oxidative Stress Markers and Serum ST2 Levels <b>2022</b> , 2022, 1358858	О
386	Classic and Novel Mechanisms of Diuretic Resistance in Cardiorenal Syndrome. 10.34067/KID.0006372021	O
385	Lifestyle and Cardiovascular Risk Factors Associated With Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors <b>2022</b> , 4, 53-65	1
384	Safety and Efficacy of Omecamtiv Mecarbil for Heart Failure: A Systematic Review and Meta-Analysis <b>2022</b> ,	O
383	Artificial Intelligence-Enabled Electrocardiography Predicts Left Ventricular Dysfunction and Future Cardiovascular Outcomes: A Retrospective Analysis <b>2022</b> , 12,	2
382	Aufbau und Organisation von Herzinsuffizienz-Netzwerken (HF-NETs) und Herzinsuffizienz-Einheiten (Heart Failure Units [HFUs]) zur Optimierung der Behandlung der akuten und chronischen Herzinsuffizienz ��pdate 2021. <b>2022</b> , 16, 142-159	О

381	30-minute CMR for common clinical indications: ´a ´Society for Cardiovascular Magnetic Resonance white paper <b>2022</b> , 24, 13		1
380	ALB-dNLR Score Predicts Mortality in Coronary Artery Disease Patients After Percutaneous Coronary Intervention <b>2022</b> , 9, 709868		Ο
379	Soluble ST2 as a Potential Biomarker for Risk Assessment of Pulmonary Hypertension in Patients Undergoing TAVR?. <b>2022</b> , 12,		0
378	Prioritizing Prevention of De Novo and Worsening Chronic Heart Failure 2022,		O
377	Impact of Autophagy on Prognosis of Patients With Dilated Cardiomyopathy <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 789-801	15.1	O
376	Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus <b>2022</b> , 23,		3
375	Renal Venous Stasis Index Reflects Renal Congestion and Predicts Adverse Outcomes in Patients With Heart Failure <b>2022</b> , 9, 772466		0
374	Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients <b>2022</b> , 1		1
373	The Role of Interleukin-6 Family Members in Cardiovascular Diseases <b>2022</b> , 9, 818890		4
372	Clinical impact of left bundle branch area pacing in heart failure with preserved ejection fraction and mid-range ejection fraction <b>2022</b> ,		1
371	Geographic variation in the use of continuous outpatient inotrope infusion therapy and beta blockers <b>2022</b> , 39, 100948		1
370	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines <b>2022</b> ,		1
369	Prevalence and Prognostic Implications of Left Ventricular Systolic Dysfunction in Adults With Congenital Heart Disease <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 1356-1365	15.1	2
368	Infective Endocarditis: Clinical Characteristics and Echocardiographic Findings <b>2022</b> , 9, 789624		0
367	Clinical Phenotypes of Cardiovascular and Heart Failure Diseases Can Be Reversed? The Holistic Principle of Systems Biology in Multifaceted Heart Diseases. <b>2022</b> , 12, 142-169		
366	Telecommunication for Advance Care Planning in Heart Failure 2022, 8, e11		O
365	Identifying Patients With Advanced Heart Failure Using Administrative Data 2022, 6, 148-155		
364	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines <i>Journal of the American College of Cardiology</i> , <b>2022</b> ,	15.1	15

363	Application of 3D Printing Technology in Heart Failure 2022, 18, 325-333		О
362	Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency department. <b>2022</b> ,		O
361	Serial multiple mediators in the relationship between symptom burden and sleep quality among patients with heart failure <b>2022</b> , e12489		0
360	A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk <b>2022</b> , 14, eabj9625		3
359	An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure <b>2022</b> , 11,		O
358	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines <i>Journal of the American College of Cardiology</i> , <b>2022</b> ,	15.1	49
357	Risk factor control among heart failure patients in the United States: Results from the NHANES 1999-2018 <b>2022</b> , 13, 200128		O
356	STAT4 and COL1A2 are potential diagnostic biomarkers and therapeutic targets for heart failure comorbided with depression <b>2022</b> , 184, 68-75		1
355	Use of Mobile Apps in Heart Failure Self-management: Qualitative Study Exploring the Patient and Primary Care Clinician Perspective <b>2022</b> , 6, e33992		2
354	Value of PTEN and Echocardiography in Predicting the Efficacy of Trimetazidine Combined with Metoprolol in the Treatment of Heart Failure <b>2021</b> , 14, 10257-10263		
353	Mortality and Readmission Rates After Heart Failure: A Systematic Review and Meta-Analysis <b>2021</b> , 17, 1307-1320		O
352	Knowledge, Attitude and Associated Factors Towards Heart Failure Management Among Nurses Working in the Cardiac Unit of Selected Government Hospitals in Addis Ababa, Ethiopia: A Cross-Sectional Study. Volume 11, 41-53		
351	Understanding diabetes-induced cardiomyopathy from the perspective of renin angiotensin aldosterone system <b>2021</b> , 474, 63		1
350	Possibilities of a new glucagon-like peptide-1 receptor agonist Semaglutide in improving left ventricular diastolic function in a patient with arterial hypertension and type 2 diabetes mellitu. <b>2021</b> , 18, 186-192		
349	Prognostic impact of left atrial function in heart failure with preserved ejection fraction in sinus rhythm vs. persistent atrial fibrillation. <b>2021</b> ,		1
348	Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study <b>2021</b> , 2021, 1829873		
347	The cost-effectiveness of B-type natriuretic peptide-guided care in compared to standard clinical assessment in outpatients with heart failure in Tehran, Iran <b>2021</b> , 19, 81		
346	Steroids. 1-50		

345	Passive longitudinal weight and cardiopulmonary monitoring in the home bed 2021, 11, 24376	О
344	Diagnosis, risk stratification and management of myocarditis 2021,	O
343	Cognitive decline and risk of dementia in individuals with heart failure: A systematic review and meta-analysis <b>2021</b> ,	О
342	Ultrafiltration for patients with acute decompensated heart failure: A systematic review and meta-analysis <b>2021</b> , 100, e28029	1
341	Outcome of Temporary Circulatory Support As a Bridge-to-Left Ventricular Assist Device Strategy in Cardiogenic Shock Patients <b>2021</b> ,	1
340	[The importance of health-related quality of life at baseline in predicting event-free survival in patients with a cardiovascular risk profile] <b>2021</b> , 67, 361-380	O
339	Polygenic risk score from a multi-ancestry GWAS uncovers susceptibility of heart failure.	1
338	Detection of sieric BAG3 in patients affected by cardiovascular diseases: State of art and perspectives <b>2021</b> ,	
337	In-Hospital Weight Loss and Outcomes in Patients With Heart Failure 2021,	
336	Biomarkers of heart failure: current state of problem. <b>2021</b> , 67-72	
335	The Impact of Advance Directive Perspectives on the Completion of Life-Sustaining Treatment Decisions in Patients with Heart Failure: A Prospective Study <b>2021</b> , 10,	
334	Phase I investigator-initiated study of the safety of MTC001 in patients with chronic ischemic heart failure <b>2021</b> , 100, e28372	
333	Impact of autoantibodies against the M2-muscarinic acetylcholine receptor on clinical outcomes in peripartum cardiomyopathy patients with standard treatment <b>2021</b> , 21, 619	
332	Reference Ranges of Left Ventricular Hemodynamic Forces in Healthy Adults: A Speckle-Tracking Echocardiographic Study <b>2021</b> , 10,	1
332	Reference Ranges of Left Ventricular Hemodynamic Forces in Healthy Adults: A Speckle-Tracking	2
	Reference Ranges of Left Ventricular Hemodynamic Forces in Healthy Adults: A Speckle-Tracking Echocardiographic Study <b>2021</b> , 10,	
331	Reference Ranges of Left Ventricular Hemodynamic Forces in Healthy Adults: A Speckle-Tracking Echocardiographic Study 2021, 10,  Proteomic Studies of Blood and Vascular Wall in Atherosclerosis 2021, 22,  8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes:	2

327	Assessing survival time of heart failure patients: using Bayesian approach. 2021, 8,		O
326	A Universal New Definition of Heart Failure With Improved Ejection Fraction for Patients With Coronary Artery Disease <b>2021</b> , 12, 770650		1
325	Autoimmune disease of the cardiovascular system. <b>2022</b> , 207-229		
324	Heart Failure in Older Adults: Medical Management and Advanced Therapies 2022, 7,		
323	Artificial Intelligence-Enabled Electrocardiogram Predicted Left Ventricle Diameter as an Independent Risk Factor of Long-Term Cardiovascular Outcome in Patients With Normal Ejection Fraction <b>2022</b> , 9, 870523		0
322	Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin-Angiotensin-Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective <b>2022</b> , 1		
321	The EPICTER score: a bedside and easy tool to predict mortality at 6 months in acute heart failure.		
320	Beta-blockers and Ambulatory Inotropic Therapy <b>2022</b> ,		
319	The Use of Mechanical Circulatory Assist Devices for ACS Patients with Cardiogenic Shock and High-Risk PCI <b>2022</b> , 1		О
318	Sex-Specific Considerations in Drug and Device Therapy of Cardiac Arrhythmias: JACC Focus Seminar 6/7 <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 1519-1529	15.1	O
317	Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials <b>2022</b> ,		O
316	Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion <b>2022</b> , 12,		1
315	Non-Invasive Assessment of Congestion by Cardiovascular and Pulmonary Ultrasound and Biomarkers in Heart Failure <b>2022</b> , 12,		О
314			
	Digoxin Use in Atrial Fibrillation; Insights from National Ambulatory Medical Care Survey <b>2022</b> , 101209	)	
313	Digoxin Use in Atrial Fibrillation; Insights from National Ambulatory Medical Care Survey <b>2022</b> , 101209  Comparison of clinical symptoms and bioimpedance to pulmonary capillary wedge pressure in heart failure. <b>2022</b> , 100133	)	
313	Comparison of clinical symptoms and bioimpedance to pulmonary capillary wedge pressure in heart		
	Comparison of clinical symptoms and bioimpedance to pulmonary capillary wedge pressure in heart failure. <b>2022</b> , 100133  Orthodromic and Antidromic Snare Techniques for Left Ventricular Lead Implantation in Cardiac	)	0

309	Data_Sheet_1.docx. <b>2019</b> ,	
308	Data_Sheet_1.docx. <b>2020</b> ,	
307	lmage_1.tif. <b>2019</b> ,	
306	Image_2.tif. <b>2019</b> ,	
305	Image_3.tif. <b>2019</b> ,	
304	lmage_4.tif. <b>2019</b> ,	
303	lmage_5.tif. <b>2019</b> ,	
302	Image_6.tif. <b>2019</b> ,	
301	Table_1.docx. <b>2019</b> ,	
300	Prognostic value of cardiac biomarkers and National Early Warning Score 2 in acute dyspnoea <b>2022</b> , 9,	О
299	Biomarkers in the clinical management of patients with atrial fibrillation and heart failure <b>2021</b> , 18, 908-951	2
298	Left Atrial Ejection Force as a Marker for the Diagnosis of Heart Failure with Preserved Ejection Fraction <b>2021</b> , 31, 125-130	
297	Predictors and patterns of polypharmacy in chronic diseases in a middle-income country <b>2021</b> , 13, 158-165	
296	Clinical Biosensors: Considerations and Development Process. <b>2022</b> , 83-98	
295	Plastic-based lateral flow immunoassay device for electrochemical detection of NT-proBNP 2022,	2
294	Biventricular Pacing. <b>2022</b> , 193-198	
293	National trend in heart failure hospitalization and outcome under public health insurance system in Thailand 2008-2013 <b>2022</b> , 22, 203	
292	Low mechano-energetic efficiency is associated with future left ventricular systolic dysfunction in hypertensives <b>2022</b> ,	1

291	Guideline-directed device therapies in heart failure: A clinical practice-based analysis using electronic health record data. <b>2022</b> , 16, 100139	
<b>2</b> 90	Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta-analysis. <b>2022</b> , 23,	0
289	Evaluation of a Pharmacist-Led Telephonic Medication Therapy Management Program in Rural Arizona: Implications for Community Health Practice. <b>2022</b> , 12, 243-252	
288	Prehospitalization Symptom Perceptions, Lay Consultations, and Treatment-Seeking for Acute Decompensating Heart Failure: Implications for Nursing Practice. <b>2022</b> ,	
287	2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders <b>2022</b> ,	1
286	Dietary quality and risk of heart failure in men <b>2022</b> ,	Ο
285	Diuretic combinations in critically ill patients with respiratory failure: A systematic review and meta-analysis. <b>2022</b> , 11, 178-191	Ο
284	Perceived symptoms as the primary indicators for 30-day heart failure readmission <b>2022</b> , 17, e0267820	Ο
283	Left Atrial Strain Has Superior Prognostic Value to Ventricular Function and Delayed-Enhancement in Dilated Cardiomyopathy. <b>2022</b> ,	1
282	Non-invasive Imaging in Women With Heart Failure - Diagnosis and Insights Into Disease Mechanisms <b>2022</b> , 1	
281	Physician adherence and patient-reported outcomes in heart failure with reduced ejection fraction in the era of angiotensin receptor-neprilysin inhibitor therapy <b>2022</b> , 12, 7730	3
<b>2</b> 80	Formulation, Characterization, and the Diuretic Effects of a New Intravenous Metolazone Emulsion <b>2022</b> ,	
279	Review the factors associated with dietary sodium adherence in patients with heart failure from selected research-based literatures <b>2022</b> , 8, 41	
278	Mitochondrial damage and activation of the cytosolic DNA sensor cGAS-STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice <b>2022</b> , 8, 258	3
277	Improving the Characterization of Stage A and B Heart Failure by Adding Global Longitudinal Strain. <b>2022</b> ,	0
276	Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment <b>2022</b> , 8, 11	0
275	Diuretic use in the adult Fontan. 2022, 8, 100387	
274	Strengths-building through life purpose, self-care goal setting and social support: Study protocol for Caregiver Support. <b>2022</b> , 28, 100917	Ο

273 Cardiac Transplantation. **2017**, 577-595

, ,			
272	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 2058-2068	15.1	4
271	The cardiosplenic axis: the prognostic role of the spleen in heart failure 2022,		O
270	Multiple comorbid conditions and healthcare resource utilization among adult patients with hyperkalemia: A retrospective observational cohort study using association rule mining <b>2022</b> , 12, 2633	55652	2 <sup>2</sup> 109883
269	Yoga for Heart Failure. <b>2022</b> , 327-334		
268	Impact of S-Wave Amplitude in Right Precordial Leads on Improvement in Mitral Regurgitation following Cardiac Resynchronization Therapy. <b>2022</b> , 9, 159		
267	Real-World Performance, Long-Term Efficacy, and Absence of Bias in the Artificial Intelligence Enhanced Electrocardiogram to Detect Left Ventricular Systolic Dysfunction.		0
266	Timing of Repair in Postinfarction Ventricular Septal Defect. 2022,		О
265	Outcomes of Cardiac Resynchronization Therapy with Image-Guided Left Ventricular Lead Placement at the Site of Latest Mechanical Activation: A Systematic Review and Meta-Analysis. <b>2022</b> , 2022, 1-10		0
264	The role of multimodality imaging in patients with heart failure with reduced and preserved ejection fraction. <b>2022</b> , 37, 285-293		
263	Novel Cell-Based Therapeutics for Diseases of the Heart and Skeletal Muscle. <b>2022</b> , 227-249		
262	Prognostic value of triglyceride glucose (TyG) index in patients with acute decompensated heart failure. <b>2022</b> , 21,		О
261	Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future. <b>2022</b> , 23, 5680		3
260	Conduction System Pacing for Cardiac Resynchronization Therapy. 2022,		О
259	Current Emergency Department Disposition of Patients with Acute Heart Failure: An Opportunity for Improvement. <b>2022</b> ,		O
258	Arrhythmias as Presentation of Genetic Cardiomyopathy. <b>2022</b> , 130, 1698-1722		О
257	Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: findings from the HF-ACTION trial. <b>2022</b> , 251, 115-115		О
256	Patient characteristics, short-term and long-term outcomes after incident heart failure admissions in a regional Australian setting. <b>2022</b> , 9, e001897		1

255	Global longitudinal strain by CMR improves prognostic stratification in acute myocarditis presenting with normal LVEF.	O
254	Heart failure with normal LVEF in BIOSTAT-CHF. <b>2022</b> ,	
253	New developments in the understanding of right ventricular function in acute care. 2022, 28, 331-339	1
252	Application of Mathematical Modeling to Quantify Ventricular Contribution Following Durable Left Ventricular Assist Device Support. <b>2022</b> , 100107	
251	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association.	8
250	Concomitant acute myopericarditis and multiple systemic arteriovenous thrombosis as a rare manifestation of post-COVID-19 syndrome. <b>2022</b> , 17, 2737-2741	O
249	Continuous-Flow Ventricular Assist Devices. <b>2022</b> , 79-119	
248	Sacubitril-valsartan therapy in a patient with heart failure due to isolated left ventricular noncompaction: a case report and literature review. <b>2022</b> , 7, 56-59	
247	Severe Obesity and Heart Failure. <b>2022</b> ,	0
246	Metolazone versus intravenous chlorothiazide for decompensated heart failure sequential nephron blockade: A retrospective cohort study. <b>2022</b> ,	
245	Diabetes and Progression of Heart Failure. Journal of the American College of Cardiology, 2022, 79, 2285-239	93 0
244	Comorbidities in heart failure with preserved ejection fraction.	O
243	Clinical Outcomes of Intraoperative Dopamine Infusion for Hypotensive Patients During Breast Reconstruction with Deep Inferior Epigastric Perforator (DIEP) Flaps. <b>2022</b> ,	
242	Outcomes of guideline-based medical therapy in patients with acute heart failure and reduced left ventricular ejection fraction. <b>2022</b> , 101, e29452	
241	Improved 30-Day Heart Failure Readmissions Following Implementation of an Advanced Cardiovascular Education (ACE) Academy. Publish Ahead of Print,	1
240	Effects of glycemic traits on left ventricular structure and function: a mendelian randomization study. <b>2022</b> , 21,	O
239	Cigarette Smoking, Cessation, and Risk of Heart Failure With Preserved and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 2298-2305	0
238	Straining to See the Future in Subclinical Heart Failure. <b>2022</b> ,	

237	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19. <i>Journal of the American College of Cardiology</i> , <b>2022</b> ,	15.1	О
236	Trends in prognosis after hospitalization for acute heart failure in Kurashiki Central hospital 2015 <b>2</b> 018: single-center prospective study.		O
235	Intermittent Fasting as Possible Treatment for Heart Failure. <b>2022</b> , 20,		1
234	Cognitive impairment, age, quality of life, and treatment strategy for atrial fibrillation in older adults: The SAGE-AF study.		
233	Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. <b>2022</b> , 14,		1
232	Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: findings from the HF-ACTION trial. <b>2022</b> ,		О
231	Differentiating Physiology from Pathology. <b>2022</b> , 41, 425-440		O
230	Swan-Ganz Catheter and Lack of Evidence: Does it Reflect Clinical Practice?. <b>2022</b> , 2, 212-213		
229	Pathophysiology of heart failure and an overview of therapies. <b>2022</b> , 149-221		
228	Managing persistent hyperkalaemia with next-generation potassium binders. 2022, 7, S1-S18		
227	The Significance of Hematologic Indices in Patients with Heart Failure. 182-185		
226	The role of temporary mechanical circulatory support as a bridge to advanced heart failure therapies or recovery. Publish Ahead of Print,		O
225	Rhythm vs. Rate control for Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction. <b>2022</b> ,		O
224	Initiation of anti-hypertensive drugs and outcomes in patients with heart failure with preserved ejection fraction and persistent hypertension. <b>2022</b> ,		
223	The difference between cystatin C- and creatinine-based assessment of kidney function in acute heart failure.		О
222	Inpatient Specialist Palliative Care in Patients With Left Ventricular Assist Devices (LVAD): A Retrospective Case Series. 9,		O
221	Reshaping Treatment of Heart Failure with Preserved Ejection Fraction. 2022, 11, 3706		
220	Cardiac microstructural alterations measured by echocardiography identify sex-specific risk for heart failure. heartjnl-2022-320876		O

219	QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-[]1 Signaling Pathway. 13,		О
218	Factors Associated With Participation Rate and Predictive of Improvement After Cardiac Rehabilitation in Patients With Heart Failure. Publish Ahead of Print,		
217	Analysis of Worsening Heart Failure Events in an Integrated Health Care System. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 80, 111-122	15.1	О
216	Cardiac remodelling in association with left ventricular dyssynchrony and systolic dysfunction in patients with coronary artery disease.		
215	Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost?. <b>2022</b> , 14, 438-445		О
214	Salt restriction and risk of adverse outcomes in heart failure with preserved ejection fraction. heartjnl-2	2022-37	21167
213	Criteria for Referral of Patients With Advanced Heart Failure for Specialized Palliative Care. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 80, 332-344	15.1	1
212	Efficacy and Safety of Ultrafiltration in Patients with Heart Failure: A Single-Center Experience.		
211	The effectiveness of thyroid hormone replacement therapy on heart failure and low T3-syndrome: An updated systematic review and meta-analysis of randomized controlled trials. <b>2022</b> ,		О
210	Association of irisin levels with cardiac magnetic resonance, inflammatory, and biochemical parameters in patients with chronic heart failure versus controls. <b>2022</b> ,		1
209	Physical activity, sedentary behaviors and all-cause mortality in patients with heart failure: Findings from the NHANES 2007 <b>1</b> 014. <b>2022</b> , 17, e0271238		О
208	A Deadly Override.		
207	Exercise Training Effects on Circulating Endothelial and Progenitor Cells in Heart Failure. <b>2022</b> , 9, 222		1
206	Steroid Sparing Immunosuppression in Management of Cardiac Sarcoidosis: A Systematic Review. <b>2022</b> , 100034		
205	Prognostic Value of Pericardial Effusion Size in Patients with Acute Heart Failure. <b>2022</b> , 20,		
204	Guideline Directed Medical Therapy in Newly Diagnosed Heart Failure with Reduced Ejection Fraction in the Community. <b>2022</b> ,		О
203	Pediatric and Adult Cardiologists and Respirologists Referral Practices to Palliative Care. 2022,		
202	Preoperative Transthoracic Echocardiography Predicts Cardiac Complications in Elderly Patients with Coronary Artery Disease Undergoing Noncardiac Surgery. Volume 17, 1151-1161		О

201	The interstitial compartment as a therapeutic target in heart failure. 9,	O
200	Severity of functional impairments by race and sex in older patients hospitalized with acute decompensated heart failure.	O
199	Performance of current risk stratification models for predicting mortality in patients with heart failure: a systematic review and meta-analysis.	1
198	Von Willebrand factor (vWF) in patients with heart failure with preserved ejection fraction (HFpEF): A retrospective observational study. <b>2022</b> , 101, e29854	O
197	The relationship between six-minute walked distance and health-related quality of life in patients with chronic heart failure. <b>2022</b> , 56, 310-315	
196	The Association Between Telemedicine Use and Changes in Health Care Usage and Outcomes in Patients With Congestive Heart Failure: Retrospective Cohort Study. <b>2022</b> , 6, e36442	
195	Ischemic Cardiomyopathy and Heart Failure After Acute Myocardial Infarction.	Ο
194	Relation of Sociodemographic Factors With Primary Cause of Hospitalization Among Patients With Left Ventricular Assist Devices (from the National Inpatient Sample 2012 to 2017). <b>2022</b> ,	1
193	A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates.	
192	Sodium nitroprusside in acute heart failure: A multicenter historic cohort study. 2022,	Ο
191	Clinical and Molecular Implications of Osteopontin in Heart Failure. <b>2022</b> , 44, 3573-3597	1
190	Strategies and outcomes of patients with severely reduced ejection fraction (115%) undergoing transvenous lead extraction: A single-center experience. 2022,	Ο
189	Comparison of Home-Based vs Center-Based Cardiac Rehabilitation in Hospitalization, Medication Adherence, and Risk Factor Control Among Patients With Cardiovascular Disease. <b>2022</b> , 5, e2228720	3
188	Statins are associated with reduced likelihood of sarcopenia in a sample of heart failure outpatients: a cross-sectional study. <b>2022</b> , 22,	O
187	The Protective Effects of Neurotrophins and MicroRNA in Diabetic Retinopathy, Nephropathy and Heart Failure via Regulating Endothelial Function. <b>2022</b> , 12, 1113	0
186	The Association Between Medication Non-Adherence and Early and Late Readmission Rates for Patients with Acute Coronary Syndrome. Volume 15, 6791-6799	
185	Effect of environment and season on acute decompensated heart failure: Data from low-to middle-income country. <b>2022</b> ,	
184	Vasodilators for acute heart failure protocol for a systematic review of randomized clinical trials with meta-analysis and Trial Sequential Analysis.	

183	A Review of Cardiac amyloidosis: Presentation, Diagnosis, and Treatment. 2022, 101366	1
182	Incremental prognostic value of left ventricular longitudinal strain over ejection fraction in coronary artery bypass grafting. <b>2022</b> ,	O
181	Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.	1
180	TomE, a 17-Month-Old Boy with Worsening Respiratory Status. <b>2022</b> , 699-712	
179	Elevated 8-isoprostane concentration is associated with thromboembolic events in patients with atrial fibrillation. <b>2022</b> , 365, 1-7	О
178	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. <b>2022</b> , 42, 101103	O
177	Early-Onset Late Gadolinium Enhancement is a Prognostic Factor for Duchenne Cardiomyopathy.	O
176	Bereaved CaregiversExperiences of End of Life Care For People With Advanced Heart Failure: A Narrative Synthesis. 003022282211246	O
175	Predictors of Changes in Peak Oxygen Uptake After Outpatient Cardiac Rehabilitation: Importance of Cardiac Rehabilitation Attendance. <b>2022</b> , 6, 428-435	O
174	The role of a multidisciplinary heart failure clinic in optimization of guideline-directed medical therapy: HF-optimize. <b>2023</b> , 57, 95-101	O
173	Hybrid Imaging Using Single Photon Emission Computed Tomography. 2022, 55-73	0
172	Systemic Treatments and Related Side Effects in Liver Tumors. <b>2022</b> , 259-270	O
171	Systemic Treatments and Related Side Effects in Thyroid Cancer. <b>2022</b> , 153-170	0
170	Left ventricular diastolic reserve by exercise stress echocardiography in prediabetes. <b>2022</b> , 0	O
169	Fate of drug-metabolizing enzymes in cardiovascular diseases: Concepts and challenges. <b>2022</b> , 231-258	0
168	Effectiveness of home-based telerehabilitation programs on functional capacity and cardiac function in elderly heart failure patients: A prospective longitudinal study. <b>2022</b> , 101, e29799	O
167	Bridge to nowhere: A retrospective single-center study on patients using chronic intravenous inotropic support as bridge therapy who do not receive surgical therapy. 9,	1
166	Neuroendocrine hormone status and diuretic response to atrial natriuretic peptide in patients with acute heart failure.	O

165	2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction. <b>2022</b> ,	О
164	The work of managing a chronic illness: A job description.	O
163	Trends in Ischemic Evaluation in New-Onset Heart Failure Without Known Coronary Artery Disease. <b>2022</b> ,	О
162	Edema formation in congestive heart failure and the underlying mechanisms. 9,	1
161	Rehospitalization of Patients with Advanced Heart Failure Receiving Continuous, Palliative Dobutamine or Milrinone. <b>2022</b> ,	1
160	Digoxin and Outcomes in Patients with Heart Failure and Preserved Ejection Fraction [HFpEF] Patients: A Systematic Review and Meta-analysis. <b>2022</b> , 23,	1
159	Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry.	0
158	Identification of a pleiotropic effect of ADIPOQ on cardiac dysfunction and Alzheimer disease based on genetic evidence and health care records. <b>2022</b> , 12,	O
157	MASP1 Gene Polymorphism and MASP-3 Serum Levels in Patients with Chronic Chagas Disease. <b>2022</b> , 51, 2108-2121	О
156	Multidisciplinary heart failure care program: an experience from Colombia. 2022, 101431	O
155	Efficacy of Implantable Cardioverter Defibrillator in Nonischemic Systolic Heart Failure According to Sex: Extended Follow-Up Study of the DANISH Trial. <b>2022</b> , 15,	0
154	Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population. <b>2022</b> , 9, e002022	O
153	Chronic Heart Failure. <b>2022</b> , 41, 363-368	O
152	Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations.	1
151	Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease.	5
150	Characteristics, Treatment Patterns, and Clinical Outcomes After Heart Failure Hospitalizations in COVID-19 Pandemic, March (Dctober 2020. <b>2022</b> ,	O
149	Trends in Outcomes of Heart Transplants Utilizing Extended Criteria Donors: A UNOS Database Analysis. <b>2022</b> ,	0
148	Heart failure with recovered ejection fraction: Current understanding and future prospects. <b>2022</b> ,	O

147	Coronary Artery Bypass Graft Surgery Brings Better Benefits to Heart Failure Hospitalization for Patients with Severe Coronary Artery Disease and Reduced Ejection Fraction. <b>2022</b> , 12, 2233	1
146	Extracellular Vesicles Regulate Sympatho-Excitation by Nrf2 in Heart Failure. <b>2022</b> , 131, 687-700	O
145	Characteristics and Outcomes of Suspected Digoxin Toxicity and Immune Fab Treatment Over the Past Two Decades 2000-2020. <b>2022</b> ,	0
144	Impact of multiple substance use on circulating ST2, a biomarker of adverse cardiac remodeling, in women. 1-13	O
143	SGLT2 Inhibitors in Heart Failure. <b>2022</b> , 18, 587-596	1
142	Myeloid cell-specific ablation of Runx2 gene exacerbates post-infarct cardiac remodeling. <b>2022</b> , 12,	O
141	Augmented Intelligence to Identify Patients With Advanced Heart Failure in an Integrated Health System. <b>2022</b> , 100123	О
140	Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction. <b>2022</b> , 40, 473-489	1
139	Right Heart Catheterization Timing and Outcomes of Cardiogenic Shock: Analysis from the National Readmission Database. <b>2022</b> , 47, 101388	0
138	Mitochondrial quality control mechanisms as molecular targets in diabetic heart. <b>2022</b> , 137, 155313	O
137	Rehabilitation Treatment for Myocarditis. <b>2022</b> , 267-276	0
136	Moderate Aortic Stenosis in Patients With Heart Failure. 52,	1
135	Systemic immune-inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction.	0
134	Spironolactone Utilization among Patients with Reduced and Preserved Ejection Fraction Heart Failure. <b>2022</b> , 1, 89-100	O
133	Incorporation of Suppression of Tumorigenicity 2 into Random Survival Forests for Enhancing Prediction of Short-Term Prognosis in Community-ACQUIRED Pneumonia. <b>2022</b> , 11, 6015	O
132	Long-term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction.	O
131	Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications. <b>2022</b> , 10, 2471	3
130	Nurses Perception of, and Barriers to, Delivering Cardiopulmonary Rehabilitation for Heart Failure Patients: A National Survey in Saudi Arabia. <b>2022</b> , 19, 13586	O

129	Can Machines Find the Sweet Spot in End-Stage Heart Failure?. 2022, 1, 100122	O
128	Prognostic Nutritional Index and Major Cardiovascular Events in Patients Undergoing Invasive Coronary Angiography: A Clinical Retrospective Study. <b>2022</b> , 12, 1679	O
127	Physiotherapists Attitudes, and Barriers of Delivering Cardiopulmonary Rehabilitation for Patients with Heart Failure in Saudi Arabia: A Cross-Sectional Study. Volume 15, 2353-2361	0
126	Safety and efficacy of pulse-induced contour cardiac output monitoring in elderly patients with coronary artery disease and severe heart failure at coronary care units. 9,	O
125	Efficacy of Xinbao pill on chronic heart failure: Study protocol of a multicenter, randomized, double-blind, placebo-controlled trial. 13,	О
124	Effects of Baduanjin exercise on quality-of-life and exercise capacity in patients with heart failure: A systematic review and meta-analysis. <b>2022</b> , 101675	O
123	Prognosis in Patients With Cardiogenic Shock Who Received Temporary Mechanical Circulatory Support. <b>2022</b> ,	O
122	Research progress on the relationship between mitochondrial function and heart failure: A bibliometric study from 2002 to 2021. 9,	1
121	Plasma brain injury markers are associated with volume status but not muscle health in heart failure patients. 2,	O
120	What is the Best Agent for Rate Control of Atrial Fibrillation With Rapid Ventricular Response?. <b>2022</b> ,	O
119	Medication Complexity Among Older Adults with HF: How Can We Assess Better?. 2022, 39, 851-861	0
118	Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review.	O
117	Nurses Beliefs and Barriers of Delivering Cardiopulmonary Rehabilitation for Heart Failure Patients in Saudi Arabia: A Cross-Sectional Study. <b>2022</b> , 5, 44	0
116	Preoperative left atrial volume index may be associated with postoperative atrial fibrillation in non-cardiac surgery. 9,	O
115	Physical performance and maximum tongue pressure associated with oral intake independence: a retrospective study on hospitalized patients with heart failure. <b>2022</b> , 12,	O
114	Reduced acetylation of TFAM promotes bioenergetic dysfunction in the failing heart.	O
113	Neurogenic cardiac outcome in patients after acute ischemic stroke: The brain and heart connection. <b>2022</b> , 31, 106859	0
112	Outcomes after implementing a heart failure diuretic pathway in an emergency department setting. <b>2023</b> , 57, 250-256	O

111	Galectin-3 as an early marker of diastolic dysfunction in children with end-stage renal disease on regular hemodialysis. <b>2022</b> , 15, 266	О
110	Psychosocial and Palliative Aspects of VAD Care. <b>2022</b> , 243-253	O
109	dATP Elevation Induces Myocardial Metabolic Remodeling to Support Improved Cardiac Function.	О
108	Advanced glycation end-products, cardiac function and heart failure in the general population: The Rotterdam Study.	2
107	Trends, Burden, and Impact of Arrhythmias on Cardiac Transplant recipients: A 16-year Nationwide Study. <b>2022</b> , 101504	1
106	The relationship between pesi score and pulmonary venous flow parameters in patients with acute pulmonary embolism.	O
105	Effect of Physical Training on the Morphology of Parasympathetic Atrial Ganglia after Unilateral Vagotomy in Rats. <b>2022</b> , 9, 391	O
104	The combination of Euroscore II with a new variable "Nongraftable coronary artery lesions" improves the discriminating power of the test in surgical patients with postinfarction ventricular septal defect and ventricular aneurysm.	O
103	Community-based participatory research application of an artificial intelligence-enhanced electrocardiogram for cardiovascular disease screening: A FAITH! Trial ancillary study. <b>2022</b> , 100431	1
102	Successful conservative management of left ventricular assist device candidates.	O
101	Nutritional Management of Heart Failure. 2022,	0
100	Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups. <b>2022</b> ,	O
99	Super Response to Cardiac Resynchronization Therapy in Orthotopic Heart Transplant with Atypical Right Bundle Branch Block and Cardiac Allograft Vasculopathy. <b>2022</b> ,	O
98	Effect of self-management intervention on prognosis of patients with chronic heart failure: A meta-analysis.	O
97	Serum Annexin A2 concentrations are increased in patients with diabetic cardiomyopathy and are linked to cardiac dysfunctions. <b>2023</b> , 195, 110196	O
96	Effects of traditional Chinese eight brocade exercise with same frequency and different durations on the quality of life, 6-min walk and brain natriuretic peptide in patients with chronic heart failure. <b>2023</b> , 172, 112059	O
95	dATP elevation induces myocardial metabolic remodeling to support improved cardiac function. <b>2023</b> , 175, 1-12	O
94	PCSK9: A emerging participant in heart failure. <b>2023</b> , 158, 114106	1

93	Adiposity and clinical outcomes in East Asian patients with heart failure and preserved ejection fraction. <b>2023</b> , 44, 101162	Ο
92	Electrocardiogram Belt guidance for left ventricular lead placement and biventricular pacing optimization. <b>2022</b> ,	1
91	Health Techequity: Opportunities for Digital Health Innovations to Improve Equity and Diversity in Cardiovascular Care.	Ο
90	Chronic heart failure, depression, and its links to selected aspects: a cross-sectional study. <b>2022</b> , 24, 286-293	Ο
89	Managing Diastolic Dysfunction Perioperatively. 108925322211424	1
88	Incidence and Outcomes of Advanced Heart Failure in Adults With Congenital Heart Disease. <b>2022</b> , 15,	1
87	Prognostic Value of Admission Peak NT-proBNP Combined with Culprit Plaque Types for Predicting Cardiovascular Risk in ST-Segment Elevated Myocardial Infarction: An Optical Coherence Tomography Study. <b>2022</b> , 9, 466	Ο
86	Impact of atherosclerosis on the postoperative complications of colorectal surgery in older patients with colorectal cancer. <b>2022</b> , 22,	Ο
85	Heart failure with preserved left ventricular ejection fraction amidst diabetes mellitus: from general mechanisms to possible therapy tactics. <b>2022</b> , 13, 115-123	О
84	Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: rationale for and design of the EMPA-AHF trial. <b>2022</b> ,	О
83	Associations of right ventricular pulsatile load and cardiac power output to clinical outcomes in heart failure: Difference from systemic circulation. <b>2022</b> ,	Ο
82	Prognostic Value of Left Ventricular Global Longitudinal Strain in Patients With Congenital Heart Disease. <b>2022</b> , 15,	Ο
81	Genetic Association between Polymorphisms of Interleukin-32 and Dilated Cardiomyopathy in Chinese Han Population. <b>2022</b> , 2022, 1-9	О
80	Studio di coorte retrospettivo sull'aumento di BNP e troponina T in pazienti pediatrici positivi al COVID-19.	Ο
79	ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison.	1
78	MitraClip: a review of its current status and future perspectives.	Ο
77	Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction. <b>2022</b> , 22,	0
76	Outcomes and predictors of one-year mortality in patients hospitalized with Acute Heart Failure. <b>2022</b> , 43, 101159	О

75	Left ventricular pseudoaneurysmectomy in patient without hemodynamic instability: A case report. <b>2023</b> , 11,	0
74	Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca2+ handling in ventricular cardiomyocytes.	O
73	Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma. <b>2023</b> , 11, 181	O
72	Differences in patient characteristics, clinical practice and outcomes of cardiac implantable electric device therapy between Japan and the USA: a cross-sectional study using data from nationally representative administrative databases. <b>2023</b> , 13, e068124	O
71	Blood coagulation disorders in heart failure: from basic science to clinical perspectives. 2023,	O
70	Amiodarone vs. metoprolol succinate in HFrEF complicated with persistent atrial fibrillation with rapid ventricular response: A prospective observational study. 9,	1
69	The Heart in Diabetic Hypertensive Patients. <b>2023</b> , 195-215	O
68	Sacubitril/valsartan cannot improve cardiac function compared with valsartan in patients suffering nonvalvular atrial fibrillation without systolic heart failure.	O
67	Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes. <b>2023</b> ,	O
66	Enhanced neutrophil extracellular traps formation in AF patients with dilated left atrium.	O
65	Prevalence and prognosis of frailty in older patients with stage B heart failure with preserved ejection fraction.	О
64	Clinical Utility of Strain Imaging in Assessment of Myocardial Fibrosis. <b>2023</b> , 12, 743	O
63	Evaluation of potential biomarkers for traditional Chinese medicine-based chronic heart failure syndromes: A case-control study. <b>2023</b> , 58, 102222	O
62	Variants Tagging LGALS-3 Haplotype Block in Association with First Myocardial Infarction and Plasma Galectin-3 Six Months after the Acute Event. <b>2023</b> , 14, 109	O
61	Evaluation of the Incarcerated Transplant Candidate. <b>2022</b> , 211-216	0
60	Extracorporeal membrane oxygenation for end-stage heart failure. <b>2023</b> , 1243-1252	O
59	Significance of standard and speckle-tracking echocardiography for early diagnosis of asymptomatic left ventricular dysfunction in type 2 diabetes. <b>2023</b> , 22, 3478	О
58	A Cardiac Magnetic Resonance Study: Comparison of Biventricular Longitudinal Function in Hypertrophic Cardiomyopathy Patients and Normal Individuals. <b>2023</b> ,	O

57	Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction.	O
56	Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney diseaseBalance of efficacy and risk. 14,	O
55	Hydralazine induced vasculitis with pulmonary-renal syndrome-A case report. 2023, 5,	0
54	Effect of estimated plasma volume status and left atrial diameter on prognosis of patients with acute heart failure. 10,	O
53	The Importance of Prognostic Variables to Monitoring Heart Failure Using Health Management Systems. <b>2023</b> , 302-310	0
52	Cardiovascular disease prevention and management in the COVID-19 era and beyond: An international perspective. <b>2023</b> ,	О
51	The Role of Dietary Salt in Metabolism and Energy Balance, Insights Beyond Cardiovascular Disease.	0
50	Management of Heart Failure with Reduced Ejection Fraction. <b>2023</b> , 101596	O
49	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. <b>2023</b> , 5, 1	2
48	Galectins detection for the diagnosis of chronic diseases: An emerging biosensor approach. <b>2023</b> , 159, 116952	O
47	Sex-related Differences in Left Ventricular Deformation in Patients With Hypertensive Heart Failure With Reduced Ejection Fraction: Assessment by Cardiac Magnetic Resonance Tissue Tracking. <b>2023</b> , 48, 101601	0
46	The Efficacy and Safety of Tolvaptan in Heart Failure Patients with Congestive Signs: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2023</b> , 3, 30-39	O
45	Validation of the Meta-Analysis Global Group in Chronic Heart Failure risk score for the prediction of 1-year mortality in a Chinese cohort. <b>2022</b> , 135, 2829-2835	O
44	Sex-Specific Predictors of Long-Term Mortality in Elderly Patients with Ischemic Cardiomyopathy. <b>2023</b> , 12, 2012	О
43	A snapshot of patient experience of illness control after a hospital readmission in adults with chronic heart failure. <b>2023</b> , 22,	O
42	AI Cardiac MRI Scar Analysis Aids Prediction of Major Arrhythmic Events in the Multicenter DERIVATE Registry.	O
41	A Computable Algorithm for Medication Optimization in Heart Failure With Reduced Ejection Fraction. <b>2023</b> , 100289	0
40	Advance directive screening among veterans with incident heart failure: Comparisons among people aging with and without HIV. <b>2023</b> , 61, 1-7	Ο

39	Clinical impact of pulmonary artery catheter in patients with cardiogenic shock: A systematic review and meta-analysis. <b>2023</b> ,	0
38	Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers. <b>2023</b> , 11, 440-450	O
37	Citalopram in the treatment of elderly chronic heart failure combined with depression: A systematic review and meta-analysis. 10,	О
36	Continuous Infusion Versus Bolus Injection of Loop Diuretics for Patients With Congestive Heart Failure: A Meta-Analysis. <b>2023</b> ,	O
35	Ginkgo biloba extract protects against diabetic cardiomyopathy by restoring autophagy via adenosine monophosphate-activated protein kinase/mammalian target of the rapamycin pathway modulation. <b>2023</b> , 37, 1377-1390	O
34	Specialist Palliative Care Referral Practices Among Oncologists, Cardiologists, Respirologists: A Comparison of National Survey Studies. <b>2023</b> ,	O
33	The effect of type 2 diabetes mellitus on multiple obstructive coronary artery disease. <b>2023</b> , 40, 235-243	O
32	Influence of chronic obstructive pulmonary disease on long-term hospitalization and mortality in patients with heart failure with reduced ejection fraction. <b>2023</b> , 23,	O
31	Post discharge management of heart failure patients: clinical findings at the first medical visit in a single-center study. <b>2023</b> , 23,	O
30	Association of Days Alive and Out of the Hospital After Ventricular Assist Device Implantation With Adverse Events and Quality of Life. <b>2023</b> , 158, e228127	1
29	A Pilot Study on Standardized In-hospital Education About Heart Failure Conducted During the First Days After Decompensation. <b>2023</b> , 22, 13-18	O
28	Written seizure action plans for adult patients with epilepsy: Distilling insights from emergency action plans for other chronic conditions. <b>2023</b> , 140, 109002	O
27	Efficacy of disease management program used among patients with chronic heart failure: protocol for a systematic review and network meta-analysis. <b>2023</b> , 12,	О
26	Bone Marrow Mesenchymal Stem Cells for Heart Failure Treatment: A Systematic Review and Meta-Analysis. <b>2023</b> ,	O
25	Physician Perspectives on the Use of Beta Blockers in Heart Failure With Preserved Ejection Fraction. <b>2023</b> , 193, 70-74	О
24	Japanese high bleeding risk criteria status predicts low thrombogenicity and bleeding events in patients undergoing percutaneous coronary intervention.	O
23	Proposed New Conceptualization for Definition of Decompensated HF. <b>2023</b> , 11, 368-371	О
22	The prognostic predictive value of the components of the PR interval in hospitalized patients with heart failure. <b>2023</b> , 23,	O

21	Diagnostic accuracy of cardiovascular magnetic resonance strain analysis and atrial size to identify heart failure with preserved ejection fraction. <b>2023</b> , 3,	О
20	Cardiovascular Side Effects of Anthracyclines and HER2 Inhibitors among Patients with Breast Cancer: A Multidisciplinary Stepwise Approach for Prevention, Early Detection, and Treatment. <b>2023</b> , 12, 2121	O
19	In-Hospital Observation on Oral Diuretics After Treatment for Acute Decompensated Heart Failure: Evaluating the Utility. <b>2023</b> , 16,	0
18	Characterization of cardiac involvement in children with LMNA-related muscular dystrophy. 11,	O
17	Sudden cardiac death in childhood hypertrophic cardiomyopathy. 2023, 69, 101548	0
16	Prognostic nutritional index and prognosis of patients with coronary artery disease: A systematic review and meta-analysis. 10,	O
15	WGCNA combined with machine learning algorithms for analyzing key genes and immune cell infiltration in heart failure due to ischemic cardiomyopathy. 10,	О
14	Beyond Stage C: Considerations in the Management of Patients with Heart Failure Progression and Gaps in Evidence. <b>2023</b> ,	O
13	Comparison of clinical outcomes between aggressive and non-aggressive intravenous hydration for acute pancreatitis: a systematic review and meta-analysis. <b>2023</b> , 27,	0
12	Evaluation of large animal models for preclinical studies of heart failure with preserved ejection fraction using clinical score systems. 10,	0
11	NON-COMPACTION CARDIOMYOPATHY: ISSUES, CONTRADICTIONS AND SEARCH FOR EFFECTIVE DIAGNOSTIC CRITERIA. LITERATURE REVIEW. PART 2. <b>2023</b> , 101723	О
10	Psychometric properties of the self-care of chronic illness inventory in Chinese older adults with multiple chronic conditions.	0
9	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. <b>2023</b> , 15, 1092	О
8	Effect of Caffeine Consumption on Cardiovascular Disease: An Updated Review. <b>2023</b> , 37, 139-151	0
7	Association of Brain Natriuretic Peptide Levels at Time of Injury with Morbidity and Mortality in Patients with Surgically Treated Hip Fractures. <b>2023</b> , 8,	О
6	Chest Emergencies in Pregnant Patients. <b>2023</b> , 64-80	O
5	Hospital-Level Variation in Cardiac Rehabilitation After Myocardial Infarction in Japan During Fiscal Years 2014[015 Using the National Database. 2023,	О
4	Challenges and opportunities for increasing patient involvement in heart failure self-care programs and self-care in the postflospital discharge period. <b>2023</b> , 9,	O

Exercise-based cardiac rehabilitation in women with heart failure: a review of enrollment, adherence, and outcomes.

Connection between Cardiac Fibrosis Biomarkers and Echocardiography Parameters in Advanced Chronic Kidney Disease Patients. 2023, 12, 3003

AHA/ACC/HFSA Guidelines Implementation Case Series: Resynchronization Pacing Preferred in Patients With Reduced Ejection Fraction. 2023, 16,